

CITATION REPORT

List of articles citing

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

DOI: 10.1056/nejm199610033351401

New England Journal of Medicine, 1996, 335, 1001-9.

Source: <https://exaly.com/paper-pdf/26739219/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2347	Cholesterol-lowering and coronary atherosclerosis: good news and bad news. 1996 , 101, 455-8		8
2346	Pathogenetic mechanisms of atherosclerosis: effect of lipid lowering on the biology of atherosclerosis. 1996 , 101, 10S-16S		21
2345	Review of cholesterol-lowering therapy: coronary angiographic and events trials. 1996 , 101, 4A34S-38S; discussion 39S		18
2344	Pharmacologic therapies after myocardial infarction. 1996 , 101, 4A61S-69S; discussion 4A69S-70S		19
2343	Beneficial effects of statins. GISSI-Prevenzione Investigators. 1996 , 348, 1582		4
2342	Cardiology. Acute coronary syndromes: Virchow's triad revisited. 1996 , 348 Suppl 2, sII2		5
2341	Cholesterol and coronary heart disease. 1996 , 5, 105-110		
2340	The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. 1996 , 17, 550-83		28
2339	Management of hyperlipidaemia. 1996 , 34, 89-93		7
2338	Advances in coronary angioplasty. <i>New England Journal of Medicine</i> , 1996 , 335, 1290-302	59.2	206
2337	The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. 1997 , 20, 469-71		69
2336	The effect of pravastatin on coronary events after myocardial infarction. <i>New England Journal of Medicine</i> , 1997 , 336, 961; author reply 962	59.2	1
2335	Use of coronary angiography and revascularization after acute myocardial infarction. <i>New England Journal of Medicine</i> , 1997 , 336, 1024-5; author reply 1025	59.2	
2334	Screening for genetic diseases. <i>New England Journal of Medicine</i> , 1997 , 336, 1314-6	59.2	35
2333	Auditing the Medicare-billing practices of teaching physicians--welcome accountability, unfair approach. <i>New England Journal of Medicine</i> , 1997 , 336, 1317-20	59.2	29
2332	Adjunctive drug therapy for acute myocardial infarction. <i>New England Journal of Medicine</i> , 1997 , 336, 1455; author reply 1455-6	59.2	0
2331	Exercise and breast cancer--time to get moving?. <i>New England Journal of Medicine</i> , 1997 , 336, 1311-2	59.2	24

2330	Recent developments in the treatment of dyslipidaemia. 1997 , 7, 441-455	3
2329	Are observational data adequate to guide lipid altering therapy in women?. 1997 , 6, 261-5	
2328	Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. 1997 , 46, 1354-9	246
2327	The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 1997 , 157, 2413	3063
2326	Adherence to National Cholesterol Education Program Treatment Goals in Postmenopausal Women With Heart Disease. 1997 , 277, 1281	141
2325	Should we treat hypercholesterolaemia in patients over 65?. 1997 , 77, 491-2	3
2324	Post-transplant hyperlipidaemia. 1997 , 73, 785-93	16
2323	Lipoprotein Lp(a) Excess and Coronary Heart Disease. 1997 , 157, 1170	95
2322	Statin Therapy and Reduced Incidence of Stroke. 1997 , 157, 1283	2
2321	Evidence-Based, Cost-effective Risk Stratification and Management After Myocardial Infarction. 1997 , 157, 273	21
2320	The Trevor Howell Lecture. Age, arterial stiffness and the endothelium. 1997 , 26 Suppl 4, 53-60	61
2319	The case for aggressive lipid regulation. 1997 , 32, 145-9, 155-6	3
2318	Fenofibrate plus simvastatin therapy versus simvastatin plus cholestyramine therapy for familial hypercholesterolaemia. 1997 , 90, 631-4	19
2317	The composition of coronary-artery plaques. <i>New England Journal of Medicine</i> , 1997 , 336, 1312-4	59.2 171
2316	General Internal Medicine. 1997 , 277, 1860	
2315	Assessing Differences in Clinical Trials Comparing Surgical vs Nonsurgical Therapy. 1997 , 278, 1432	8
2314	Treatment of Hypercholesterolemia in Women. 1997 , 277, 1320	3
2313	Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. <i>New England Journal of Medicine</i> , 1997 , 337, 1360-9	59.2 1070

2312	Reductase Inhibitor Monotherapy and Stroke Prevention. 1997 , 157, 1305	107
2311	Cholesterol lowering after participation in the Scandinavian Simvastatin Survival Study (4S) in Finland. 1997 , 18, 1725-7	14
2310	Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. 1997 , 18, 394-413	229
2309	EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. 1997 , 18, 1569-82	553
2308	Therapy and clinical trials. 1997 , 8, 329-31	
2307	The role of tobacco cessation, antiplatelet and lipid-lowering therapies in the treatment of peripheral arterial disease. 1997 , 2, 243-51	83
2306	Psychological distress in HIV-1 disease in relationship to hypocholesterolemia. 1997 , 27, 159-71	5
2305	Evidence-based medicine holds the key to the future for geriatric medicine. 1997 , 45, 1268-72	6
2304	Optimizing cholesterol lowering therapy: contribution of the Post Coronary Artery Bypass Graft Trial. 1997 , 18, 1683-5	3
2303	Clarifying the direct relation between total cholesterol levels and death from coronary heart disease in older persons. 1997 , 126, 753-60	166
2302	Integrating heterogeneous pieces of evidence in systematic reviews. 1997 , 127, 989-95	63
2301	Drugs affecting lipid metabolism. 1997 , 408-410	
2300	Is cholesterol the major lipoprotein risk factor in coronary heart disease?--a Franco-Scottish overview. 1997 , 13, 603-16	8
2299	Cholesterol management in general practice. 1997 , 14, 53-62	1
2298	Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease. 1997 , 11, 89-110	11
2297	A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients. 1997 , 12, 384-408	4
2296	HMG-CoA reductase inhibitors: a first-line option. 1997 , 9, 1-6	1
2295	Hyperlipidaemia: when should treatment be initiated?. 1997 , 9, 7-13	1

2294 Are HMG-CoA reductase inhibitors cost effective?. **1997**, 9, 14-16

2293 Lipids and lipoproteins in women. **1997**, 72, 235-44

40

2292 Prevention of atherosclerosis in coronary-artery bypass grafts. *New England Journal of Medicine*, **1997**, 336, 212-3

59.2 21

2291 Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. **1997**, 32, 403-25

379

2290 Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease. **1997**, 53, 299-336

59

2289 Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. **1997**, 53, 828-47

211

2288 Primary prevention of coronary heart disease. What has WOSCOPS told us and what questions remain? West Of Scotland Coronary Prevention Study. **1997**, 54, 1-8

155

2287 Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. **1997**, 54, 615-33

103

2286 Cholesterol and prevention of coronary heart disease. **1997**, 349, 210

2285 Cholesterol and prevention of coronary heart disease. **1997**, 349, 210-1

1

2284 CAPRIE trial. **1997**, 349, 354; author reply 356

3

2283 The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. **1997**, 3, 249-54

290

2282 Optimising Outcomes in Secondary Prevention of Coronary Heart Disease. **1997**, 2, 281-290

2281 Optimising Outcomes in Primary Prevention of Coronary Heart Disease. **1997**, 2, 238-247

2280 Evidence-Based Performance and Outcome Measures for Diabetes Care. **1997**, 2, 124-133

4

2279 Management of Lower Limb Intermittent Claudication. **1997**, 2, 18-29

2278 Management of lipid disorders in the elderly. **1997**, 10, 444-62

11

2277 Planned, ongoing and recently completed clinical trials for atherosclerosis prevention and regression: an update. **1997**, 6, 31-50

4

2276	The secondary prevention of coronary artery disease. 1997 , 102, 572-81	33
2275	Hypercholesterolemia in the United States: how far have we come?. 1997 , 102, 3-6	622
2274	Management of high serum cholesterol and related disorders in patients at risk for coronary heart disease. 1997 , 102, 15-22	34
2273	Adults aged 20 and older should have their cholesterol measured. 1997 , 102, 31-6	9
2272	Healthcare decisions and product labeling: results of a consumer comprehension study of prototype labeling for proposed over-the-counter cholestyramine. 1997 , 102, 50-6	19
2271	Cardiovascular complications following renal transplantation. 1997 , 11, 111-126	11
2270	Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond. 1997 , 1, 34-5	
2269	Aggressive as opposed to moderate low-density lipoprotein cholesterol lowering strategies reduced the progression of atherosclerosis in grafts and reduced further revascularization. 1997 , 1, 49	
2268	The management of a patient with non-insulin-dependent diabetes mellitus and hyperlipidaemia. 1997 , 1, 101-104	
2267	Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. 1997 , 410, 254-8	39
2266	An audit of secondary prevention of ischaemic heart disease using aspirin and cholesterol-lowering. 1997 , 1, 27-29	
2265	Simvastatin reduces monocyte-tissue-factor expression type IIa hypercholesterolaemia. 1997 , 350, 1222	50
2264	Drug therapy for coronary heart disease: the Sheffield table. 1997 , 350, 1853-4	1
2263	Statins and hypercholesterolaemia: UK Standing Medical Advisory Committee guidelines. 1997 , 350, 1174-5	11
2262	Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial. 1997 , 350, 441-2; author reply 443-4	2
2261	Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial. 1997 , 350, 442	3
2260	Total cholesterol and risk of mortality in the oldest old. 1997 , 350, 1119-23	365
2259	Coronary angioplasty versus medical therapy for angina: the second Randomised Intervention Treatment of Angina (RITA-2) trial. 1997 , 350, 461-468	407

2258	Coronary heart disease. Women's hearts are hard to break. 1997 , 349 Suppl 1, s13-6	10
2257	Beta-adrenergic blocking agents or angiotensin-converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction. 1997 , 29, 237-9	13
2256	Endothelial dysfunction: does it matter? Is it reversible?. 1997 , 30, 325-33	535
2255	Effect of pravastatin on angiographic restenosis after coronary balloon angioplasty. The PREDICT Trial Investigators. Prevention of Restenosis by Elisor after Transluminal Coronary Angioplasty. 1997 , 30, 863-9	115
2254	Changing paradigms in thrombolysis in acute myocardial infarction. 1997 , 59, 227-42	4
2253	Serum cholesterol and coronary heart disease--a public health perspective. 1997 , 51, 1-9	1
2252	LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update. 1997 , 51, 16-27	
2251	The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is ... or is it?. 1997 , 350 Suppl 1, S14-9	141
2250	What cardiologists need to know about diabetes. 1997 , 350 Suppl 1, S123-8	44
2249	Cardiovascular disease prevention in postmenopausal women: a clinician's perspective. 1997 , 27, 1-3	3
2248	Point Status of lipid and lipoprotein standardization. 1997 , 43, 1306-1310	21
2247	Counterpoint To (measure apo)B or not to (measure apo)B: a critique of modern medical decision-making. 1997 , 43, 1310-1314	20
2246	Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. 1997 , 102, 81-4, 87-90	7
2245	Lipid-lowering drugs and mortality. 1997 , 170, 289	
2244	Update in general internal medicine. 1997 , 127, 43-51	1
2243	Effect of phenotype on the transcription of the genes for platelet-derived growth factor (PDGF) isoforms in human smooth muscle cells, monocyte-derived macrophages, and endothelial cells in vitro. 1997 , 17, 2897-903	15
2242	Familial resemblance of plasma lipids, lipoproteins and postheparin lipoprotein and hepatic lipases in the HERITAGE Family Study. 1997 , 17, 3263-9	134
2241	Early Initiation of Chronic Dialysis: Role of Incremental Dialysis. 1997 , 17, 426-430	45

2240	Cholesterol reduction and clinical benefit. Are there limits to our expectations?. 1997 , 17, 3527-33		41
2239	Lipid modifying agents: mechanisms of action and reduction of cardiovascular disease. 1997 , 24, A26-8		5
2238	Do codeine and caffeine enhance the analgesic effect of aspirin?--A systematic overview. 1997 , 22, 79-97		44
2237	Non-pharmacological modification of cardiac risk factors: Part 2. The role of diet. 1997 , 22, 99-108		2
2236	Prescription of statins: cost implications of evidence-based treatment applied to a health authority population. 1997 , 22, 379-89		2
2235	Progress in Interventional Cardiology. 1997 , 10, 93-96		
2234	Beyond calories: other benefits of macronutrient substitutes. Effects on chronic disease. 1997 , 819, 221-8		
2233	Can single photon emission computed tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia?. 1997 , 4, 555-68		6
2232	Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. <i>American Journal of Cardiology</i> , 1997 , 79, 1298-301	3	17
2231	Cell dysfunction in atherosclerosis and the ischemic manifestations of coronary artery disease. <i>American Journal of Cardiology</i> , 1997 , 79, 17-23	3	38
2230	Results of recent large cholesterol-lowering trials and implications for clinical management. <i>American Journal of Cardiology</i> , 1997 , 79, 1663-6	3	21
2229	Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). <i>American Journal of Cardiology</i> , 1997 , 80, 278-86	3	273
2228	Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. <i>American Journal of Cardiology</i> , 1997 , 80, 608-13	3	132
2227	Frequency of sudden cardiac death and profiles of risk. <i>American Journal of Cardiology</i> , 1997 , 80, 10F-19F		307
2226	Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. <i>American Journal of Cardiology</i> , 1997 , 80, 799-802	3	11
2225	Treatment goals for low-density lipoprotein cholesterol in the secondary prevention of coronary heart disease: absolute levels or extent of lowering?. <i>American Journal of Cardiology</i> , 1997 , 80, 1287-94	3	13
2224	Treatment of hyperlipidemia by specialists versus generalists as secondary prevention of coronary artery disease. <i>American Journal of Cardiology</i> , 1997 , 80, 1345-7	3	12
2223	Role of endothelial dysfunction in coronary artery disease and implications for therapy. <i>American Journal of Cardiology</i> , 1997 , 80, 111-161	3	102

2222	Effects of Lipid Lowering on Coronary Plaques and Coronary Events. <i>American Journal of Cardiology</i> , 1997 , 80, 8H-9H	3	
2221	Review of recent clinical trials of lipid lowering in coronary artery disease. <i>American Journal of Cardiology</i> , 1997 , 80, 10H-13H	3	20
2220	Performance assessment model for guideline-recommended pharmacotherapy in the secondary prevention of coronary artery disease and treatment of left ventricular dysfunction. <i>American Journal of Cardiology</i> , 1997 , 80, 53H-56H	3	13
2219	Implementing quality assurance programs in multigroup practices for treating hypercholesterolemia in patients with coronary artery disease. <i>American Journal of Cardiology</i> , 1997 , 80, 57H-61H	3	16
2218	Symposium summary remarks. <i>American Journal of Cardiology</i> , 1997 , 80, 89H-90H	3	
2217	Treatment and outcome in silent myocardial ischemia: more pieces of the puzzle. <i>American Journal of Cardiology</i> , 1997 , 80, 1474-5	3	2
2216	[Goals and practical implementation of lipid therapy in coronary heart disease]. 1997 , 22, 134-40		1
2215	[Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients]. 1997 , 92, 363-9		5
2214	Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. 1997 , 19, 230-8		15
2213	Use of lipid-lowering drugs from 1990 to 1994: an international comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway and Sweden. 1997 , 53, 185-9		37
2212	Cardiac ischaemia: possibilities for future drug therapy. 1997 , 32, 687-707		6
2211	Guidelines and reported practice for the treatment of hypertension and hypercholesterolaemia. 1997 , 242, 173-8		18
2210	Primary prevention of coronary heart disease: role of cholesterol control in the United States. 1997 , 241, 295-306		27
2209	Treatment of osteoarthritis with aspartame. 1998 , 63, 580-93		14
2208	Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. 1998 , 63, 332-41		343
2207	Hyperlipidaemia: differences in management practices and attitudes in two regions in Europe--Sicily and the Stockholm area. 1998 , 14, 477-82		3
2206	Endothelial function: strategies for early intervention. 1998 , 12 Suppl 1, 125-34		13
2205	The limits of evidence-based cardiovascular therapy. 1998 , 12, 487-91		

2204	Selection of drug therapy in stable angina pectoris. 1998 , 12, 197-210	11
2203	Effect of lipid-lowering therapy on myocardial ischemia. 1998 , 12 Suppl 1, 135-9	1
2202	Treatment challenges in hypercholesterolemia. 1998 , 12, 325-37	2
2201	The controversy surrounding cholesterol treatment in older people. 1998 , 8, 11-4	
2200	[Epidemiology of coronary heart disease]. 1998 , 87 Suppl 2, 3-7	9
2199	[Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesterolemia]. 1998 , 87 Suppl 2, 136-44	7
2198	[Lipid lowering therapy for primary prevention of coronary heart disease--pro lipid lowering therapy]. 1998 , 87 Suppl 2, 205-9	1
2197	Gibt es eine prognostische Indikation zur PTCA?. 1998 , 87, s22-s27	
2196	[Cholesterol synthesis inhibitors. Clinical studies on lowering coronary risk and plaque stabilization]. 1998 , 39, 934-42	3
2195	The importance of lowering cholesterol in patients with coronary heart disease. 1998 , 21, 81-4	8
2194	The need for a prognosis trial of revascularization and aggressive medical therapy in patients with asymptomatic cardiac ischemia. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot. 1998 , 21, 154-6	1
2193	Pathophysiologic bases for adjunctive therapies in the treatment and secondary prevention of acute myocardial infarction. 1998 , 21, 161-8	11
2192	Hormones and the cardiologist. 1998 , 21, 218-22	2
2191	Cerivastatin (BAY w 6228): A Novel HMG-CoA Reductase Inhibitor. 1998 , 16, 236-263	16
2190	Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study). 1998 , 28, 327-33	16
2189	A decade of clinical trial developments in postmyocardial infarction, congestive heart failure, and sustained ventricular tachyarrhythmia patients: from CAST to AVID and beyond. Cardiac Arrhythmic Suppression Trial. Antiarrhythmic Versus Implantable Defibrillators. 1998 , 9, 864-91	37
2188	First-line testing. 1998 , 5, 86-9	
2187	Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). <i>American Journal of Cardiology</i> , 1998 , 81, 333-5	3 376

2186	Effect of early captopril treatment on blood adrenaline levels in acute myocardial infarction (the substudy of ISIS-4). International Study of Infarct Survival-4. <i>American Journal of Cardiology</i> , 1998 , 81, 335-9	3	2
2185	Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. <i>American Journal of Cardiology</i> , 1998 , 81, 578-81	3	65
2184	Dyslipidemias have a detrimental effect on left ventricular systolic function in patients with a first acute myocardial infarction. <i>American Journal of Cardiology</i> , 1998 , 81, 531-7	3	34
2183	Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial). <i>American Journal of Cardiology</i> , 1998 , 81, 632-6	3	10
2182	The new cholesterol education imperative and some comments on niacin. <i>American Journal of Cardiology</i> , 1998 , 81, 492-4	3	5
2181	Correspondence. <i>American Journal of Cardiology</i> , 1998 , 81, 259-260	3	3
2180	Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. <i>American Journal of Cardiology</i> , 1998 , 81, 912-7	3	158
2179	Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. <i>American Journal of Cardiology</i> , 1998 , 81, 18B-25B	3	378
2178	Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men. <i>American Journal of Cardiology</i> , 1998 , 81, 36B-42B	3	41
2177	Treatment of diabetic dyslipidemia. <i>American Journal of Cardiology</i> , 1998 , 81, 47B-51B	3	41
2176	Serum triglycerides and clinical benefit in lipid-lowering trials. <i>American Journal of Cardiology</i> , 1998 , 81, 70B-73B	3	8
2175	On the statins, correcting plasma lipid levels, and preventing the clinical sequelae of atherosclerotic coronary heart disease. <i>American Journal of Cardiology</i> , 1998 , 81, 1045-6	3	4
2174	Serum cholesterol levels are undervalued and undertreated. <i>American Journal of Cardiology</i> , 1998 , 81, 1353-6	3	21
2173	Early efficacy and safety studies. <i>American Journal of Cardiology</i> , 1998 , 81, 13F-16F	3	
2172	Clinical trial assessment of lipid-acting drugs in diabetic patients. <i>American Journal of Cardiology</i> , 1998 , 81, 58F-59F	3	2
2171	Eugene Braunwald, MD: a conversation with the editor. Interview by William Clifford Roberts. <i>American Journal of Cardiology</i> , 1998 , 82, 93-108	3	1
2170	Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results. <i>American Journal of Cardiology</i> , 1998 , 82, 505-7	3	9
2169	Underutilization of lipid-lowering drugs in older persons with prior myocardial infarction and a serum low-density lipoprotein cholesterol > 125 mg/dl. <i>American Journal of Cardiology</i> , 1998 , 82, 668-9, A6, A8	3	42

2168	Current and future treatment of hyperlipidemia: the role of statins. <i>American Journal of Cardiology</i> , 1998 , 82, 3J-10J	3	123
2167	Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. <i>American Journal of Cardiology</i> , 1998 , 82, 40J-46J	3	28
2166	Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Prevention of Events with Angiotensin-Converting Enzyme Inhibition. <i>American Journal of Cardiology</i> , 1998 , 82, 25H-30H	3	70
2165	Secondary prevention practices after acute myocardial infarction in a large city hospital. <i>American Journal of Cardiology</i> , 1998 , 82, 987-9	3	7
2164	Clinical trial endpoints: angiograms, events, and plaque instability. <i>American Journal of Cardiology</i> , 1998 , 82, 5M-11M	3	48
2163	Coronary arteriography and lipid lowering: limitations, new concepts, and new paradigms in cardiovascular medicine. <i>American Journal of Cardiology</i> , 1998 , 82, 12M-21M	3	4
2162	Relation of clinical benefit to metabolic effects in lipid-lowering therapy. <i>American Journal of Cardiology</i> , 1998 , 82, 22M-25M	3	1
2161	Economic implications of lipid-lowering trials: current considerations in selecting a statin. <i>American Journal of Cardiology</i> , 1998 , 82, 26M-31M	3	11
2160	Future of lipid-lowering trials: what else do we need to know?. <i>American Journal of Cardiology</i> , 1998 , 82, 32M-38M	3	1
2159	Changing the treatment paradigm for coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 2T-4T	3	663
2158	Need for a paradigm shift: the importance of risk factor reduction therapy in treating patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 1998 , 82, 10T-13T	3	50
2157	Why cholesterol as a central theme in coronary artery disease?. <i>American Journal of Cardiology</i> , 1998 , 82, 14T-17T	3	40
2156	Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial. <i>American Journal of Cardiology</i> , 1998 , 82, 45T-48T	3	14
2155	Preventing coronary artery disease in the West of Scotland: implications for primary prevention. <i>American Journal of Cardiology</i> , 1998 , 82, 57T-59T	3	114
2154	From heart surgery to prevention. <i>American Journal of Cardiology</i> , 1998 , 82, 66T-71T	3	32
2153	A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. <i>American Journal of Cardiology</i> , 1998 , 82, 29U-34U; discussion 39U-41U	3	114
2152	Introduction. <i>American Journal of Cardiology</i> , 1998 , 82, 1-2	3	11
2151	Low-density lipoproteins and risk for coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 3Q-12Q	3	270

2150	Triglyceride as a risk factor for coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 22Q-25Q		311
2149	Did grandma give you heart disease? The new battle against coronary artery disease. <i>American Journal of Cardiology</i> , 1998 , 82, 34Q-46Q	3	42
2148	Primary and secondary prevention of coronary artery disease: trials of lipid lowering with statins. <i>American Journal of Cardiology</i> , 1998 , 82, 28S-30S	3	7
2147	Diabetic dyslipidemia. <i>American Journal of Cardiology</i> , 1998 , 82, 67U-73U; discussion 85U-86U	3	122
2146	Treatment of hyperlipidemia with combined niacin-statin regimens. <i>American Journal of Cardiology</i> , 1998 , 82, 82U-84U; discussion 85-86U	3	74
2145	State-of-the-art update and review: clinical trials of lipid-lowering agents. <i>American Journal of Cardiology</i> , 1998 , 82, 3U-17U; discussion 39U-41U	3	38
2144	Primary and secondary prevention of coronary artery disease: Trials of lipid lowering with statins. <i>American Journal of Cardiology</i> , 1998 , 82, S28-S30	3	7
2143	Aggressive lipid therapy in the statin era. 1998 , 41, 71-94		30
2142	Treatment strategies for management of serum lipids: lessons learned from lipid metabolism, recent clinical trials, and experience with the HMG CoA reductase inhibitors. 1998 , 41, 95-116		12
2141	Cholesterol, cholesterol lowering, and endothelial function. 1998 , 41, 117-36		55
2140	The role of diet and exercise in the statin era. 1998 , 41, 137-50		5
2139	Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar?. 1998 , 80, 1-34		185
2138	Lipid-lowering drugs in the management of hyperlipidaemia. 1998 , 79, 205-30		52
2137	Vascular morbidity and mortality during long-term follow-up in claudicants selected for peripheral bypass surgery. 1998 , 16, 292-300		10
2136	The management of hypercholesterolemia in patients with coronary artery disease: guidelines for primary care. 1998 , 1, 51-64		3
2135	Vascular surgery. 1998 , 186, 247-62		1
2134	Broader metabolic control in diabetes management. 1998 , 14, S39-S43		
2133	Which drugs benefit diabetic patients for secondary prevention of myocardial infarction? DARTS/MEMO Collaboration. 1998 , 15, 282-9		26

2132	The metabolic syndrome: overeating, inactivity, poor compliance or bad advice?. 1998 , 15, S29-S31	1
2131	Association and linkage of LDLR gene variation with variation in plasma low density lipoprotein cholesterol. 1998 , 43, 153-9	35
2130	[Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study]. 1998 , 23, 319-29	13
2129	[Coronary heart disease as inflammatory disease of the vascular bed? Etiology, sequela or misconception?]. 1998 , 23, 147-52	
2128	[Arteriosclerosis and coronary heart disease--strengths and weaknesses in the classical risk factor concept]. 1998 , 23, 153-62	1
2127	The benefit of lowering cholesterol: relative risk can be absolutely misleading!. 1998 , 167, 92-3	
2126	[HMG-CoA reductase inhibitor and risk of stroke]. 1998 , 69, 717-21	4
2125	A 47 year old diabetic male with dyspnoea: "The ticking time bomb" 1998 , 15, 187-189	1
2124	Landmark trials in lipid reduction. 1998 , 1, 110-4	1
2123	Prevention of heart disease: is LDL reduction the outcome of choice? Absolutely yes. 1998 , 1, 115-9	1
2122	Cardiovascular disease and lipoproteins: available evidence and remaining questions. Reactor panel and open forum. 1998 , 1, 125-30	2
2121	The economics of hypercholesterolemia and lipid-lowering therapy: a brief historical tour. 1998 , 1, 159-65	2
2120	Lipid-lowering pharmacoeconomic studies. Reactor panel and open forum. 1998 , 1, 167-70	
2119	Compliance in the real world. 1998 , 1, 171-3	10
2118	Economic modeling and sensitivity analysis. 1998 , 1, 187-93	10
2117	Methodology issues in lipid pharmacoeconomic investigations. Reactor panel and open forum. 1998 , 1, 195-200	
2116	What is happening in the real world in lipid therapy and is it appropriate? The need for a paradigm shift. 1998 , 1, 204-7	1
2115	Commentary on Langley and McKenney Papers. 1998 , 1, 216-7	

2114 A Canadian perspective. **1998**, 1, 218-23

2113 From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forum. **1998**, 1, 243-50

2112 Does cholesterol lowering prevent stroke?. **1998**, 23, 337-44

5

2111 Pharmacological treatment of diabetic patients with cardiovascular complications. **1998**, 243, 181-9

10

2110 Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. **1998**, 243, 373-80

56

2109 Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. **1998**, 244, 143-7

15

2108 Lipid disorders in NIDDM: implications for treatment. **1998**, 244, 361-70

18

2107 Anaesthesia and evidence-based medicine. **1998**, 53, 353-68

21

2106 Thrombolysis in acute myocardial infarction improves prognosis and prolongs life but will increase the prevalence of heart failure in the geriatric population. **1998**, 65 Suppl 1, S29-35

2

2105 Association between coronary angiograms and cardiac events--a prospective 3-year follow-up. INTACT-Investigators. International Nifedipine Trial on Antiatherosclerotic Therapy. **1998**, 65, 271-9

4

2104 The management of hypercholesterolaemia in patients with coronary artery disease referred for coronary angiography. **1998**, 67, 247-9

0

2103 Screening with exercise thallium testing after coronary-artery-bypass grafting. **1998**, 351, 1586-1587

2102 Statins for prevention of stroke. **1998**, 351, 1002-3

13

2101 Nomenclature of enterotoxins. **1998**, 351, 1003

4

2100 The arterial organ in cardiovascular disease: ADAPT (arterial disease assessment, prevention, and treatment) clinic. **1998**, 352, 1700-2

6

2099 Prevention of stroke. **1998**, 352 Suppl 3, S1115-8

25

2098 Overview of atherosclerosis. **1998**, 20 Suppl B, B2-17

41

2097 A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia. **1998**, 20, 539-48

5

2096 [Cholesterolemia and pathology: update]. **1998**, 19, 180-4

2095 Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. **1998**, 97, 2433-44

481

2094 Lovastatin is effective in primary prevention of acute coronary events. **1998**, 2, 101

2093 Plasma LDL concentrations achieved by pravastatin reduced coronary event rate. **1998**, 2, 116-7

2092 An elderly woman with hypercholesterolaemia but no symptoms. **1998**, 2, 39-44

2091 A middle-aged man presents with a number of risk factors. **1998**, 2, 158-163

2090 10trans, 12cis-Linoleic acid reduces apolipoprotein B secretion in HepG2 cells. **1998**, 31, 403-409

56

2089 P-value interpretation and alpha allocation in clinical trials. **1998**, 8, 351-7

46

2088 Mortality rates in treated hypertensive men with additional risk factors are high but can be reduced: a randomized intervention study. **1998**, 11, 14-22

20

2087 Treatment of early onset atherosclerosis. **1998**, 123, 720-2

2086 Serum lipid physiology and the influence of glaucoma medications. **1998**, 43, 233-44

13

2085 Iatrogenic problems caused by immunosuppressive drugs in transplant recipients. **1998**, 30, 14S-19S

5

2084 Effects of variable dietary sitostanol concentrations on plasma lipid profile and phytosterol metabolism in hamsters. **1998**, 1390, 237-44

44

2083 Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. **1998**, 31, 519-25

102

2082 Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. **1998**, 31, 684-91

311

2081 Cost-effectiveness of tests to assess the risk of sudden death after acute myocardial infarction. **1998**, 31, 1490-2

5

2080 Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. **1998**, 32, 140-6

193

2079 Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. **1998**, 32, 711-6

97

2078	Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. 1998 , 32, 665-72	137
2077	The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease. 1998 , 32, 1244-50	40
2076	Evidence-based medicine criteria applied to hypolipidemic and antihypertensive drug trials: is drug efficacy always the same?. 1998 , 37, 339-43	2
2075	Dyslipoproteinemia and diabetes. 1998 , 27, 613-25, ix-x	22
2074	Clinical trials of reducing low-density lipoprotein concentrations. 1998 , 27, 585-95, viii-ix	8
2073	Cholesterol and coronary heart disease in women. 1998 , 16, 9-15	4
2072	Vascular disease and lipids in diabetes. 1998 , 82, 931-48	34
2071	The role of cholesterol management in coronary disease risk reduction in elderly patients. 1998 , 27, 655-75, x	12
2070	Hyperlipidemia and diabetes mellitus. 1998 , 73, 969-76	97
2069	Control of lipid disorders in patients with atherosclerotic vascular disease. 1998 , 78, 431-46	1
2068	Leukocyte-Mediated Endothelial Injury. 1998 , 9, 675-677	
2067	Gender differences in cardiac rehabilitation. 1998 , 16, 37-43	38
2066	[Is the exercise test performed after myocardial infarct really useful in improving prognosis? Arguments contra]. 1998 , 51, 541-6	3
2065	Special Communication. 1998 , 27, 1152-1192	1
2064	Post-statin approaches to hyperlipidaemia. 1998 , 7, 1997-2009	1
2063	New prospects for lipid-lowering drugs. 1998 , 7, 715-27	3
2062	Do lipid lowering drugs reduce the risk of coronary heart disease?. 1998 , 35, 603-21	15
2061	Serum cholesterol, lifestyle, working capacity and quality of life in patients with coronary artery disease. Experiences from a hospital-based secondary prevention programme. 1998 , 50, 1-20	26

2060	Impact of dyslipidaemia. Lessons from clinical trials. 1998 , 14 Suppl 3, 1-9	1
2059	Resource utilisation in the management of dyslipidaemia. 1998 , 14 Suppl 3, 11-8	6
2058	The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines. 1998 , 14 Suppl 3, 19-28	13
2057	Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols. 1998 , 14 Suppl 3, 29-38	5
2056	The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin. 1998 , 14, 59-70	38
2055	Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease. 1998 , 14, 217-36	8
2054	Secondary Prevention after Myocardial Infarction. 1998 , 4, 6-10	7
2053	Comparison of the Heart and Estrogen/Progestin Replacement Study (HERS) cohort with women with coronary disease from the National Health and Nutrition Examination Survey III (NHANES III). 1998 , 136, 115-24	36
2052	Current and novel pharmacologic approaches in advanced heart failure. 1998 , 135, S249-63	18
2051	Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. 1998 , 104, 2S-5S	71
2050	Risk factor modification: rationale for management of dyslipidemia. 1998 , 104, 6S-8S	17
2049	Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy. 1998 , 104, 9S-13S	34
2048	New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. 1998 , 104, 2S-17S	145
2047	The future: screening and effective intervention. 1998 , 104, 54S-59S	0
2046	Biologic markers as predictors of cardiovascular disease. 1998 , 104, 18S-27S	78
2045	Lessons from cholesterol-lowering trials. 1998 , 104, 28S-32S	13
2044	The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. 1998 , 104, 42S-49S	14
2043	The deadly quartet revisited. 1998 , 105, 1S-3S	28

2042	Cardiovascular risk continuum: implications of insulin resistance and diabetes. 1998 , 105, 4S-14S		124
2041	The American College of Physicians guidelines for screening blood cholesterol levels: a commentary. 1998 , 105, 75S-76S		3
2040	Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials. 1998 , 105, 63S-68S		7
2039	A perspective on hyperlipidemia: concepts of management in the prevention of coronary artery disease. 1998 , 105, 69S-74S		8
2038	The cardiovascular dysmetabolic syndrome. 1998 , 105, 77S-82S		84
2037	Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. <i>New England Journal of Medicine</i> , 1998 , 339, 229-34	59.2	517 ^o
2036	Drug administration in patients with diabetes mellitus. Safety considerations. 1998 , 18, 441-55		12
2035	Cerivastatin. 1998 , 55, 415-20; discussion 421-2		34
2034	Are there potential non-lipid-lowering uses of statins?. 1998 , 56, 517-22		42
2033	Effectiveness and Tolerability of 12-Week Treatment with Micronised Fenofibrate 200mg in a Drug-Monitoring Programme Involving 9884 Patients with Dyslipidaemia. 1998 , 15, 197-204		17
2032	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. 1998 , 16, 219-27		12
2031	HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. 1998 , 138, 11-24		88
2030	Quantitative analysis of cholesterol and cholesteryl esters in human atherosclerotic plaques using near-infrared Raman spectroscopy. 1998 , 140, 81-8		262
2029	Dyslipoproteinaemia and hyperoxidative stress in the pathogenesis of endothelial dysfunction in non-insulin dependent diabetes mellitus: an hypothesis. 1998 , 141, 17-30		93
2028	Can we afford to treat hyperlipidaemia as we should? Strategies for rational treatment. 1998 , 139 Suppl 1, S1-5		46
2027	Cerivastatin in primary hyperlipidemia—a multicenter analysis of efficacy and safety. 1998 , 139 Suppl 1, S15-22		16
2026	Triglycerides are more important in atherosclerosis than epidemiology has suggested. 1998 , 141 Suppl 1, S57-62		52
2025	New evidence, new guidelines. 1998 , 140, 197-8		3

2024	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. 1998 , 140, 199-270	422
2023	Dietary treatment of people at high coronary risk. 1998 , 11, 273-280	
2022	Detection and evaluation of dyslipoproteinemia. 1998 , 27, 597-611, ix	10
2021	Women, dyslipoproteinemia, and estrogens. 1998 , 27, 627-39, x	5
2020	Risk factors for coronary heart disease in women. 1998 , 16, 1-8	36
2019	The role of lipid-lowering therapy in multiple risk factor management. 1998 , 56 Suppl 1, 1-7; discussion 33	5
2018	Extending therapy options in treating lipid disorders: a clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor. 1998 , 56 Suppl 1, 25-31; discussion 33	16
2017	Guidelines for the Prevention of Coronary Heart Disease. 1998 , 4, 217-224	
2016	Pharmacoeconomic Models in Disease Management. 1998 , 4, 119-134	12
2015	Management of Dyslipidaemias. 1998 , 3, 293-311	2
2014	International conference on biomedical aspects of aging research. 1998 , 10, 141-177	1
2013	Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease. <i>New England Journal of Medicine</i> , 1998 , 338, 1577-84	59.2 150
2012	Implications of Serum Cholesterol Measurement for the Vascular Surgeon. 1998 , 32, 241-244	1
2011	Insulin and coronary artery disease: is syndrome X the unifying hypothesis?. 1998 , 32, 233-47	22
2010	Identifying patient populations at high risk for stroke. 1998 , 51, S27-30	40
2009	Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. 1998 , 98, 839-44	1104
2008	Cholesterol reduction yields clinical benefit: impact of statin trials. 1998 , 97, 946-52	351
2007	Medical Therapy for Coronary Artery Disease: Primary and Secondary Prevention. 1998 , 6, 245-249	

2006	Secondary prevention in coronary heart disease: baseline survey of provision in general practice. 1998 , 316, 1430-4	152
2005	Statin trials and goals of cholesterol-lowering therapy. 1998 , 97, 1436-9	156
2004	Use of Lipid Drugs With Acute Myocardial Infarction Patients: An Examination of Physician Prescribing Behaviors. 1998 , 3, 217-222	3
2003	Triglyceride: the forgotten risk factor. 1998 , 97, 1027-8	93
2002	Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. 1998 , 279, 1615-22	3654
2001	Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin. 1998 , 49, 743-8	12
2000	Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. 1998 , 98, 2513-9	772
1999	Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention. 1998 , 3, 77-84	0
1998	Cholesterol lowering and coronary artery disease: mechanisms of risk reduction. 1998 , 80, 543-7	14
1997	Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. 1998 , 97, 1095-102	205
1996	Associations between lipoproteins and the progression of coronary and vein-graft atherosclerosis in a controlled trial with gemfibrozil in men with low baseline levels of HDL cholesterol. 1998 , 98, 1993-9	64
1995	Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. 1998 , 83, 1015-26	124
1994	Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. 1998 , 280, 605-13	4189
1993	Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. <i>New England Journal of Medicine</i> , 1998 , 339, 1349-57 ²	454 ⁰
1992	The National Cholesterol Education Program: progress and prospects. 1998 , 280, 2099-104	88
1991	3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. 1998 , 83, 490-500	35 ⁰
1990	The potential role of soluble fibre in the treatment of hypercholesterolaemia. 1998 , 74, 391-4	8
1989	Cholesterol and coronary heart disease: screening and treatment. 1998 , 7, 232-9	14

1988	Primary prevention of coronary heart disease: guidance from Framingham: a statement for healthcare professionals from the AHA Task Force on Risk Reduction. American Heart Association. 1998 , 97, 1876-87		432
1987	Atherothrombosis: mechanisms and clinical therapeutic approaches. 1998 , 3, 231-9		46
1986	The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice. 1998 , 74, 600-1		8
1985	Polymorphism of the cholesteryl ester transfer protein gene. <i>New England Journal of Medicine</i> , 1998 , 338, 1624-5; author reply 1625-6	59.2	4
1984	Management of Non-Q-Wave Myocardial Infarction. <i>New England Journal of Medicine</i> , 1998 , 339, 1395-1398	59.2	1
1983	Diabetes and coronary heart disease. <i>New England Journal of Medicine</i> , 1998 , 339, 1714-5; author reply 1716	59.2	38
1982	Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. 1998 , 158, 1181-7		263
1981	Recent advances. <i>Cardiology</i> . 1998 , 316, 911-5		2
1980	Persistence of use of lipid-lowering medications: a cross-national study. 1998 , 279, 1458-62		462
1979	Stroke risk factors and stroke prevention. 1998 , 18, 429-40		83
1978	Call to action: cardiovascular disease in women. 1998 , 7, 37-43		9
1977	Hormone and nonhormone therapy for the maintenance of postmenopausal health: the need for randomized controlled trials of estrogen and raloxifene. 1998 , 7, 839-47		46
1976	Endothelial dysfunction: implications for therapy of cardiovascular diseases. 1998 , 32, 459-70		27
1975	A lipid hypothesis: prediction, observation and the triglyceride/HDL gap. 1998 , 14, 65-78		4
1974	Preventing coronary disease in women: brief observations from the clinical data. 1998 , 7, 195-7		1
1973	Chronic heart failure in the United States: a manifestation of coronary artery disease. 1998 , 97, 282-9		640
1972	Cardiovascular disease prevention: a challenge for Latin America. 1998 , 98, 2103-4		9
1971	Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. 1998 , 97, 1446-52		311

1970	Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. 1998 , 21, 477-81	42
1969	Echo-lucency of computerized ultrasound images of carotid atherosclerotic plaques are associated with increased levels of triglyceride-rich lipoproteins as well as increased plaque lipid content. 1998 , 97, 34-40	170
1968	Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. LIPID Trial Research Group. 1998 , 97, 1784-90	214
1967	Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. 1998 , 97, 916-31	887
1966	Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. 1998 , 32, 1030-43	36
1965	Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA Myocardial Infarction Register Study Group. 1998 , 21, 69-75	530
1964	Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. 1998 , 158, 1238-44	164
1963	Clinical criteria versus DNA diagnosis in heterozygous familial hypercholesterolemia: Is molecular diagnosis superior to clinical diagnosis?. 1998 , 18, 331-2	9
1962	Multiple Risk Factors in Cardiovascular Disease. 1998 ,	
1961	Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland. 1998 , 97, 1087-94	73
1960	Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). 1998 , 97, 1453-60	516
1959	Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. 1998 , 97, 1514-21	180
1958	Intensive medical therapy versus coronary angioplasty for suppression of myocardial ischemia in survivors of acute myocardial infarction: a prospective, randomized pilot study. 1998 , 98, 2017-23	95
1957	Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. 1998 , 98, 851-5	146
1956	3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. 1998 , 83, 683-90	287
1955	Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. 1998 , 316, 894-898	716
1954	Lipids in hypertensive patients. 1998 , 11, 887-9	2
1953	Present status of HMG reductase inhibitors in treatment of dyslipidemia. 1998 , 49, 801-5	1

1952	Invited Review. 1998 , 32, 245-247	1
1951	Secondary prevention in coronary heart disease: a randomised trial of nurse led clinics in primary care. 1998 , 80, 447-52	174
1950	Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. <i>off.</i> 1998 , 158, 1301-6	102
1949	Number needed to treat: solid science or a path to pernicious rationing?. 1998 , 11, 128S-134S; discussion 135S-137S	10
1948	Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). 1998 , 97, 1440-5	659
1947	Statins and the kidney. 1998 , 7, 579-84	11
1946	Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. 1998 , 279, 1445-51	517
1945	Why do we need randomised controlled trials to assess behavioural interventions?. 1998 , 316, 611-3	110
1944	Animal fat and cholesterol may have helped primitive man evolve a large brain. 1998 , 41, 417-25	9
1943	Usual care dietary practice, achievement and implications for medication in the management of hypercholesterolaemia. Data from the U.K. Lipid Clinics Programme. 1998 , 19, 1328-33	14
1942	Improvement of myocardial ischaemia by lipid lowering drugs. 1998 , 19, 230-4	4
1941	Cardiac rehabilitation. 1998 , 19, 1004-10	14
1940	Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. 1998 , 19, 1434-503	757
1939	The clinical implications of diabetic heart disease. 1998 , 19, 1617-27	35
1938	Identifying patients at risk for coronary heart disease: treatment implications. 1998 , 19, 1776-83	11
1937	Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. 1998 , 95, 8880-5	839
1936	Time trend analysis and variations in prescribing lipid lowering drugs in general practice. 1998 , 317, 1134-5	38
1935	Drugs affecting lipid metabolism. 1998 , 458-462	

1934	Patients' action during their cardiac event: qualitative study exploring differences and modifiable factors. 1998 , 316, 1060-4	116
1933	Detecting and correcting hyperlipidemia. 1998 , 33, 83-90, 95-9; discussion 99-100, 102	
1932	Time trends in the use of cholesterol-lowering agents in older adults: the Cardiovascular Health Study. 1998 , 158, 1761-8	66
1931	Underutilization of measurement of serum low-density lipoprotein cholesterol levels and of lipid-lowering therapy in older patients with manifest atherosclerotic disease. 1998 , 46, 1128-31	28
1930	Systemic immune reactions to HMG-CoA reductase inhibitors. Report of 4 cases and review of the literature. <i>Medicine (United States)</i> , 1998 , 77, 378-83	1.8 25
1929	Contemporary Practice: Treatment Gap in Lipid-Lowering Therapy. 1998 , 11, 318-322	
1928	Interim report from project ImPACT: hyperlipidemia. 1998 , 38, 529-34	16
1927	Estimating the benefits of modifying risk factors of cardiovascular disease: a comparison of primary vs secondary prevention. 1998 , 158, 655-62	107
1926	From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. 1998 , 317, 1130-4	97
1925	Calcium channel blockers. The jury is still out on whether they cause heart attacks and suicide. 1998 , 316, 1471-3	20
1924	Implications of applying widely accepted cholesterol screening and management guidelines to a British adult population: cross sectional study of cardiovascular disease and risk factors. 1998 , 317, 1125-30	33
1923	Dietary fatty acids and the regulation of plasma low density lipoprotein cholesterol concentrations. 1998 , 128, 444S-448S	154
1922	Secondary prevention in acute myocardial infarction. 1998 , 316, 838-42	27
1921	Management of older persons after myocardial infarction. 1998 , 46, 1459-68	10
1920	Cholesterol reduction for the secondary prevention of coronary heart disease: a successful multi-disciplinary approach to implementing evidence-based treatment in a district general hospital. 1998 , 3, 156-160	
1919	Prevalence of coronary artery disease, atherothrombotic brain infarction, and peripheral arterial disease: associated risk factors in older Hispanics in an academic hospital-based geriatrics practice. 1998 , 46, 481-3	17
1918	Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. 1998 , 129, 681-9	297
1917	Effect of HMGCoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials. 1998 , 128, 89-95	144

1916	Ultrasonography of leg veins in patients suspected of having pulmonary embolism. 1998 , 128, 243; author reply 244-5	25
1915	Maximizing the cost-effectiveness of lipid-lowering therapy. 1998 , 158, 1977-89	54
1914	Modulation of the nitric oxide synthase pathway in atherosclerosis. 1998 , 83, 573-84	24
1913	Influence of age on the safety, tolerability, and pharmacokinetics of the novel HMG-CoA reductase inhibitor cerivastatin in healthy male volunteers. 1998 , 38, 715-9	3
1912	Alterations in mood after changing to a low-fat diet. 1998 , 79, 23-30	50
1911	Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?. 1998 , 158, 375-81	23
1910	Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. 1998 , 62, 7-14	40
1909	Modulators of dyslipidaemia. 1998 , 3, 147-172	20
1908	Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. 1998 , 128, 728-32	159
1907	Recent advances. General medicine. 1998 , 317, 792-5	
1906	Angiotensin II and coronary sympathetic vasodilation. 1998 , 97, 1873-4	1
1905	Passive Smoking and Coronary Heart Disease. 1998 , 97, 1871-1871	0
1904	Prevention of coronary heart disease in clinical practice. European recommendations revised and reinforced. 1998 , 19, 1413-5	14
1903	Management of lipids in the elderly. 1998 , 91, 189-91	3
1902	Functional evaluation of lipid-lowering therapy by pravastatin. 1998 , 97, 1874-5	1
1901	Management of peripheral arterial disease. 1998 , 55, S21-7	9
1900	Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. 1998 , 55, 2253-67; quiz 2302-3	41
1899	Endothelium and acute coronary syndromes. 1998 , 44, 1799-1808	76

1898 Coronary risk factors 6-12 months after coronary arter bypass surgery. **1998**, 169, 174-175

1897 Clinical experience and evidence-based medicine. **1998**, 128, 245

1896 Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes. **1998**, 279, 445-9 27

1895 Components of the insulin resistance syndrome are associated with progression of atherosclerosis in non-grafted arteries 5 years after coronary artery bypass surgery. **1998**, 19, 711-9 13

1894 Clinical Experience and Evidence-Based Medicine. **1998**, 128, 245

1893 [Comparison of hypercholesterolemic men and women at high risk for atherosclerosis. Study of risk factors and response to pravastatin treatment]. **1998**, 70, 383-7 1

1892 The atheromatous lipid core. **1998**, 19, 16-8 35

1891 Stroke prevention and intervention. New options for improved outcomes. **1998**, 103, 43-5, 49-50, 56-8 passim 13

1890 Lipids and stroke: neglect of a useful preventive measure?. **1998**, 40, 265-71 20

1889 Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?. **1998**, 104, 117-20, 123-4, 129 4

1888 Total Cholesterol and Death from Coronary Heart Disease in Older Persons. **1998**, 128, 242

1887 Ultrasonography of leg veins in patients suspected of having pulmonary embolism. **1998**, 128, 244; author reply 244-5

1886 [Trends in cholesterol levels in the adult population of São José do Rio Preto]. **1998**, 71, 699-704 3

1885 Regulation of the Thrombotic Potential of Atheroma. **1999**, 82, 736-741 28

1884 Update in women's health. **1999**, 131, 952-8 2

1883 Vitamin C increases nitric oxide availability in coronary atherosclerosis. **1999**, 131, 156-7 18

1882 Iron in multivitamin supplements. **1999**, 131, 158

1881 Risk factors for infective endocarditis. **1999**, 131, 154; author reply 155

1880	Coronary artery disease and diabetes. 1999 , 105, 66-8, 71-2, 77-80	4
1879	Statins as cellular antithrombotics. 1999 , 29, 166-9	4
1878	Vitamin E and vascular homeostasis: implications for atherosclerosis. 1999 , 13, 965-75	130
1877	Celiac disease during interferon treatment. 1999 , 131, 157-8	44
1876	Is there a Place for LDL-apheresis in Non-Homozygous Patients?. 1999 , 22, 723-725	3
1875	Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?. 1999 , 72, 657-68	3
1874	Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. 1999 , 56, 1726-32	21
1873	Atorvastatin Increases ecNOS Levels in Human Platelets of Hyperlipidemic Subjects. 1999 , 82, 1390-1394	62
1872	Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-blind, placebo-controlled study. 1999 , 27, 115-29	13
1871	Use of aspirin, beta-blockers, and lipid-lowering medications before recurrent acute myocardial infarction: missed opportunities for prevention?. 1999 , 159, 561-7	66
1870	Pharmacist-coordinated program to improve use of pharmacotherapies for reducing risk of coronary artery disease in low-income adults. 1999 , 56, 2319-24	16
1869	Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. 1999 , 56, 1437-41	5
1868	Outcomes Improvement Following Minimally Invasive Direct Coronary Artery Bypass Surgery. 1999 , 11, 177-188	4
1867	Rationale, design, and baseline results of the Pravastatin-to-Simvastatin Conversion Lipid Optimization Program (PSCOP). 1999 , 56, 1107-13	5
1866	Abstracts from the Evidence Supported Medicine Union/NHS Executive West Midlands Conference, 17-18 March 1999, Birmingham. 1999 , 3, 11-64	
1865	The Role of Chlamydia Pneumoniae in the Pathogenesis of Coronary Heart Disease. 1999 , 15, 157-161	
1864	Cardiology. 12. The role of oestrogen in cardiovascular disease: benefit or harm?. 1999 , 171, 490-5	1
1863	2. Cholesterol in perspective. 1999 , 170, 385-390	1

1862	Familial hypercholesterolemia in Utah kindred with novel 2412-6 Ins G mutations in exon 17 of the LDL receptor gene. 1999 , 40, 435-41		4
1861	Recommendations for the Treatment of Lipid Disorders in Patients on Peritoneal Dialysis. 1999 , 19, 8-17		12
1860	Major and Minor Risk Factors for Cardiovascular Disease in Continuous Ambulatory Peritoneal Dialysis Patients. 1999 , 19, 133-137		8
1859	An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. 1999 , 282, 2051-7		75
1858	Evidence-based guidelines for early stroke management. 1999 , 60, 105-14		2
1857	MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. 1999 , 20, 725-41		175
1856	Lipids and coronary restenosis:an elusive link. 1999 , 20, 1371-4		2
1855	How to use natriuretic peptide levels for diagnosis and prognosis. 1999 , 20, 1374-5		18
1854	Coronary artery calcification as an indicator of preclinical coronary artery disease. 1999 , 19, 1409-19		22
1853	Therapeutic controversy: Hormone replacement therapy--where are we going?. 1999 , 84, 1798-812		20
1852	Why not optimism?. 1999 , 211, 287-8		4
1851	Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. 1999 , 82, 325-32		67
1850	Pravastatin and coronary heart disease. <i>New England Journal of Medicine</i> , 1999 , 340, 1115-6; author reply 1116-7	59.2	5
1849	Carotid endarterectomy. <i>New England Journal of Medicine</i> , 1999 , 340, 1209; author reply 1210-1	59.2	
1848	Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. <i>New England Journal of Medicine</i> , 1999 , 341, 70-6	59.2	711
1847	LIPIDS. 1999 , 311-378		4
1846	Ultrasound and lipoproteins as predictors of lipid-rich, rupture-prone plaques in the carotid artery. 1999 , 19, 2-13		153
1845	Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. 1999 , 100, 475-82		123

1844	State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. 1999 , 34, 987-96		113
1843	Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading. 1999 , 318, 1548-51		203
1842	Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease. A worldwide view. International Task force for the Prevention of Coronary Heart disease. 1999 , 19, 1819-24		108
1841	Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. 1999 , 99, 475-81		129
1840	Incidence and determinants of mortality and cardiovascular events in diabetes mellitus: a meta-analysis. 1999 , 4, 67-75		35
1839	Statins and cerebrovascular disease: plaque attack to prevent brain attack. 1999 , 4, 269-72		8
1838	Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. <i>New England Journal of Medicine</i> , 1999 , 341, 410-8	59.2	2809
1837	Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. 1999 , 100, 1215-22		124
1836	Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats. 1999 , 19, 2894-900		199
1835	Antioxidant therapy for coronary artery disease: don't paint the walls without treating the termites!. 1999 , 159, 1279-80		6
1834	Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. 1999 , 99, 2003-10		121
1833	Lipid modification and coronary heart disease in type 2 diabetes: different from the general population?. 1999 , 81, 10-1		13
1832	The role of coronary angioplasty and stenting in acute myocardial infarction. 1999 , 75, 591-8		1
1831	Risk stratification for the detection of preclinical coronary artery disease. 1999 , 99, 2610-2		27
1830	When should patients with heterozygous familial hypercholesterolemia be treated?. 1999 , 281, 180-1		10
1829	Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. 1999 , 282, 2012-8		454
1828	Is cholesterol a risk factor for stroke?: No. 1999 , 56, 1521-4		29
1827	Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. 1999 , 99, E1-7		64

1826	Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. 1999 , 281, 1112-20	308
1825	Clinical outcomes in statin treatment trials: a meta-analysis. 1999 , 159, 1793-802	147
1824	Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. 1999 , 159, 1670-8	79
1823	Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. 1999 , 159, 593-600	51
1822	Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. 1999 , 282, 2043-50	111
1821	Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives. 1999 , 159, 1038-40	7
1820	Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. 1999 , 100, 230-5	1259
1819	Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG. 1999 , 15, 394-9; discussion 399-400	91
1818	Is cholesterol a risk factor for stroke?: Yes. 1999 , 56, 1518-20; discussion 1524	41
1817	Systematic review on the risk and benefit of different cholesterol-lowering interventions. 1999 , 19, 187-95	167
1816	Gauging the impact of statins using number needed to treat. 1999 , 282, 1899-901	44
1815	Primary prevention of coronary heart disease: integrating risk assessment with intervention. 1999 , 100, 988-98	164
1814	Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. 1999 , 99, 1959-64	230
1813	Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators. 1999 , 99, 216-23	357
1812	Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. 1999 , 99, 3227-33	433
1811	Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators. 1999 , 99, 3241-7	77
1810	Antihypertensives: much ado about lipids. 1999 , 159, 535-7	4
1809	Selective Increase of the Contractile Response to Endothelin-1 in Subcutaneous Arteries from Patients with Essential Hypertension. 1999 , 8, 9-15	8

1808	Concurrent use of simvastatin and estrogen--progestin therapy compared with each therapy alone for hypercholesterolemia in postmenopausal women. 1999 , 2, 181-8	12
1807	Treating patients with hypertriglyceridaemia saves lives: triglyceride revisited. 1999 , 15, 65-77	12
1806	Platelet function and lipid-lowering interventions. 1999 , 10, 357-67	35
1805	3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). 1999 , 274, 21926-31	299
1804	Pharmacotherapy of dyslipidemia in postmenopausal women: weighing the evidence. 1999 , 8, 901-17	1
1803	Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. 1999 , 100, 1481-92	815
1802	Inhibition of arterial thrombus formation by ApoA1 Milano. 1999 , 19, 378-83	126
1801	Lipides et risque cardiovasculaire au cours de l'insuffisance rñale chronique. 1999 , 13, 187-190	0
1800	LDL particle size: an important drug target?. 1999 , 48, 125-33	41
1799	Secondary prevention of coronary heart disease in clinical practice: special considerations for intensified lifestyle modification. 1999 , 29, 365-8	1
1798	Effect of inhibiting HMG-CoA reductase on 7 alpha-hydroxy-4-cholesten-3-one, a marker of bile acid synthesis: contrasting findings in patients with and without prior up-regulation of the latter pathway. 1999 , 29, 404-12	15
1797	Dyslipidaemia and cardiovascular risk in diabetes. 1999 , 1, 189-98	24
1796	Clinical management of diabetic nephropathy. 1999 , 1, 307-15	4
1795	Developing risk stratification charts for diabetic and nondiabetic subjects. 1999 , 16, 219-27	38
1794	Intensive lipid-lowering strategy in patients with diabetes mellitus. 1999 , 16, 500-8	17
1793	Laboratory-based calculation of coronary heart disease risk in a hospital diabetic clinic. 1999 , 16, 697-701	13
1792	Non-lipid properties of statins. 1999 , 24, 3-5	8
1791	Fluvastatin in combination with cyclosporin in renal transplant recipients: a review of clinical and safety experience. 1999 , 24, 397-408	43

1790	Postmarketing studies: benefits and risks. 1999 , 2, 295-307	3
1789	Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke. 1999 , 14, 763-74	26
1788	Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. 1999 , 14, 711-7	97
1787	Review: the oxidant/antioxidant balance during regular low density lipoprotein apheresis. 1999 , 3, 219-26	31
1786	Type 2 diabetes towards the new millennium--the relative importance of glycaemic versus lipid control. 1999 , 29, 249-53	
1785	Evaluation of the effects of a new fermented milk product (Gaio) on primary hypercholesterolemia. 1999 , 53, 97-101	78
1784	What nutrition knowledge and skills do primary care physicians need to have, and how should this be communicated?. 1999 , 53 Suppl 2, S67-71	12
1783	Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. 1999 , 13, 569-92	455
1782	Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca ²⁺ signalling and insulin secretion due to blockade of L-type Ca ²⁺ channels in rat islet beta-cells. 1999 , 126, 1205-13	176
1781	Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. 1999 , 65, 439-47	86
1780	[When statins alone are insufficient for lowering lipid levels. Efficacy and risks of lipid lowering combination therapies, in particular, that of statin-fibrate combination]. 1999 , 40, 1338-45	
1779	[Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease. Results from the Lipid-Coronary Artery Disease (L-CAD) Study]. 1999 , 88, 582-90	5
1778	Advances in the medical management of acute coronary syndromes. 1999 , 7, 171-89	7
1777	Platelet PLA ₂ polymorphism and thromboembolic events: from inherited risk to pharmacogenetics. 1999 , 8, 89-103	12
1776	The importance of randomized clinical trials and evidence-based medicine: a clinician's perspective. 1999 , 22, 6-12	16
1775	Diabetes epidemiology as a tool to trigger diabetes research and care. 1999 , 42, 499-518	190
1774	[Ambulatory cardiac phase II rehabilitation--"the Cologne model"--including 3-year-outcome after termination of rehabilitation]. 1999 , 24 Suppl 1, 9-23	7
1773	[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]. 1999 , 24, 3-12	2

1772	[Therapy with CSE inhibitors--more than lipid lowering?]. 1999 , 24, 42-50		1
1771	Lipid lowering and beyond: results from the CARE study on lipoproteins and inflammation. Cholesterol and Recurrent Events. 1999 , 24, 51-6		18
1770	[Regulation of endothelial NO production by Rho GTPase]. 1999 , 94, 211-8		17
1769	Carotid artery stenting: rationale, indications, and results. <i>Comprehensive Therapy</i> , 1999 , 25, 438-45		30
1768	Dietary fatty acids and coronary heart disease. 1999 , 34 Suppl, S19-22		24
1767	[Primary and secondary prevention of coronary heart disease: what can we afford?]. 1999 , 88, 85-9		1
1766	Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells. 1999 , 94, 322-32		47
1765	The Best + ICD Trial. 1999 , 10, S015-S022		
1764	Prevention of cardiovascular events in elderly hypercholesterolemic patients. 1999 , 1, 9-15		2
1763	Combination drug therapy for dyslipidemia. 1999 , 1, 44-9		8
1762	Effect of lipid-lowering therapy on vasomotion and endothelial function. 1999 , 1, 238-43		11
1761	The Hypertension Optimal Treatment Study: what did it give us?. 1999 , 1, 337-41		3
1760	Ischemic Stroke Prevention. 1999 , 1, 113-126		3
1759	Interpreting meta-analyses of pharmacologic interventions: the pitfalls and how to identify them. 1999 , 19, 741-5		
1758	New insights into the pharmacodynamic and pharmacokinetic properties of statins. 1999 , 84, 413-28		592
1757	Economic evaluation in the field of cardiology: theory and practice. 1999 , 42, 167-73		9
1756	Prognostic utility of myocardial viability assessment. <i>American Journal of Cardiology</i> , 1999 , 83, 696-702, A7	3	31
1755	Which strategy is "best" after myocardial infarction? The Beta-blocker Strategy plus Implantable Cardioverter Defibrillator Trial: rationale and study design. <i>American Journal of Cardiology</i> , 1999 , 83, 104D-111D	3	21

1754	Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. <i>American Journal of Cardiology</i> , 1999 , 83, 852-6	3	122
1753	Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. <i>American Journal of Cardiology</i> , 1999 , 83, 1303-7	3	221
1752	Age as a risk factor: you are as old as your arteries. <i>American Journal of Cardiology</i> , 1999 , 83, 1455-7, A7	3	72
1751	Diabetes, hyperlipidemia, and coronary artery disease. <i>American Journal of Cardiology</i> , 1999 , 83, 17F-21F ₃		73
1750	Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease. <i>American Journal of Cardiology</i> , 1999 , 83, 3F-12F	3	385
1749	Future cardiovascular end point studies: where will the research take us?. <i>American Journal of Cardiology</i> , 1999 , 84, 454-8	3	5
1748	Association of lipids and lipoprotein level with total mortality and mortality caused by cardiovascular and cancer diseases (Poland and United States collaborative study on cardiovascular epidemiology). <i>American Journal of Cardiology</i> , 1999 , 84, 540-8	3	24
1747	The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. <i>American Journal of Cardiology</i> , 1999 , 84, 1192-7	3	243
1746	Sudden cardiac death. 1999 , 24, 461-538		10
1745	The secondary prevention of myocardial infarction. 1999 , 24, 617-77		2
1744	Diagnosis and management of patients with unstable angina. 1999 , 24, 681-744		8
1743	The diabetic patient as paradigm for selective antihypertensive therapy. 1999 , 2, 1-12		9
1742	A vaccine approach to healthy lipoprotein levels. 1999 , 5, 281		1
1741	Glycemic control and cardiovascular disease in type 2 diabetes: a review. 1999 , 15, 197-204		13
1740	Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. 1999 , 74, 243-52		659
1739	Screening for cardiovascular disease. Concepts, conflicts, and consensus. 1999 , 83, 1339-73		3
1738	Cholesterol and long-term mortality after acute myocardial infarction in elderly patients. 1999 , 28, 313-5		2
1737	The health care burden of unstable angina. 1999 , 17, 247-61		7

1736	The treatment of hypertension and dyslipidemia in diabetes mellitus. 1999 , 26, 951-64	3
1735	Neuroprotective properties of statins in cerebral ischemia and stroke. 1999 , 30, 1969-73	312
1734	Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP): a randomized trial design of the effect of a community pharmacist intervention program on serum cholesterol risk. 1999 , 33, 910-9	45
1733	Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. 1999 , 15, 47-74	60
1732	Reconciling decision models with the real world. An application to anaemia of renal failure. 1999 , 15, 481-93	1
1731	1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. 1999 , 21, 1009-60	410
1730	Efficacy and safety of cerivastatin, 0.2 mg and 0.4 mg, in patients with primary hypercholesterolaemia: a multinational, randomised, double-blind study. Cerivastatin Study Group. 1999 , 15, 228-40	21
1729	Vegetarian diet: panacea for modern lifestyle diseases?. 1999 , 92, 531-44	63
1728	A middle-aged man presents with nephrotic syndrome and hyperlipidaemia. 1999 , 3, 153-158	
1727	Lipid management in ischaemic heart disease. 1999 , 3, 62-66	1
1726	How many patients with coronary heart disease and normal serum total cholesterol are at increased risk of further events because of low serum high-density lipoprotein cholesterol?. 1999 , 3, 38-42	
1725	Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia. 1999 , 10, 33-39	5
1724	Prevention of mortality from coronary heart disease with pravastatin. 1999 , 53, 405-8	
1723	Quality measurement issues in heart disease in women. 1999 , 9, 241-8; discussion 248-9	
1722	Effects of growth hormone on hepatic cholesterol metabolism. Lessons from studies in rats and humans. 1999 , 9 Suppl A, 1-7	10
1721	Lipid-lowering medication and risk of cancer. 1999 , 52, 167-9	29
1720	Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. 1999 , 12, 673-81	58
1719	Pharmacological profile of survivors of acute myocardial infarction at Turkish academic hospitals. 1999 , 68, 309-16	7

1718	Statin + fibrate combination therapy fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease. 1999 , 69, 237-44	48
1717	Hormone replacement therapy and lipid-lipoprotein concentrations. 1999 , 85, 31-41	17
1716	Clinical efficacy of raloxifene in postmenopausal women. 1999 , 85, 43-6	7
1715	Gambling with cardiovascular risk: picking the winners and the losers. 1999 , 353, 254-5	8
1714	Better coronary risk assessment in women. 1999 , 353, 1637-8	6
1713	Indications for cholesterol-lowering medication: comparison of risk-assessment methods. 1999 , 353, 278-81	74
1712	Clinical trials, consensus conferences, and clinical practice. 1999 , 354, 327-30	40
1711	Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. 1999 , 354, 1234-41	474
1710	Current and novel pharmacologic approaches in advanced heart failure. 1999 , 28, 227-42	1
1709	Changes in cholesterol levels in women after coronary artery bypass surgery. 1999 , 28, 270-5	3
1708	Effectiveness of antihyperlipidemic drug management in clinical practice. 1999 , 21, 1973-87	9
1707	Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy. 1999 , 21, 218-35	2
1706	Use of a tiered review for evaluation of appropriate use of hydroxymethylglutaryl coenzyme A reductase-inhibitor therapy. 1999 , 21, 422-9	1
1705	A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. 1999 , 21, 536-62	24
1704	Double-masked comparison of the quality of life of hypercholesterolemic men treated with simvastatin or pravastatin. International Quality of Life Multicenter Group. 1999 , 21, 1758-70	5
1703	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. 1999 , 100, 1134-46	1470
1702	Hyperglycemia and cardiovascular disease in type 2 diabetes. 1999 , 48, 937-42	560
1701	Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. 1999 , 33, 234-41	304

1700	Influence of baseline lipids on effectiveness of pravastatin in the CARE Trial. Cholesterol And Recurrent Events. 1999 , 33, 125-30	73
1699	Quantity and function of high density lipoprotein as an indicator of coronary atherosclerosis. 1999 , 33, 436-43	52
1698	The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged menAppendix. 1999 , 33, 909-915	9
1697	Lipids and vascular disease: what we do and do not know. 1999 , 286, 7-22	5
1696	A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk. 1999 , 60, 379-391	26
1695	Synthesis and in vitro biological activity of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha,12 alpha-diol, a 12alpha-hydroxyl analog of 4alpha-(2-propenyl)-5alpha-cholest-24-en-3alpha-ol: the latter is a potent activator of the low-density lipoprotein receptor promoter. 1999 , 64, 735-41	2
1694	Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. 1999 , 65, 1329-37	85
1693	Low-density lipoprotein particle size and coronary artery disease in a childhood-onset type 1 diabetes population. 1999 , 48, 531-4	20
1692	Combined effect of vegetable protein (soy) and soluble fiber added to a standard cholesterol-lowering diet. 1999 , 48, 809-16	46
1691	Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac. 1999 , 117, 838-47	170
1690	Imaging of coronary artery calcification. Its importance in assessing atherosclerotic disease. 1999 , 37, 257-72, v	27
1689	Thrombosis and coagulation abnormalities in the acute coronary syndromes. 1999 , 17, 283-94, viii	13
1688	Defining and measuring quality of diabetes care. 1999 , 26, 841-55	10
1687	Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: importance of diet, exercise, weight control, and drug therapy. 1999 , 74, 466-73	14
1686	Improving the adverse cardiovascular prognosis of type 2 diabetes. 1999 , 74, 171-80	68
1685	Heart failure. 1999 , 17, 123-35	27
1684	Cardiac rehabilitation and preventive cardiology in the elderly. 1999 , 17, 233-42	11
1683	Fluvastatin: a review of its use in lipid disorders. 1999 , 57, 583-606	50

1682	Selective estrogen receptor modulators: a look ahead. 1999 , 57, 653-63		95
1681	How to use calcium antagonists in hypertension: putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. 1999 , 58, 579-87		13
1680	A Pooled Efficacy Analysis of Cerivastatin in the Treatment of Primary Hyperlipidaemia. 1999 , 18, 433-444		9
1679	Drug treatment of lipid disorders. <i>New England Journal of Medicine</i> , 1999 , 341, 498-511	59.2	718
1678	Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. 1999 , 33, 1294-304		164
1677	The anti-thrombotic effects of statins. 1999 , 33, 1305-7		52
1676	Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia. 1999 , 33, 1286-93		112
1675	The Framingham Offspring Study: a commentary. 1980. 1999 , 33, 1136-40		6
1674	Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators. 1999 , 34, 106-12		82
1673	ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). 1999 , 33, 2092-197		482
1672	How much to lower serum cholesterol: is it the wrong question?. 1999 , 34, 289-92		4
1671	The relative influence of secondary versus primary prevention using the National Cholesterol Education Program Adult Treatment Panel II guidelines. 1999 , 34, 768-76		24
1670	Arterial remodeling in the left coronary system: the role of high-density lipoprotein cholesterol. 1999 , 34, 760-7		49
1669	AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. 1999 , 34, 1348-59		319
1668	Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. 1999 , 142, 105-112		323
1667	Analysis of serum lipid levels in Japanese men and women according to body mass index. Increase in risk of atherosclerosis in postmenopausal women. Research Group on Serum Lipid Survey 1990 in Japan. 1999 , 143, 55-73		36
1666	Heart rate variability and plasma lipids in men with and without ischaemic heart disease. 1999 , 145, 181-6		45
1665	Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. 1999 , 144, 177-84		95

1664	Atherogenicity of lipoprotein(a) and oxidized low density lipoprotein: insight from in vivo studies of arterial wall influx, degradation and efflux. 1999 , 143, 229-43	80
1663	Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma. 1999 , 145, 405-13	21
1662	Best practice--ongoing polemics. 1999 , 143 Suppl 1, S3-6	3
1661	The future of best practice. 1999 , 143 Suppl 1, S17-21	34
1660	Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?. 1999 , 145, 1-15	29
1659	HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease. 1999 , 147, 237-42	91
1658	Editorial. 1999 , 147, S1-S2	
1657	Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. 1999 , 147 Suppl 1, S3-10	41
1656	Beyond lipids - the role of the endothelium in coronary artery disease. 1999 , 147 Suppl 1, S11-6	33
1655	Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events. 1999 , 147 Suppl 1, S17-21	13
1654	'Fire and forget?' - pharmacological considerations in coronary care. 1999 , 147 Suppl 1, S23-30	15
1653	The therapeutic gap--compliance with medication and guidelines. 1999 , 147 Suppl 1, S31-7	21
1652	After 4S, CARE and LIPID--is evidence-based medicine being practised?. 1999 , 147 Suppl 1, S39-44	18
1651	From best evidence to best practice - what are the obstacles?. 1999 , 147 Suppl 1, S45-51	11
1650	Diabetic dyslipidaemia. 1999 , 13, 265-78	19
1649	Diabetes and myocardial infarction. 1999 , 13, 331-43	1
1648	Diabetes and ischemic heart disease. 1999 , 138, S366-75	28
1647	Atherosclerotic disease in non-insulin-dependent diabetes mellitus: role of abnormal lipids and the place for lipid-altering therapies. 1999 , 138, S406-12	2

1646	WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics. 1999 , 138, S542-4	24
1645	Statin trials and goals of cholesterol-lowering therapy after AMI. 1999 , 138, S177-82	22
1644	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Comparative economic data regarding lipid-lowering drugs. 1999 , 137, S97-104	5
1643	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective. 1999 , 137, S105-10	4
1642	Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective. 1999 , 137, S111-4	1
1641	Primary prevention of coronary heart disease: selection of patients for aggressive cholesterol management. 1999 , 107, 2S-6S	4
1640	Assessment for subclinical ischemia: bridging the gap between primary and secondary prevention. 1999 , 107, 28S-30S	18
1639	Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). 1999 , 107, 36S-39S	12
1638	Patients with type 2 diabetes: the case for primary prevention. 1999 , 107, 43S-45S	5
1637	Cholesterol lowering and endothelial function. 1999 , 107, 479-87	109
1636	Low density lipoprotein (LDL)-mediated suppression of Lewis lung carcinoma in hypercholesterolemic LDL receptor-deficient mice. 1999 , 255, 377-81	3
1635	Cancer and low levels of plasma cholesterol: the relevance of cholesterol precursors and products to incidence of cancer. 1999 , 29, 383-90	15
1634	The Epidemiology of Cardiovascular Disease in Postmenopausal Women. 1999 , 84, 1803-1806	15
1633	New perspectives on the management of low levels of high-density lipoprotein cholesterol. 1999 , 159, 1049-57	49
1632	Factors associated with implementation of preventive care measures in patients with diabetes mellitus. 1999 , 159, 294-302	56
1631	Health Promoting Medications in Older People. 1999 , 29, 273-278	1
1630	Lisinopril improves arterial function in hyperlipidaemia. 1999 , 96, 441-448	17
1629	Lisinopril improves arterial function in hyperlipidaemia. 1999 , 96, 441	2

1628	A simple computer program for guiding management of cardiovascular risk factors and prescribing. 1999 , 318, 101-5	76
1627	Cholesterol-lowering effects of dietary fiber: a meta-analysis. 1999 , 69, 30-42	1233
1626	Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement. 1999 , 69, 231-6	376
1625	Evidence-based secondary prevention after myocardial infarction. 1999 , 54, 293-8	
1624	Will Aging Baby Boomers Bust the Federal Budget?. 1999 , 13, 117-140	49
1623	Achieving National Cholesterol Education Program Goals for Low-Density Lipoprotein Cholesterol in Cardiac Patients:Importance of Diet, Exercise, Weight Control, and Drug Therapy. 1999 , 74, 466-473	40
1622	The proving of the lipid hypothesis. 1999 , 10, 201-5	8
1621	Does the Intervention of Identifying Homeless Clients Who Should Receive Lipid Altering Therapy Decrease the Occurrence of Cardiovascular Events?. 1999 , 12, 166-169	
1620	Fibrates, dyslipoproteinaemia and cardiovascular disease. 1999 , 10, 561-74	110
1619	Less heat, more light. 1999 , 10, 219-23	2
1618	Preventing ischemic stroke in patients with prior stroke and transient ischemic attack : a statement for healthcare professionals from the Stroke Council of the American Heart Association. 1999 , 30, 1991-4	285
1617	1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 17, 151-183	467
1616	Low-density lipoprotein-cholesterol determines vascular responsiveness to angiotensin II in normocholesterolaemic humans. 1999 , 17, 1933-9	16
1615	Cholesterol and stroke. 1999 , 9, 1-12	2
1614	Coronary artery disease in the elderly. 1999 , 9, 13-21	2
1613	Hypertension in the elderly. 1999 , 9, 39-54	
1612	A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial. 1999 , 20, 58-69	170
1611	Underutilization of cardiac medications in the Pacemaker Selection in the Elderly study. 1999 , 47, 252-5	1

1610	AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. 1999 , 30, 2502-11	135
1609	1999 World Health Organization International Society of Hypertension Guidelines for the Management of Hypertension. 1999 , 8, 9-43	42
1608	Hyperlipidaemia management after primary coronary artery bypass surgery: a survey of patients and general practitioners. 1999 , 6, 263-7	4
1607	Managing dyslipidemia in older adults. 1999 , 47, 1458-65	17
1606	Implication of recent trials with b-hydroxy-b-methylglutaryl coenzyme A reductase inhibitors for hypertension management. 1999 , 17, 1641-6	1
1605	Modification of coronary artery disease progression by cholesterol-lowering therapy: the angiographic studies. 1999 , 10, 527-34	10
1604	Dyslipidemia and atherosclerosis: how much more evidence do we need?. 1999 , 10, 383-6	4
1603	Effects of statins on carotid disease and stroke. 1999 , 10, 535-41	5
1602	Nutrition. 1999 , 10, 1-2	
1601	Clinical lipidology at the end of the millennium. 1999 , 10, 521-6	14
1600	Genetics and molecular biology. 1999 , 10, 627-630	
1599	Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation. 1999 , 39, 111-8	35
1598	Prevalence and phenotypic distribution of dyslipidemia in type 1 diabetes mellitus: effect of glycemic control. 2000 , 160, 2756-62	49
1597	Treatment of hyperlipidemia. 2000 , 39, 765-72	2
1596	Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. 2000 , 132, 769-79	148
1595	"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?. 2000 , 133, 549-54	32
1594	Quality improvement initiative and its impact on the management of patients with acute myocardial infarction. 2000 , 160, 3057-62	47
1593	Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. 2000 , 133, 111-22	180

1592	Ten year audit of secondary prevention in coronary bypass patients. 2000 , 321, 22-3	11
1591	Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. 2000 , 132, 780-7	66
1590	Improving diabetes care in a large health care system: an enhanced primary care approach. 2000 , 26, 615-22	51
1589	Risk factors and stroke prevention. European Stroke Initiative (EUSI). 2000 , 10 Suppl 3, 12-21	38
1588	Cholesterol reduction and stroke occurrence: an overview of randomized clinical trials. 2000 , 10, 85-92	79
1587	The Role of Non-High-Density Lipoprotein-Cholesterol in Evaluation and Treatment of Lipid Disorders. 2000 , 85, 2105-2108	
1586	Risk factors for non-fatal acute myocardial infarction in middle-aged and older Japanese. Fukuoka Heart Study Group. 2000 , 64, 103-9	29
1585	Using cost-effectiveness analysis to target cholesterol reduction. 2000 , 132, 833-5	7
1584	[Strategy for primary prevention of coronary heart disease based on results of health check-up]. 2000 , 42, 81-7	0
1583	Statins: where are we now?. 2000 , 61, 789-92	1
1582	Cholesterol lowering with pravastatin improves resistance artery endothelial function: report of six subjects with normal coronary arteriograms. 2000 , 118, 756-60	21
1581	Should antibiotics now be part of routine treatment of coronary heart disease?. 2000 , 45, 163-6	
1580	Effects of Fluvastatin and Bezafibrate Combination on Plasma Fibrinogen, t-plasminogen Activator Inhibitor and C Reactive Protein Levels in Coronary Artery Disease Patients with Mixed Hyperlipidaemia (FACT Study). 2000 , 83, 549-553	49
1579	Lipoprotein(a), other lipoproteins and hemostatic profiles in patients with ischemic stroke: the relation to cardiogenic embolism. 2000 , 10, 110-7	24
1578	Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. 2000 , 321, 1322-5	109
1577	Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter?. 2000 , 102, 820-2	23
1576	Lipid-lowering drug therapy: more knowledge leads to more problems for composers of guidelines. 2000 , 11, 345-9	1
1575	Effects of Menopause and Estrogen Replacement Therapy or Hormone Replacement Therapy in Women With Diabetes Mellitus. 2000 , 7, 87-95	31

1574	EPIDEMIOLOGIC DATA IN CLINICAL PRACTICE. 2000 , 48, 1157-1162	32
1573	Is hypercholesterolemia a risk factor and should it be treated in the elderly?. 2000 , 14, 347-56	11
1572	Hyperlipidaemia and primary prevention of coronary heart disease: are the right patients being treated?. 2000 , 7, 245-9	6
1571	Therapy and clinical trials. 2000 , 11, 671-3	
1570	Pharmaceutical care services and results in project ImPACT: hyperlipidemia. 2000 , 40, 157-65	158
1569	The Comorbidity Symptom Scale: a combined disease inventory and assessment of symptom severity. 2000 , 48, 1674-8	33
1568	Cardiovascular Drugs. 2000 ,	
1567	Therapy and clinical trials. 2000 , 11, 223-5	
1566	Lipid lowering and coronary bypass graft surgery. 2000 , 15, 395-9	24
1565	Thiazolidinediones, dyslipidaemia and insulin resistance syndrome. 2000 , 11, 397-402	20
1564	Debate: at what level of coronary heart disease risk should a statin be prescribed?. 2000 , 11, 357-61	6
1563	Dyslipidemia in women with diabetes. 2000 , 7, 38-43	
1562	Pravastatin treatment of very low density, intermediate density and low density lipoproteins in hypercholesterolemia and combined hyperlipidemia secondary to the nephrotic syndrome. 2000 , 20, 12-7	10
1561	Cost-effectiveness of statins. 2000 , 11, 351-6	6
1560	At what level of coronary heart disease risk should a statin be prescribed?. 2000 , 11, 363-7	7
1559	Therapeutic approaches to reducing the LDL- and HDL-associated risks of coronary heart disease. 2000 , 11, 567-70	4
1558	Therapeutic modulation of low-density lipoprotein size. 2000 , 11, 597-602	11
1557	The past, the present and the future o oestrogen and progestogen therapy for cardiovascular disease in postmenopausal women. 2000 , 6, 9-14	

1556	Do statins and hormonal replacement therapy in combination reduce cardiovascular risk in postmenopausal women?. 2000 , 21, 178-80	2
1555	Improved long-term prognosis for patients with unstable coronary syndromes 1988-1995. 2000 , 21, 533-9	16
1554	Microinflammatory state in CRI, PD-/HD-patients. 2000 , 15, 149-154	1
1553	Lipid-lowering drug therapies: the evidence. 2000 , 59, 423-4	
1552	Alpha calculus in clinical trials: considerations and commentary for the new millennium. 2000 , 19, 767-79	51
1551	MANAGING DYSLIPIDAEMIA IN TYPE 2 DIABETES IN PRIMARY CARE. 2000 , 17, S1-S8	1
1550	High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. 2000 , 33, 601-10	67
1549	Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market. 2000 , 3, 181-5	1
1548	Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies. 2000 , 4, 213-7	16
1547	Diabetes and vascular disease. 2000 , 2 Suppl 2, S1-5	5
1546	Vascular disease prevention in patients with diabetes. 2000 , 2 Suppl 2, S25-36	5
1545	Case presentations--challenging problems in the management of type 2 diabetes. 2000 , 2 Suppl 1, S49-55	
1544	Diabetic dyslipidaemia. 2000 , 2 Suppl 1, S31-6	34
1543	Regulation of the angiotensin AT1 receptor by hypercholesterolaemia. 2000 , 2, 223-8	14
1542	Ethnicity and risk factors for coronary heart disease in diabetes mellitus. 2000 , 2, 91-7	26
1541	Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough?. 2000 , 2, 263-70	2
1540	Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia. 2000 , 2, 355-62	38
1539	Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45). UK Prospective Diabetes Study Group. 2000 , 17, 518-23	50

1538	Diabetes and lipids--a conundrum. 2000 , 17, 623-4	4
1537	Drugs used in secondary prevention after myocardial infarction: case presentation. 2000 , 50, 405-17	3
1536	Acute effect of H.E.L.P. treatment on radical scavenging enzyme activities, total glutathione concentrations in granulocytes, and selenium in plasma. 2000 , 30, 26-32	12
1535	The effect of apolipoprotein B xbal polymorphism on plasma lipid response to dietary fat. 2000 , 30, 678-84	11
1534	Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. 2000 , 247, 563-9	77
1533	The EWA (estrogen in women with atherosclerosis) study: a randomized study of the use of hormone replacement therapy in women with angiographically verified coronary artery disease. Characteristics of the study population. Effects on lipids and lipoproteins. 2000 , 247, 433-41	22
1532	Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. 2000 , 15, 871-9	27
1531	Are statins anti-inflammatory?. 2000 , 1, 161-165	69
1530	Microvascular complications of diabetes: the role of angiotensin converting enzyme inhibitors. Proceedings of a Round Table Meeting, June 1999, San Diego, USA. 2000 , 17, S1-S12	
1529	The Heart and Estrogen/Progestin Replacement Study (HERS) in perspective [Results not very surprising. 2000 , 79, 1037-1041	1
1528	Endothelial nitric oxide synthase-dependent cerebral blood flow augmentation by L-arginine after chronic statin treatment. 2000 , 20, 709-17	123
1527	The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. 2000 , 6, 1004-10	1230
1526	Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. 2000 , 129, 1748-54	242
1525	Mechanisms underlying the chronic pravastatin treatment-induced improvement in the impaired endothelium-dependent aortic relaxation seen in streptozotocin-induced diabetic rats. 2000 , 131, 231-8	64
1524	The influence of cholesterol on mortality after transplantation is age dependent. 2000 , 13, S117-S119	1
1523	Progress in Interventional Cardiology. 2000 , 13, 73-76	
1522	Plant Stanol/Sterol Ester-Containing Foods and Cardiovascular Disease Risk. 2000 , 3, 274-278	5
1521	Direct vascular effects of HMG-CoA reductase inhibitors. 2000 , 10, 143-8	128

1520	Obesity and cardiovascular disease. Pathogenetic role of the metabolic syndrome and therapeutic implications. 2000 , 14, 154-74		100
1519	Modern management of acute myocardial infarction. 2000 , 25, 677-782		8
1518	Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms. 2000 , 182, 545-52		59
1517	Hormone replacement therapy should not be used as secondary prevention of coronary heart disease. 2000 , 20, 1021-7		2
1516	Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals. 2000 , 20, 1375-83		61
1515	The low-density lipoprotein cholesterol-lowering effect of pravastatin and factors associated with achieving targeted low-density lipoprotein levels in an African-American population. 2000 , 20, 1454-63		5
1514	Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. 2000 , 20, 1508-16		103
1513	Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: a randomized, controlled trial. 2000 , 20, 410-6		89
1512	Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. 2000 , 20, 819-22		17
1511	Recent advances in cardiovascular pharmacology. 2000 , 25, 227-95		1
1510	A novel telephone-based system for management of secondary prevention to a low-density lipoprotein cholesterol American Journal of Cardiology, 2000 , 85, 305-8	3	35
1509	Raising low levels of high-density lipoprotein cholesterol is an important target of therapy. <i>American Journal of Cardiology</i> , 2000 , 85, 645-50, A10	3	46
1508	Effect of statin therapy on restenosis after coronary stent implantation. <i>American Journal of Cardiology</i> , 2000 , 85, 962-8	3	133
1507	Cholesterol management in the era of managed care. <i>American Journal of Cardiology</i> , 2000 , 85, 3A-9A	3	13
1506	Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles. <i>American Journal of Cardiology</i> , 2000 , 85, 10A-17A	3	58
1505	Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative. <i>American Journal of Cardiology</i> , 2000 , 85, 23A-29A	3	13
1504	Strategies for implementing lipid-lowering therapy: pharmacy-based approach. <i>American Journal of Cardiology</i> , 2000 , 85, 30A-35A	3	21
1503	Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience). <i>American Journal of Cardiology</i> , 2000 , 85, 36A-42A	3	28

1502 Over-the-counter statin medications: emerging opportunities for RDs.. **2000**, 100, 1126, 1128,1130

1501 Post-hospitalization management of high-risk coronary patients. *American Journal of Cardiology*, **2000**, 85, 13B-20B 3 116

1500 Management of coronary risk factors by registered nurses versus usual care in patients with unstable angina pectoris (a chest pain evaluation in the emergency room [CHEER] substudy). *American Journal of Cardiology*, **2000**, 86, 133-8 3 46

1499 Aggressive Lipid-Lowering Initiation Abates New Cardiac Events (ALLIANCE)-rationale and design of atorvastatin versus usual care in hypercholesterolemic patients with coronary artery disease. *American Journal of Cardiology*, **2000**, 86, 250-2 3 18

1498 Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. *American Journal of Cardiology*, **2000**, 86, 257-62 3 227

1497 Effects of age, sex, race, diagnosis-related group, and hospital setting on lipid management in patients with coronary artery disease. *American Journal of Cardiology*, **2000**, 86, 328-30 3 11

1496 Bridging the treatment gap. *American Journal of Cardiology*, **2000**, 85, 3E-7E 3 74

1495 Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population. *American Journal of Cardiology*, **2000**, 85, 8E-14E 3 50

1494 Population benefits of cholesterol reduction: epidemiology, economics, and ethics. *American Journal of Cardiology*, **2000**, 85, 20E-3E 3 28

1493 Cholesterol lowering in atherosclerosis. *American Journal of Cardiology*, **2000**, 86, 29H-32H 3 15

1492 Estrogen and atherothrombosis. *American Journal of Cardiology*, **2000**, 86, 482-3 3

1491 Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors. *American Journal of Cardiology*, **2000**, 86, 1123-7 3 15

1490 Role of plaque rupture in acute coronary syndromes. *American Journal of Cardiology*, **2000**, 86, 15J-23J 3 14

1489 Usefulness of brachial artery reactivity to isometric handgrip exercise in identifying patients at risk and with coronary artery disease. *American Journal of Cardiology*, **2000**, 86, 1161-5 3 6

1488 Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. *American Journal of Cardiology*, **2000**, 86, 1176-81 3 31

1487 Lipid treatment goals achieved in patients treated with statin drugs in Norwegian general practice. *American Journal of Cardiology*, **2000**, 86, 1250-3, A6 3 24

1486 Improvement in endothelium-dependent brachial artery flow-mediated vasodilation with low-density lipoprotein cholesterol levels. *American Journal of Cardiology*, **2000**, 86, 1256-9, A6 3 22

1485 Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?. *American Journal of Cardiology*, **2000**, 86, 35J-42J; discussion 42J-43J 3 4

1484	Exploring new strategies for the management of acute coronary syndromes. <i>American Journal of Cardiology</i> , 2000 , 86, 44J-49J; discussion 49J-50J	3	12
1483	Beneficial effects of pravastatin (+/-colestyramine/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study). <i>American Journal of Cardiology</i> , 2000 , 86, 1293-8	3	122
1482	Coronary artery injury and the biology of atherosclerosis: inflammation, thrombosis, and stabilization. <i>American Journal of Cardiology</i> , 2000 , 86, 3J-8J; discussion 8J-9J	3	166
1481	Medical therapy of unstable angina and non-Q-wave myocardial infarction. <i>American Journal of Cardiology</i> , 2000 , 86, 24J-33J; discussion 33J-34J	3	11
1480	Raising high-density lipoprotein cholesterol and lowering low-density lipoprotein cholesterol as adjunctive therapy to coronary artery revascularization. <i>American Journal of Cardiology</i> , 2000 , 86, 28L-34L		6
1479	Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. 2000 , 63, 225-34		43
1478	Is it advantageous to lower cholesterol in the elderly hypertensive?. 2000 , 14, 397-405		19
1477	The interpretation and clinical application of data from trials on sudden cardiac death. 2000 , 4 Suppl 1, 95-102		2
1476	Antiarrhythmic Impact of Anti-Ischemic, Anti-Failure and Other Cardiovascular Strategies. 2000 , 4, 194-205		2
1475	Growth in use of statins after trials is not targeted to most appropriate patients. 2000 , 67, 438-41		30
1474	Mortality, risk indicators for death, and mode of death in younger and elderly patients during five years after coronary artery bypass graft. 2000 , 23, 421-6		4
1473	Overview of the relationship between ischemia and congestive heart failure. 2000 , 23, IV4-8		25
1472	Beyond cholesterol lowering: deciphering the benefits of dietary intervention on cardiovascular diseases. 2000 , 2, 461-6		5
1471	Percutaneous coronary intervention versus medical therapy for coronary heart disease. 2000 , 2, 290-6		5
1470	Treating ambulatory ischemia in coronary disease by manipulating the cell biology of atherosclerosis. 2000 , 2, 321-6		4
1469	Lipid modulation and atherosclerotic events: extending the clinical spectrum with fibrates and statins. 2000 , 2, 11-3		1
1468	Do pleiotropic effects of statins beyond lipid alterations exist in vivo? What are they and how do they differ between statins?. 2000 , 2, 20-5		18
1467	Re-emergence of fibrates in the management of dyslipidemia and cardiovascular risk. 2000 , 2, 29-35		38

1466	Basic mechanisms of stroke prevention with lipid-lowering therapy. 2000 , 2, 120-5	2
1465	Benefits of lipid-lowering agents in stroke and coronary heart disease: pharmacoeconomics. 2000 , 2, 144-50	4
1464	Implications of the atorvastatin versus revascularization treatment (AVERT) study for the clinician. 2000 , 2, 433-8	3
1463	The role of fibric acid derivatives in the secondary prevention of coronary heart disease. 2000 , 2, 452-8	4
1462	Are statins anti-inflammatory? Issues in the design and conduct of the pravastatin inflammation C-reactive protein evaluation. 2000 , 2, 269-73	15
1461	Hypercholesterolemia and Dyslipidemia. 2000 , 2, 173-187	7
1460	Transient Ischemic Attack and Secondary Stroke. 2000 , 2, 329-342	
1459	The dietary prevention and treatment of coronary heart disease in the new millennium. <i>Comprehensive Therapy</i> , 2000 , 26, 276-82	1
1458	Non lipid, dose-dependent effects of pravastatin treatment on hemostatic system and inflammatory response. 2000 , 56, 277-84	27
1457	The influence of cholesterol on mortality after transplantation is age dependent. 2000 , 13 Suppl 1, S117-9	
1456	[Primary prevention of sporadic colorectal carcinoma by diet modification and drugs?]. 2000 , 41, 868-75	8
1455	HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering?. 2000 , 25, 117-25	22
1454	[Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial]. 2000 , 25, 487-94	5
1453	[Cost-benefit analysis of an evidence-based secondary prevention of coronary heart diseases by statins. An analysis for Germany from a social security perspective]. 2000 , 95, 305-13	5
1452	Current concepts in secondary prevention after acute myocardial infarction. 2000 , 25, 47-60	3
1451	The potential for drug interactions with statin therapy in Ireland. 2000 , 169, 176-9	30
1450	Physiologic and related behavioral outcomes from the Women's Lifestyle Heart Trial. 2000 , 22, 1-9	95
1449	Role of platelets in tissue factor expression by monocytes in normal and hypercholesterolemic subjects. In vitro effect of cerivastatin. 2000 , 30, 147-56	26

1448	[Recommendations of the International Cardiology Forum (ICF) 1998 on revision of the current guidelines for the diagnosis and treatment of unstable angina pectoris and nontransmural myocardial infarct]. 2000 , 89, 706-21	2
1447	Prevention of recurrent stroke. 2000 , 21, 67-72	29
1446	Cholesterol and strokes. Cholesterol lowering is indicated for strokes due to carotid atheroma. 2000 , 320, 459-60	21
1445	Analytical and Clinical Performance of a Detergent-based Homogeneous LDL-Cholesterol Assay: A Multicenter Evaluation. 2000 , 46, 506-514	52
1444	Major and Minor Risk Factors for Cardiovascular Disease in Peritoneal Dialysis. 2000 , 20, 154-159	11
1443	Indications for Treatment of Asymptomatic Carotid Stenosis. 2000 , 11, 247-264	2
1442	Was ist gesichert in der Diagnostik, Therapie und Prophylaxe zerebraler Ischämien?. 2000 , 20, 70-76	1
1441	Long-term assessment of psychological well-being in a randomized placebo-controlled trial of cholesterol reduction with pravastatin. The LIPID Study Investigators. 2000 , 160, 3144-52	64
1440	Dietary fat and adult diseases and the implications for childhood nutrition: an epidemiologic approach. 2000 , 72, 1291S-1296S	65
1439	Twenty questions on atherosclerosis. 2000 , 13, 139-43	7
1438	Hypertriglyceridemia and Coronary Heart Disease. 2000 , 85, 2098-2105	10
1437	Fluvastatin Inhibits Basal and Stimulated Plasminogen Activator Inhibitor 1, but Induces Tissue Type Plasminogen Activator in Cultured Human Endothelial Cells. 2000 , 84, 59-64	50
1436	Effects of continuous estrogen and estrogen-progestin replacement regimens on cardiovascular risk markers in postmenopausal women. 2000 , 160, 3315-25	66
1435	Pravastatin, blood pressure, and stroke. 2000 , 36, E1-2	3
1434	Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial. 2000 , 21, 1029-31	4
1433	Oral montelukast versus inhaled salmeterol to prevent exercise-induced bronchoconstriction. 2000 , 133, 392; author reply 392-3	
1432	Short-term Prognostic Value of Lipid Measurements in Patients with Angina pectoris. 2000 , 84, 955-960	42
1431	PANDORA - Survey of Brazilian cardiologists about cholesterol reduction. 2000 , 75, 289-302	2

1430	Effect of Management of Dyslipidemia on Prevention of Coronary Artery Disease in Women. 2000 , 30, 1055	
1429	Simvastatin upregulates coronary vascular endothelial nitric oxide production in conscious dogs. 2000 , 279, H2649-57	70
1428	Heart disease in women. Gender-specific statistics and prevention strategies for a population at risk. 2000 , 107, 111-6; quiz 156	11
1427	Special Turku Coronary Risk Factor Intervention Project for Babies (STRIP). 2000 , 72, 1316S-1331S	43
1426	Regular review: treatment possibilities for unstable angina. 2000 , 321, 1269-75	3
1425	What is the optimal age for starting lipid lowering treatment? A mathematical model. 2000 , 320, 1134-40	26
1424	Evaluation of a Homogeneous Direct LDL-Cholesterol Assay in Diabetic Patients: Effect of Glycemic Control. 2000 , 46, 1848-1851	21
1423	References. 2000 , 173, S83	
1422	Flow Cytometric Assessment of LDL Ligand Function for Detection of Heterozygous Familial Defective Apolipoprotein B-100. 2000 , 46, 224-233	3
1421	Opportunistic Discovery of Occult Disease by Use of Test Panels in New, Symptomatic Primary Care Outpatients: Yield and Cost of Case Finding. 2000 , 46, 1091-1098	5
1420	Random Thoughts and Opinions. 2000 , 85, 2110-2112	0
1419	Reply to EG Bliznakov. 2000 , 71, 153-154	
1418	Quality, Equity and Partnership West Midlands Partnership for Developing Quality/NHS Executive Conference, 15-16 March 2000, Birmingham. 2000 , 4, 1-68	
1417	Are Patients With Hyperlipidemia Being Treated?. 2000 , 93, 283-286	5
1416	Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?. 2000 , 102, 722-7	58
1415	[Diabetic dyslipidemia: clinical significance and therapeutic attitude]. 2000 , 200, 688-90	0
1414	Effect of a pharmacist-managed diabetes care program in a free medical clinic. 2000 , 15, 137-42	82
1413	Statins induce hypothrombotic states?. 2000 , 6, 18-21	8

1412	Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators. 2000 , 102, 157-65	202
1411	Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. 2000 , 102, 846-51	111
1410	Coronary artery disease and human immunodeficiency virus infection. 2000 , 31, 787-97	104
1409	Efficacy and safety of cerivastatin 0.8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. Cerivastatin Study Group. 2000 , 28, 47-68	35
1408	The thyroid-cholesterol connection: an association between varying degrees of hypothyroidism and hypercholesterolemia in women. 2000 , 9, 333-6	7
1407	Need for large scale randomised evidence about lowering LDL cholesterol in people with diabetes mellitus: MRC/BHF heart protection study and other major trials. 2000 , 84, 357-60	29
1406	HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention. 2000 , 54, 790-6	101
1405	Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). 2000 , 102, 1748-54	216
1404	Age, sex and practice variations in the use of statins in general practice in England and Wales. 2000 , 22, 275-9	38
1403	LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. 2000 , 20, 830-5	221
1402	Preoperative Cholesterol and Thrombotic Complications after Coronary Bypass. 2000 , 8, 315-321	
1401	Diabetes mellitus: subclinical cardiovascular disease and risk of incident cardiovascular disease and all-cause mortality. 2000 , 20, 823-9	147
1400	Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). 2000 , 21, 1627-33	9
1399	How well are patients with atherosclerotic disease treated? Secondary prevention in primary care. 2000 , 18, 232-6	8
1398	Cholesterol-lowering treatment is associated with improvement in coronary vascular remodeling and endothelial function in patients with normal or mildly diseased coronary arteries. 2000 , 20, 737-43	46
1397	Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. 2000 , 21, 365-70	173
1396	Aortic stiffness: a predictor of acute coronary events?. 2000 , 21, 342-4	13
1395	Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK). 2000 , 21, 1450-7	109

1394	Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. 2000 , 21, 1750-8	123
1393	Antihypertensive management in PD- and HD-patients. 2000 , 15, 135-136	
1392	Management of acute ischaemic heart disease. 2000 , 15, 143-144	2
1391	C-reactive protein, inflammation and atherosclerosis: do we really understand it yet?. 2000 , 21, 958-60	13
1390	Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis. 2000 , 15, 684-8	28
1389	Management of diabetic patients on dialysis. 2000 , 15, 141-142	
1388	Management of heart failure. 2000 , 15, 147-148	13
1387	Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy. 2000 , 93, 567-74	27
1386	Management of dyslipidaemia. 2000 , 15, 129-130	1
1385	Management of patients with diabetic nephropathy. 2000 , 15, 139-140	5
1384	Management of diabetic patients with microalbuminuria. 2000 , 15, 137-138	
1383	The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. 2000 , 160, 459-67	776
1382	Cell adhesion molecules in relation to simvastatin and hormone replacement therapy in coronary artery disease. 2000 , 21, 975-80	28
1381	Assessment of cardiovascular risk factors. 2000 , 15, 127-128	1
1380	General management of hypertension. 2000 , 15, 131-132	1
1379	Fluvastatin: effects beyond cholesterol lowering. 2000 , 5, 161-75	38
1378	[Secondary prevention in coronary patients after inpatient rehabilitation]. 2000 , 125, 1457-61	14
1377	Insulin resistance - how important is it to treat?. 2000 , 108, 274-280	6

1376	Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. 2000 , 26, 341-8	127
1375	Hyperlipidemia: diagnostic and therapeutic perspectives. 2000 , 85, 2089-112	37
1374	HDL-cholesterol and the Treatment of Coronary Heart Disease: Contrasting Effects of Atorvastatin and Simvastatin. 2000 , 16, 139-146	48
1373	Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data. National Health and Nutrition Examination Survey. 2000 , 160, 1361-9	60
1372	Lipoproteins and the endothelium: insights from clinical research. 2000 , 26, 513-9	5
1371	Nitric Oxide and the Cardiovascular System. 2000 ,	0
1370	Cerivastatin: the low-dose HMG-COA reductase inhibitor. 2000 , 9, 161-6	2
1369	The Management of Chronic Ischemic Heart Disease in the Elderly. 2000 , 9, 145-150	
1368	Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. 2000 , 31, 2442-9	310
1367	Pharmacotherapy following myocardial infarction--a review of current treatment practices. 2000 , 1, 1105-16	4
1366	Non-lipid-related effects of statins. 2000 , 32, 164-76	269
1365	CME Paper: Hormone Replacement Therapy for Prevention or Treatment of Atherosclerosis in Postmenopausal Women: Promises, Controversies, and Clinical Trials. 2000 , 9, 81-88	4
1364	Treatment of dyslipidemia: room for improvement?. 2000 , 20, 2333-5	9
1363	Early detection of high cholesterol levels in young adults. 2000 , 284, 365-7	12
1362	An overview of acute stroke therapy: past, present, and future. 2000 , 160, 3196-206	89
1361	From bench to bedside: the future is now. Presented at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Georgia. 2000 , 101, 942-5	6
1360	Lipoprotein (a) and stroke. 2000 , 53, 487-96	73
1359	Low-density lipoprotein postsecretory modification, monocyte function, and circulating adhesion molecules in type 2 diabetic patients with and without macrovascular complications: the effect of alpha-tocopherol supplementation. 2000 , 102, 191-6	156

1358	Stroke: management and rehabilitation. Part III of III. 2000 , 51, 977-84	3
1357	Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project. 2000 , 102, 1893-900	313
1356	The association of low serum cholesterol with depression and suicidal behaviours: new hypotheses for the missing link. 2000 , 28, 247-57	31
1355	Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction. 2000 , 101, 2149-53	765
1354	Secondary prevention of hypercholesterolaemia: results of an audit conducted in South Wales. 2000 , 84, E3	7
1353	Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. 2000 , 102, 1503-10	498
1352	Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). 2000 , 101, 477-84	462
1351	Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. 2000 , 102, 21-7	1079
1350	Giant cell arteritis after influenza vaccination. 2000 , 160, 2677	29
1349	Effects of lovastatin and pravastatin on the survival of hamsters with inherited cardiomyopathy. 2000 , 5, 275-9	29
1348	Oral L-arginine in patients with coronary artery disease on medical management. 2000 , 101, 2160-4	139
1347	Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial. 2000 , 181 Suppl 3, S572-8	49
1346	Beneficial effects of statins in coronary artery disease--beyond lowering cholesterol. 2000 , 34, 1432-9	45
1345	Measurement of cholesterol and other lipoprotein constituents in the clinical laboratory. 2000 , 38, 287-300	21
1344	Acute renal failure after cardiopulmonary bypass: a possible association with drugs of the fibrate group. 2000 , 5, 33-9	13
1343	Ratio of triglycerides to HDL cholesterol is an indicator of LDL particle size in patients with type 2 diabetes and normal HDL cholesterol levels. 2000 , 23, 1679-85	119
1342	HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. 2000 , 20, 556-62	244
1341	Clinical goals and performance measures for cholesterol management in secondary prevention of coronary heart disease. 2000 , 283, 94-8	29

1340	Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause. 2000 , 53, 120-4	2
1339	Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice. 2000 , 20, 1831-4	75
1338	Lipid lowering drugs for patients who continue to smoke?. 2000 , 83, 619-20	5
1337	Lipid lowering: statins and the future. 2000 , 84 Suppl 1, i46-7; discussion i50	3
1336	Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. 2000 , 20, 2408-13	117
1335	Differential effect of National Cholesterol Education Program (NCEP) Step II diet on HDL cholesterol, its subfractions, and apoprotein A-I levels in hypercholesterolemic women and men after 1 year: the beFIT Study. 2000 , 20, 1580-7	55
1334	Secondary prevention of coronary heart disease: the role of fibric acids. 2000 , 102, 2-4	34
1333	Stroke: epidemiology, clinical picture, and risk factors--Part I of III. 2000 , 51, 793-808	68
1332	The VA HDL intervention trial: clinical implications. 2000 , 21, 1113-5	6
1331	Cerivastatin suppresses lipopolysaccharide-induced ICAM-1 expression through inhibition of Rho GTPase in BAEC. 2000 , 269, 97-102	96
1330	Infection and inflammation-induced proatherogenic changes of lipoproteins. 2000 , 181 Suppl 3, S462-72	263
1329	High-density lipoprotein and coronary heart disease: lessons from recent intervention trials. 2000 , 3, 33-39	3
1328	Plant stanol ester: review of cholesterol-lowering efficacy and implications for coronary heart disease risk reduction. 2000 , 3, 121-130	17
1327	Perspectives: Benefits of reducing low-density lipoprotein cholesterol concentrations to . 2000 , 3, 136-139	4
1326	Lipid risk factor correlates of ischemic heart disease as diagnosed by myocardial perfusion scintigraphy. 2000 , 3, 154-159	4
1325	The gap between knowledge and practice in the treatment and prevention of cardiovascular disease. 2000 , 3, 167-171	7
1324	Statins: effective antiatherosclerotic therapy. 2000 , 139, 577-83	131
1323	The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials. 2000 , 139, S143-54	10

1322	Guidelines for the diagnosis and management of unstable angina and non-Q-wave myocardial infarction: proposed revisions. International Cardiology Forum. 2000 , 139, 461-75	45
1321	Use of cholesterol-lowering medications in the United States from 1991 to 1997. 2000 , 108, 496-9	50
1320	Effects of lovastatin on cognitive function and psychological well-being. 2000 , 108, 538-46	238
1319	Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events?. 2000 , 139, 734-8	33
1318	Benefits of early lipid-lowering intervention in high-risk patients: the lipid intervention strategies for coronary patients study. 2000 , 22, 949-60	9
1317	Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. 2000 , 76, 125-33	112
1316	Effects of HMG-CoA reductase inhibitor on hemostasis. 2000 , 76, 23-32	42
1315	The undertreatment of LDL-cholesterol: addressing the challenge. 2000 , 74 Suppl 1, S23-8	30
1314	Correlation between apolipoprotein B and endothelin-1-induced vasoconstriction in humans. 2000 , 21, 871-4	8
1313	Recent advances in stroke management. 2000 , 9, 95-105	2
1312	Secondary prevention after myocardial infarction: reducing the risk of further cardiovascular events. 2000 , 4, 82-91	4
1311	High-density lipoprotein and coronary heart disease [an update]. 2000 , 4, 111-116	0
1310	Subgroups, treatment effects, and baseline risks: some lessons from major cardiovascular trials. 2000 , 139, 952-61	48
1309	Atorvastatin versus revascularization treatment (AVERT): fact or fancy?. 2000 , 140, 6-9	8
1308	Current perspectives on the management of hypertriglyceridemia. 2000 , 140, 232-40	37
1307	Effect of atorvastatin on blood lipid levels in the first 2 weeks of treatment: a randomized, placebo-controlled study. 2000 , 140, 249-52	23
1306	Endothelium-dependent responses in patients with hypercholesterolemic coronary artery disease under the effects of simvastatin and enalapril, either separately or combined. 2000 , 140, 684-9	27
1305	Effective and safe modification of multiple atherosclerotic risk factors in patients with peripheral arterial disease. 2000 , 140, 792-803	19

1304	Cholesterol and atherosclerosis. 2000 , 1529, 299-309	87
1303	Computerised systematic secondary prevention in ischaemic heart disease: a study in one practice. 2000 , 114, 169-75	8
1302	Efficacy and safety of pravastatin vs simvastatin after cardiac transplantation. 2000 , 19, 529-37	79
1301	Statins after cardiac transplantation: which statin, what dose, and how low should we go?. 2000 , 19, 515-7	19
1300	Systematic, immediate in-hospital initiation of lipid-lowering drugs during acute coronary events improves lipid control. 2000 , 11, 309-316	6
1299	Postoperative drug therapy to extend survival after coronary artery bypass grafting. 2000 , 69, 1315-6	8
1298	Clinical relevance of the oxidative stress concept. 2000 , 49, 30-4	35
1297	The effect on serum lipids and oxidized low-density lipoprotein of supplementing self-selected low-fat diets with soluble-fiber, soy, and vegetable protein foods. 2000 , 49, 67-72	28
1296	Analytical performance and clinical efficacy of three routine procedures for LDL cholesterol measurement compared with the ultracentrifugation-dextran sulfate-Mg(2+) method. 2000 , 294, 77-92	27
1295	Lipoprotein abnormalities in patients with asymptomatic acute porphyria. 2000 , 294, 37-43	10
1294	Effects of bezafibrate plus policosanol or placebo in patients with combined dyslipidemia: A pilot study. 2000 , 61, 346-357	9
1293	Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant coronary risk factors. 2000 , 61, 137-146	26
1292	Dose-dependent cholesterol-lowering effects of d-003 on normocholesterolemic rabbits. 2000 , 61, 460-468	33
1291	Effects of pravastatin treatment on lipoprotein levels and composition in patients with type 2 diabetes mellitus and hypercholesterolemia. 2000 , 61, 107-118	1
1290	Design and baseline characteristics of a cohort study in Japanese patients with hypercholesterolemia: the Japan lipid intervention trial (J-LIT). 2000 , 61, 219-243	14
1289	Preventing, stopping, or reversing coronary artery disease--triglyceride-rich lipoproteins and associated lipoprotein and metabolic abnormalities: the need for recognition and treatment. 2000 , 46, 421-503	5
1288	Incidence and risk reduction of long-term outcomes: a comparison of benign prostatic hyperplasia with several other disease areas. 2000 , 56, 9-18	6
1287	Acute relief or future prevention: is urology ready for preventive health care?. 2000 , 56, 12-9	17

1286	Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. 2000 , 356, 1871-5	55
1285	Pravastatin therapy and the risk of stroke. <i>New England Journal of Medicine</i> , 2000 , 343, 317-26	59.2 268
1284	Attaining United States and European Guideline LDL-cholesterol Levels with Simvastatin in Patients with Coronary Heart Disease (the GOALLS Study). 2000 , 16, 208-219	16
1283	Lipid Clinics as Disease Management Programmes in the United States. 2000 , 8, 65-78	
1282	Management of Dyslipidaemias. 2000 , 7, 83-109	3
1281	Beneficial and detrimental effects of intensive glycaemic control, with emphasis on type 2 diabetes mellitus. 2000 , 17, 463-76	11
1280	Differential pharmacokinetics of digoxin in elderly patients. 2000 , 17, 353-62	62
1279	The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients. 2000 , 17, 33-51	12
1278	Risks of coronary heart disease in women: current understanding and evolving concepts. 2000 , 75, 1289-303	29
1277	[Coronary risk and prescription in primary care patients with hypercholesterolemia]. 2000 , 25, 209-13	5
1276	VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. 2000 , 102, 1886-92	386
1275	Prevention of coronary artery disease with statin therapy is usually cost effective. 2000 , 15, 13-16	
1274	Role of lipid-lowering pharmacotherapy in children. 2000 , 2, 11-22	12
1273	Novel lipid-regulating drugs. 2000 , 9, 2619-28	17
1272	Current perspectives on statins. 2000 , 101, 207-13	958
1271	Modern adjunctive pharmacotherapy of myocardial infarction. 2000 , 1, 405-18	4
1270	Achieving LDL-C Target Levels: The Role of Statins. 2000 , 16, 285-295	
1269	Safety of drugs commonly used to treat hypertension, dyslipidemia, and type 2 diabetes (the metabolic syndrome): part 1. 2000 , 2, 101-10	12

1268	Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. 2000 , 9, 2663-71	41
1267	Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus. 2000 , 9, 194-201	31
1266	[Control of cholesterolemia in Spain, 2000. A tool for cardiovascular prevention]. 2000 , 53, 815-37	51
1265	Effects of exercise and cardiac rehabilitation on cardiovascular outcomes. 2000 , 84, 251-65, x-xi	37
1264	[How many patients need treatment for hypercholesterolemia?]. 2000 , 25, 395-9	3
1263	Cardiac rehabilitation and secondary prevention programs for elderly cardiac patients. 2000 , 16, 619-29	8
1262	Guías de práctica clínica de la Sociedad Española de Cardiología en la angina estable. 2000 , 53, 967-996	4
1261	Prevención secundaria de la cardiopatía isquémica en la provincia de Ciudad Real. Efectividad de la terapéutica hipolipemiente en atención primaria. 2000 , 115, 321-325	13
1260	[Cholesterolemia control in Spain, 2000: a tool for cardiovascular disease prevention]. 2000 , 200, 494-515	8
1259	Stroke prevention: hypertension, diabetes, tobacco, and lipids. 2000 , 18, 309-19	36
1258	Hyperlipidemia. 2000 , 27, 541-87,v	23
1257	[The quality of the drug treatment in hyperlipemia patients from 4 health areas. The VICAF Group]. 2000 , 26, 368-73	7
1256	Decreasing mortality with primary percutaneous coronary intervention in patients with acute myocardial infarction: the Mayo Clinic experience from 1991 through 1997. 2000 , 75, 994-1001	11
1255	Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group. 2000 , 75, 1124-32	16
1254	Management of hypercholesterolemia. 2000 , 84, 23-42	45
1253	Putting prevention into daily practice. 2000 , 84, 267-78	3
1252	[Which statin is more efficient? Concepts and applications in economic evaluation]. 2000 , 26, 333-8	1
1251	The acute myocardial infarction. 2000 , 27, 631-49;vi	19

1250	Heart disease in women. 2000 , 27, 741-66;vii	14
1249	Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíaca. 2000 , 53, 1095-1120	36
1248	La hipertensión arterial en la diabetes mellitus tipo 2. 2000 , 17, 272-283	
1247	Raising HDL-cholesterol [HIT or miss?]. 2000 , 4, 109-110	
1246	HMG-CoA reductase inhibitors and myotoxicity. 2000 , 22, 441-57	203
1245	Comparative tolerability of the HMG-CoA reductase inhibitors. 2000 , 23, 197-213	128
1244	Clinical pharmacokinetics of cerivastatin. 2000 , 39, 99-116	91
1243	HMG-CoA reductase inhibitors in the prevention of stroke. 2000 , 59, 1-6	12
1242	Diabetic dyslipidaemia: current treatment recommendations. 2000 , 59, 1101-11	33
1241	Lipid-lowering treatment in coronary artery disease: how low should cholesterol go?. 2000 , 59, 1127-35	5
1240	Current, new and future treatments in dyslipidaemia and atherosclerosis. 2000 , 60, 55-93	53
1239	Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. 2000 , 60, 1179-206	20
1238	A Working-Day Evaluation of Dyslipidaemia in a Spanish Population (JADE Study). 2000 , 19, 131-142	6
1237	LIPI-WATCH, a Belgian/Luxembourg Survey on Achievement of European Atherosclerosis Society Lipid Goals. 2000 , 19, 219-229	15
1236	Additional Efficacy of Milligram-Equivalent Doses of Atorvastatin over Simvastatin. 2000 , 19, 327-334	5
1235	Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). 2000 , 150, 429-36	57
1234	Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. 2000 , 153, 181-9	114
1233	The effects of lifibrol (K12.148) on the cholesterol metabolism of cultured cells: evidence for sterol independent stimulation of the LDL receptor pathway. 2000 , 153, 69-80	6

1232	Cardiovascular risk changes after lipid lowering medications: are they predictable?. 2000 , 152, 1-8	12
1231	The revised joint guidelines. 2000 , 1, 3-7	3
1230	Are we treating to target?. 2000 , 1, 9-14	8
1229	The benefit of aggressive lipid lowering. 2000 , 1, 15-9	1
1228	Treating to target with statins. 2000 , 1, 21-5	6
1227	Potential for cholesterol lowering in secondary prevention of coronary heart disease in europe: findings from EUROASPIRE study. European Action on Secondary Prevention through Intervention to Reduce Events. 2000 , 153, 505-17	18
1226	HDL-cholesterol as a marker of coronary heart disease risk: the Qubec cardiovascular study. 2000 , 153, 263-72	246
1225	Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia. 2000 , 153, 525-6	1
1224	Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. 2000 , 148, 215-29	31
1223	Inhibition of tissue-factor-mediated thrombin generation by simvastatin. 2000 , 149, 111-6	86
1222	Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels. 2000 , 149, 123-9	31
1221	Hyperlipemic-very low density lipoprotein, intermediate density lipoprotein and low density lipoprotein act synergistically with serotonin on vascular smooth muscle cell proliferation. 2000 , 149, 61-7	12
1220	HDL steady state levels are not affected, but HDL apoA-I turnover is enhanced by Lofibrol in patients with hypercholesterolemia and mixed hyperlipidemia. 2000 , 150, 113-20	12
1219	Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture. 2000 , 150, 331-41	44
1218	Achievement of target plasma cholesterol levels in hypercholesterolaemic patients being treated in general practice. 2000 , 149, 199-205	19
1217	Intima-media thickness after pravastatin stabilizes also in patients with moderate to no reduction in LDL-cholesterol levels: the carotid atherosclerosis Italian ultrasound study. 2000 , 151, 575-83	35
1216	Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death. 2000 , 152, 217-27	86
1215	Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. 2000 , 152, 489-96	22

1214	Simvastatin inhibits the monocyte expression of proinflammatory cytokines in patients with hypercholesterolemia. 2000 , 36, 427-31	165
1213	Prevention of recurrent life-threatening arrhythmias: will lipid-lowering therapy make a difference?. 2000 , 36, 773-5	5
1212	The aggressive low density lipoprotein lowering controversy. 2000 , 36, 1419-25	18
1211	Prediction of coronary events with electron beam computed tomography. 2000 , 36, 1253-60	618
1210	ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2000 , 36, 970-1062	731
1209	HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. 2000 , 36, 1691-7	94
1208	Statin therapy, lipid levels, C-reactive protein and the survival of patients with angiographically severe coronary artery disease. 2000 , 36, 1774-80	107
1207	The framingham offspring study: A commentary. 2000 , 35, 13B-17B	4
1206	The evolving role of statins in the management of atherosclerosis. 2000 , 35, 1-10	458
1205	Cholesterol reduction improves myocardial perfusion abnormalities in patients with coronary artery disease and average cholesterol levels. 2000 , 35, 76-82	41
1204	Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. 2000 , 35, 640-6	19
1203	Optimal management of non-ST segment elevation myocardial infarction remains unclear. 2000 , 35, 903-6	5
1202	Diabetes mellitus: the disease. 2000 , 1-24	
1201	Effect of computerized coronary heart disease risk assessment on the use of lipid-lowering therapy in general practice patients. 2001 , 5, 4-8	5
1200	Clinical pharmacokinetics of fluvastatin. 2001 , 40, 263-81	116
1199	Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust. 2001 , 61, 197-206	73
1198	Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. 2001 , 61, 1835-81	111
1197	Comparison of the Efficacy, Safety and Tolerability of Policosanol versus Fluvastatin in Elderly Hypercholesterolaemic Women. 2001 , 21, 103-113	17

1196	Effects of Policosanol on Lipid Profile and Cardiac Events in Older Hypercholesterolaemic Patients with Coronary Disease. 2001 , 21, 485-497	23
1195	Lipid-lowering efficacy, safety, and costs of a large-scale therapeutic statin formulary conversion program. 2001 , 21, 1130-9	20
1194	The effect of amlodipine on endothelial function in young adults with a strong family history of premature coronary artery disease: a randomised double blind study. 2001 , 154, 171-7	8
1193	Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control. 2001 , 154, 469-74	25
1192	Oxidized LDL and thickness of carotid intima-media are associated with coronary atherosclerosis in middle-aged men: lower levels of oxidized LDL with statin therapy. 2001 , 155, 403-12	90
1191	Fenofibrate raises plasma homocysteine levels in the fasted and fed states. 2001 , 155, 455-62	60
1190	Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. 2001 , 156, 277-87	37
1189	Reduced levels of TNF alpha in hypercholesterolemic individuals after treatment with pravastatin for 8 weeks. 2001 , 157, 411-5	49
1188	Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. 2001 , 157, 423-9	56
1187	Effect of simvastatin on monocyte adhesion molecule expression in patients with hypercholesterolemia. 2001 , 157, 505-12	42
1186	Cholesteryl ester transfer protein and atherosclerosis in Japanese subjects: a study based on coronary angiography. 2001 , 159, 153-63	41
1185	Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. 2001 , 159, 201-8	77
1184	The associations among thoracic aortic atherosclerosis, coronary atherosclerosis and the function of high density lipoprotein. 2001 , 159, 407-16	5
1183	Atorvastatin improves blood rheology in patients with familial hypercholesterolemia (FH) on long-term LDL apheresis treatment. 2001 , 159, 513-9	36
1182	Intermittent claudication: an objective office-based assessment. 2001 , 37, 1381-5	49
1181	ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) ³¹ This document was approved by the American College of Cardiology Board of Trustees in April 2001 and by the American Heart Association Science Advisory and Coordinating Committee in March 2001. ³² When citing this document, the American College of Cardiology and	86
1180	Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. 2001 , 38, 2006-12 ³¹ Jakes D, Kern MJ, Kuntz. 2001 , 37, 2239	102
1179	Use of statins in CNS disorders. 2001 , 187, 81-9	101

1178	Lipids and atherosclerosis: clinical management of hypercholesterolaemia. 2001 , 2, 419-30	9
1177	Manejo terapéutico de la arterioesclerosis. tratamiento de las hiperlipemias. 2001 , 8, 2240-2249	
1176	Tratamiento hipolipemiante en ancianos. 2001 , 36, 195-209	
1175	Cartas al Editor. 2001 , 116, 398	
1174	How well tolerated are lipid-lowering drugs?. 2001 , 18, 665-83	21
1173	Contemporary management of chronic stable angina. 2001 , 18, 109-21	8
1172	Improving Quality of Life for Patients with Angina Pectoris. 2001 , 9, 473-481	3
1171	Cardiac rehabilitation and secondary prevention of coronary heart disease. <i>New England Journal of Medicine</i> , 2001 , 345, 892-902	59.2 551
1170	Approach to the Patient with Hyperlipidemia. 2001 , 115-132	
1169	Prognostic significance of endothelial dysfunction in hypertensive patients. 2001 , 104, 191-6	901
1168	Perspectives-- Focus on statins: lipid-lowering mechanisms and beyond. 2001 , 4, 89-92	3
1167	Effect of Controlling Hypercholesterolemia on Myocardial Ischemia. 2001 , 4, 126-131	
1166	Resolving the Coronary Artery Disease Epidemic Through Plant-Based Nutrition. 2001 , 4, 171-177	31
1165	An Association Between Varying Degrees of Hypothyroidism and Hypercholesterolemia in Women: The Thyroid-Cholesterol Connection. 2001 , 4, 179-182	2
1164	Perspectives: Benefits of a new, nonsystemic lipid-lowering agent: the clinician's perspective. 2001 , 4, 38-39	
1163	The last frontier in cardiovascular health: a landmark lecture for the XVII World Congress of the International Society for Heart Research. 2001 , 33, 2063-9	1
1162	Efficacy and safety of combination simvastatin and colesevlam in patients with primary hypercholesterolemia. 2001 , 110, 352-60	166
1161	Clinical context: current concepts of coronary heart disease management. 2001 , 110 Suppl 6A, 3S-11S	28

1160	A means to an end: an overview of a hyperlipidemia outcomes management program. 2001 , 110 Suppl 6A, 12S-16S	50
1159	A case-management program of medium intensity does not improve cardiovascular risk factor control in coronary artery disease patients: the Heartcare I trial. 2001 , 110, 543-50	17
1158	Do statins cause cancer? A meta-analysis of large randomized clinical trials. 2001 , 110, 716-23	164
1157	Statins and cancer: a case of meta-uncertainty. 2001 , 110, 738-40	12
1156	Medical therapy or coronary artery bypass graft surgery for chronic stable angina: an update using decision analysis. 2001 , 111, 89-95	18
1155	Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. 2001 , 111, 185-91	150
1154	Clinically relevant differences between the statins: implications for therapeutic selection. 2001 , 111, 390-400	154
1153	Clinical relevance of statins: instituting treatment early in acute coronary syndrome patients. 2001 , 2, 15-9	11
1152	Clinical relevance of statins: their role in secondary prevention. 2001 , 2, 21-5	9
1151	Changing the practice of cardiovascular medicine. 2001 , 2, 27-30	3
1150	Apoptosis in atherosclerosis: pathological and pharmacological implications. 2001 , 44, 59-71	26
1149	The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs. 2001 , 50, 1234-41	77
1148	Lipid lowering therapy and coronary heart disease risk assessment in general practice. 2001 , 5, 1-3	2
1147	Cholesterol: an important but relatively overemphasized risk factor for ischemic heart disease. 2001 , 57, 593-601	5
1146	Essential fatty acids as possible mediators of the actions of statins. 2001 , 65, 37-40	51
1145	Aggressive versus moderate lipid-lowering therapy in postmenopausal women with hypercholesterolemia: Rationale and design of the Beyond Endorsed Lipid Lowering with EBT Scanning (BELLES) trial. 2001 , 141, 722-6	30
1144	Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. 2001 , 141, 727-34	78
1143	Noninvasive tests of vascular function and structure: why and how to perform them. 2001 , 141, 694-703	76

1142	PRINCE's prospects: statins, inflammation, and coronary risk. 2001 , 141, 881-3	20
1141	Randomized clinical trials and recent patterns in the use of statins. 2001 , 141, 957-63	30
1140	Long-term survival in 11,661 patients with multivessel coronary artery disease in the era of stenting: a report from the Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease (APPROACH) Investigators. 2001 , 142, 119-26	108
1139	The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. 2001 , 142, 211-7	78
1138	Highlights from the American College of Cardiology Forty-Ninth Annual Scientific Sessions: March 18 to 21, 2001. 2001 , 142, 363-374	3
1137	Primary percutaneous coronary interventions in patients with acute myocardial infarction and prior coronary artery bypass grafting. 2001 , 142, 452-9	46
1136	The continuation of the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) Trial. 2001 , 142, 375-7	15
1135	Effectiveness of a planned strategy using cardiac rehabilitation nurses for the management of dyslipidemia in patients with coronary artery disease. 2001 , 142, 975-81	14
1134	Multifactorial cardiovascular disease prevention in patients aged 75 years and older: A randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study. 2001 , 142, 945-51	49
1133	Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. 2001 , 23, 177-92	64
1132	A comparison of the efficacy and tolerability of titrate-to-goal regimens of simvastatin and fluvastatin: a randomized, double-blind study in adult patients at moderate to high risk for cardiovascular disease. 2001 , 23, 467-78	6
1131	STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Simvastatin Treats Asians to Target. 2001 , 23, 858-70	17
1130	Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness. 2001 , 23, 1492-507	5
1129	Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. 2001 , 1, 105-18	103
1128	HMG-CoA reductase inhibitors. 2001 , 56, 77-114	31
1127	Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. 2001 , 285, 1711-8	1718
1126	High-density lipoprotein cholesterol: an updated view. 2001 , 1, 109-12	5
1125	New approaches to the pharmacological treatment of angina. 2001 , 1, 151-8	2

1124	Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency. 2001 , 37, 484-489	163
1123	Coronary heart disease in the statin and aspirin era: are results of clinical trials being put into practice?. 2001 , 12, 490-5	2
1122	Secondary prevention with fluvastatin decreases levels of adhesion molecules, neopterin and C-reactive protein. 2001 , 12, 503-9	51
1121	Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. 2001 , 62, 194-208	8
1120	Comparison of the effects of D-003 and policosanol on lipid profile and endothelial cells in normocholesterolemic rabbits. 2001 , 62, 209-220	25
1119	Randomized, controlled trial of secondary prevention of coronary sclerosis in normocholesterolemic patients using pravastatin: two-year follow-up of the prevention of coronary sclerosis study. 2001 , 62, 473-485	4
1118	Optimal medical management of patients with chronic ischemic heart disease. 2001 , 47, 154-96	
1117	Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. 2001 , 357, 995-1001	576
1116	Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. 2001 , 357, 1063-8	247
1115	Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. 2001 , 358, 1033-41	2580
1114	Economics of drug treatment: for which patients is it costeffective to lower cholesterol?. 2001 , 358, 1251-6	22
1113	Cholesterol and all-cause mortality in Honolulu. 2001 , 358, 1904-5; author reply 1906	2
1112	[Chromatic computerized analysis is an early predictor of cardiovascular risk associated to hypercholesterolemia]. 2001 , 54, 1417-25	5
1111	Los fitosteroles, el colesterol y la prevención de las enfermedades cardiovasculares. 2001 , 13, 209-218	3
1110	Eficacia y seguridad de la atorvastatina en la práctica médica habitual en España (estudio Zar). 2001 , 13, 19-25	
1109	Diabetes mellitus and coronary heart disease. 2001 , 30, 857-81	36
1108	[Subclinical carotid atherosclerosis in patients with coronary disease]. 2001 , 116, 441-5	4
1107	[Risk factor prevalence and drug treatment in coronary patients at hospital discharge. Results of a national multicenter registry (3C Program)]. 2001 , 54, 159-68	15

1106	Estatinas: ¿est[Justificada su prescripci[para indicaciones distintas a la hipercolesterolemia? 2001 , 8, 404-413	
1105	Hipolipemiantes y medicina basada en la evidencia. 2001 , 116, 397-398	0
1104	Efectividad del tratamiento hipocolesterolemia a largo plazo. 2001 , 13, 118-120	
1103	Smoking diminishes the beneficial effect of statins: observations from the landmark trials. 2001 , 52, 575-87	46
1102	[Cellular and molecular biology of atherosclerotic lesions]. 2001 , 54, 218-31	13
1101	Definition, classification, and pathophysiology of acute coronary ischemic syndromes. 2001 , 19, 259-67	10
1100	Estratificaci[de riesgo y prevenci[secundaria postinfarto. 2001 , 8, 2380-2384	
1099	Involvement of oxidation-sensitive mechanisms in the cardiovascular effects of hypercholesterolemia. 2001 , 76, 619-31	38
1098	V.F. Gil Guill[y J. Merino. 2001 , 116, 396-397	
1097	Evidence-based treatment of patients with ischemic cerebrovascular disease. 2001 , 19, 79-105	6
1096	Effectiveness of colesvelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. 2001 , 76, 971-82	122
1095	Evaluaci[farmacoecon[ica de la reducci[de colesterol con inhibidores de la HMG-CoA reductasa (estatinas) en la hipercolesterolemia. 2001 , 13, 241-253	3
1094	[Cost-effectiveness of atorvastatin against simvastatin as hypolipemic treatment in hypercholesterolemic patients in primary care]. 2001 , 27, 18-24	5
1093	Adjunctive therapies in the treatment of acute coronary syndromes. 2001 , 76, 391-405	1
1092	Arterioesclerosis. factores de riesgo e implicaciones en la calidad de vida. 2001 , 8, 2217-2222	
1091	[Secondary prevention of ischemic heart disease in primary care (PRESENCIAP)]. 2001 , 27, 29-32	7
1090	Treatment of dyslipidemia in diabetes. 2001 , 30, 999-1010	12
1089	MANAGEMENT OF HYPERCHOLESTEROLEMIA. 2001 , 19, 295-310	1

1088	Pharmacology and clinical experience with simvastatin. 2001 , 2, 153-63	20
1087	Novel agents for managing dyslipidaemia. 2001 , 10, 1901-11	6
1086	Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial. 2001 , 19, 411-20	39
1085	Do statins afford neuroprotection in patients with cerebral ischaemia and stroke?. 2001 , 15, 589-96	23
1084	HMG-CoA reductase inhibitors: useful in stroke prevention?. 2001 , 17, 10-12	
1083	The HMG-CoA reductase inhibitors [new safety concerns?. 2001 , 17, 11-15	
1082	Drug treatment of combined hyperlipidemia. 2001 , 1, 327-36	18
1081	Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy. 2001 , 1, 411-20	50
1080	Can a Mediterranean-style diet reduce heart disease?. 2001 , 103, 1821-2	52
1079	Statins in the 21st century: end of the simple story?. 2001 , 10, 1755-66	17
1078	Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. 2001 , 22, 554-72	628
1077	Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. 2001 , 103, 357-62	700
1076	Non-invasive evaluation of endothelial function with B-mode ultrasound imaging of flow-induced brachial artery reactivity. 2001 , 162-172	
1075	Recognition, pathophysiology, and management of acute myocardial infarction. 2001 , 58, 1709-1718	10
1074	Achieving blood lipid goals in patients with coronary artery disease. 2001 , 58, 415-419	
1073	Akuter Myokardinfarkt bei Patienten mit Diabetes mellitus. 2001 , 21, 176-185	
1072	. 2001 ,	4
1071	. 2001 ,	16

1070	Prevention of a first myocardial infarction. 2001 , 41, 359-67	3
1069	Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in the treatment of endothelial dysfunction?. 2001 , 280, H2484-8	47
1068	High-Sensitivity C-Reactive Protein: A Novel and Promising Marker of Coronary Heart Disease. 2001 , 47, 403-411	394
1067	The United Kingdom Prospective Diabetes Study: An Epidemiological Perspective. 425-429	
1066	Cardiovascular Complications in Proteinuric Diabetic Patients. 155-174	
1065	A randomized, double-blind, placebo-controlled, 8-week study to evaluate the efficacy and safety of once daily atorvastatin (10 mg) in patients with elevated LDL-cholesterol. 2001 , 42, 725-38	19
1064	A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE). 2001 , 8, 33-44	57
1063	Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a National Cholesterol Education Program Step I diet. 2001 , 74, 33-43	141
1062	Global Perspectives of Familial Hypercholesterolemia. 2001 , 4, 61-67	3
1061	Assessment and Management of Acute Cardiac Chest Pain. 2001 , 13, 259-269	
1060	Role of cardiac ATP-sensitive K ⁺ channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts. 2001 , 24, 573-7	16
1059	Fluvastatin inhibits O ₂ - and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. 2001 , 281, H655-60	17
1058	Limitation of heart growth in neonatal piglets by simvastatin and atorvastatin: comparison with pravastatin. 2001 , 280, H2746-51	7
1057	Hepatic lipase as a focal point for the development and treatment of coronary artery disease. 2001 , 49, 112-8	20
1056	New challenges in the etiopathogenesis of atherothrombosis. 2001 , 11 Suppl 1, 80-4	3
1055	Alternative therapy use and adherence to antihyperlipidemic drugs in a lipid clinic. 2001 , 58, 1017-21	3
1054	Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol. 2001 , 58, 1734-9	14
1053	The Discovery of the Pathophysiological Aspects of Atherosclerosis [A Review]. 2001 , 101, 162-169	31

1052	Lipid lowering and coronary heart disease risk: how appropriate are the national guidelines?. 2001 , 175, 471-5		7
1051	Lipid-lowering therapy following major cardiac events: progress and deficits. 2001 , 175, 138-40		4
1050	Normocholesterolaemic dyslipidaemia: is there a role for fibrates?. 2001 , 174, 66-7		3
1049	11. References. 2001 , 175, S84		
1048	Statins, cholesterol and coronary risk. 2001 , 12, 227-230		
1047	Temporal trends (1986-1997) in cholesterol level assessment and management practices in patients with acute myocardial infarction: a population-based perspective. 2001 , 161, 1521-8		20
1046	Action of an HMG CoA reductase inhibitor, lovastatin, on apoptosis of untransformed and ts-SV40 transformed human smooth muscle cells derived from saphenous vein. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 161-73	3.1	9
1045	Issues surrounding age: vascular disease in the elderly. 2001 , 12, 601-9		24
1044	The use of fibrates and of statins in preventing atherosclerosis in diabetes. 2001 , 12, 611-7		17
1043	Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. 2001 , 12, 305-11		28
1042	ABCs of cardiovascular disease risk management. 2001 , 9, 96-105		13
1041	Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial. 2001 , 16, 390-3		5
1040	Major trauma in elderly adults receiving lipid-lowering medications. 2001 , 50, 678-83		4
1039	. 2001 , 8, 127-132		6
1038	. 2001 , 8, 383-390		115
1037	Coronary vascular endothelial function and myocardial ischemia: why should we worry about endothelial dysfunction?. 2001 , 12, 475-84		11
1036	Adjunctive Therapies in the Treatment of Acute Coronary Syndromes. 2001 , 76, 391-405		8
1035	Pleiotropic effects of statins: do they matter?. 2001 , 12, 391-4		47

1034	Nutraceuticals: vitamins and other nutrients in coronary heart disease. 2001 , 12, 639-46		24
1033	Atherosclerosis: cell biology and lipoproteins. 2001 , 12, 671-3		
1032	. 2001 , 8, 63-71		54
1031	. 2001 , 8, 119-126		1
1030	The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. 2001 , 12, 413-23		175
1029	. 2001 , 8, 243-248		8
1028	. 2001 , 8, 291-297		92
1027	Statin therapy and stroke prevention. 2001 , 16, 219-24		27
1026	Naringin has an antiatherogenic effect with the inhibition of intercellular adhesion molecule-1 in hypercholesterolemic rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 947-55	3.1	121
1025	. 2001 , 8, 73-79		11
1024	If LDL-C is the answer...what was the question? What do the data really show?. 2001 , 3, 2-13		1
1023	Cholesterol absorption inhibition: filling an unmet need in lipid-lowering management. 2001 , 3, E17-E23		25
1022	Reduction of LDL cholesterol in patients with primary hypercholesterolemia by SCH 48461: results of a multicenter dose-ranging study. 2001 , 41, 70-8		14
1021	The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1. 2001 , 41, 779-82		3
1020	Healthy ageing: addressing acute coronary syndrome?. 2001 , 3 Suppl N, N11-5		1
1019	High-density lipoprotein: epidemiology, metabolism, and antiatherogenic effects. 2001 , 47, 369-416		14
1018	The Treatment of Coronary Heart Disease: An Update. 2001 , 17, 34-37		11
1017	The Treatment of Coronary Heart Disease: An Update Part 5: Selected Comments and Questions Compiled by. 2001 , 17, 41-42		

1016	Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 37, 502-11	3.1	34
1015	Lipid disorders in patients with type 2 diabetes. Meeting the challenges of early, aggressive treatment. 2001 , 110, 111-4, 117-8, 121-3		6
1014	Effects of a two-week, hospitalized phase II cardiac rehabilitation program on physical capacity, lipid profiles and psychological variables in patients with acute myocardial infarction. 2001 , 65, 87-93		22
1013	Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors. 2001 , 11 Suppl 1, 85-95		29
1012	Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. 2001 , 41, 1055-8		11
1011	Guidelines for the management of patients with chronic stable angina: treatment. 2001 , 135, 616-32		41
1010	[Lipid-lowering drugs]. 2001 , 118, 389-95		7
1009	SSM Health Care clinical collaboratives: improving the value of patient care in a health care system. 2001 , 27, 5-19		12
1008	Thrombus formation on atherosclerotic plaques: pathogenesis and clinical consequences. 2001 , 134, 224-38		201
1007	Risk factors for coronary heart disease in men 18 to 39 years of age. 2001 , 134, 433-9		73
1006	Community-based education improves stroke knowledge. 2001 , 11, 34-43		117
1005	Fatal Rhabdomyolysis Caused by Lipid-Lowering Therapy. 2001 , 94, 1023-1026		1
1004	Perspectives on vascular biology and diabetes. 2001 , 49, 100-3		0
1003	Use of the statins in patients after acute myocardial infarction: does evidence change practice?. 2001 , 161, 183-8		42
1002	Analisi costi-efficacia del trattamento con n-3 PUFA nel post-infarto miocardico: i risultati dello studio GISSI-Prevenzione. 2001 , 3, 105-114		
1001	Low-density lipoprotein size, pravastatin treatment, and coronary events. 2001 , 286, 1468-74		93
1000	Transforming exercise-based cardiac rehabilitation programs into secondary prevention centers: a national imperative. 2001 , 21, 263-72		40
999	Cardiovascular Risk Management in Type 2 Diabetes: From Clinical Trials to Clinical Practice. 2001 , 11, 474-490		5

998	Involvement of Oxidation-Sensitive Mechanisms in the Cardiovascular Effects of Hypercholesterolemia. 2001 , 76, 619-631	64
997	Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. 2001 , 19, 1139-47	195
996	Reversal of endothelial dysfunction in humans. 2001 , 12, 463-73	13
995	Vascular complications in diabetes and their prevention. 2001 , 6, 249-55	32
994	Current Lipid-lowering Strategies for the Treatment of Diabetic Dyslipidemia: An Integrated Approach to Therapy. 2001 , 11, 368-383	3
993	Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. 2001 , 32, 280-99	34 ¹
992	Sex inequalities in ischaemic heart disease in general practice: cross sectional survey. 2001 , 322, 832	113
991	Similar Effects of Atorvastatin, Simvastatin and Pravastatin on Thrombogenic and Inflammatory Parameters in Patients with Hypercholesterolemia. 2001 , 85, 47-51	94
990	Simvastatin protects against long-lasting behavioral and morphological consequences of neonatal hypoxic/ischemic brain injury. 2001 , 32, 2185-91	76
989	Coronary heart disease in African Americans. 2001 , 3, 97-108	116
988	Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. 2001 , 104, 2376-83	211
987	[Statins do not prevent restenosis after coronary angioplasty: where to go from here?]. 2001 , 26, 119-28	4
986	[Drug therapy of hyperlipidemia. Current status in Germany]. 2001 , 26, 507-12	
985	[Cost effectiveness of lipid lowering therapy]. 2001 , 26, 552-60	3
984	[Progression of coronary arteriosclerosis as monitoring the therapeutic success of hyperlipidemia]. 2001 , 26, 545-51	
983	Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population. 2001 , 57, 343-8	15
982	Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). 2001 , 57, 357-64	143
981	[Lipid therapy. Prevention of arteriosclerotic cardiovascular diseases]. 2001 , 42, 92-110	2

980	[Pharmacotherapy after cardiac infarction]. 2001 , 42, 699-712	1
979	Statin trials in progress: unanswered questions. 2001 , 3, 9-13	6
978	Diabetes: statins, fibrates, or both?. 2001 , 3, 19-28	18
977	Statins, hormones, and women: benefits and drawbacks for atherosclerosis and osteoporosis. 2001 , 3, 35-42	10
976	Herbs and atherosclerosis. 2001 , 3, 93-6	31
975	Diet and drug therapy: a dynamic duo for reducing coronary heart disease risk. 2001 , 3, 507-13	5
974	Clinical trial evidence for the cardioprotective effects of omega-3 fatty acids. 2001 , 3, 174-9	27
973	Potential use of Ca ⁺⁺ scanning to determine the need for and intensity of lipid-lowering therapy in asymptomatic adults. 2001 , 3, 408-15	5
972	Statins and blood pressure regulation. 2001 , 3, 281-8	40
971	Choices in medical management for prevention of acute ischemic stroke. 2001 , 1, 33-8	3
970	Transplant Coronary Vasculopathy. 2001 , 3, 55-63	4
969	Dyslipidemia. 2001 , 3, 347-357	1
968	[The anti-atherogenic mechanism of action of physical training in patients with coronary heart disease]. 2001 , 90, 799-806	3
967	Hebben fibraten een gunstig effect op de mortaliteit?. 2001 , 39, 262-263	
966	Debate: "How low should LDL cholesterol be lowered?" Viewpoint: "It doesn't need to be very low". 2001 , 2, 8-11	6
965	Debate: "How low should LDL cholesterol be lowered for optimum prevention of vascular disease?" Viewpoint: "Below 100 mg/dl". 2001 , 2, 12-15	3
964	Treating patients with low high-density lipoprotein cholesterol: choices, issues and opportunities. 2001 , 2, 118-122	16
963	A review of clinical trials in dietary interventions to decrease the incidence of coronary artery disease. 2001 , 2, 123-128	10

962	Cardiac rehabilitation: a comprehensive review. 2001 , 2, 221-232	19
961	Debate: Should statin be used in patients with heart failure?. 2001 , 2, 266-267	10
960	Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial. 2001 , 60, 1990-7	77
959	Using an electronic medical record to identify opportunities to improve compliance with cholesterol guidelines. 2001 , 16, 531-7	45
958	Direct adsorption of lipoproteins from whole blood by DALI apheresis: technique and effects. 2001 , 5, 239-43	14
957	Effects of low-density lipoprotein apheresis on coronary and carotid atherosclerosis and diabetic scleredema in patients with severe hypercholesterolemia. 2001 , 5, 244-51	11
956	Comparative accuracy of cardiovascular risk prediction methods in patients with diabetes mellitus. 2001 , 3, 279-86	12
955	Therapeutic considerations for postprandial dyslipidaemia. 2001 , 3, 143-56	6
954	Coronary heart disease risk assessment in diabetes mellitus--a comparison of PROCAM and Framingham risk assessment functions. 2001 , 18, 355-9	31
953	Limited impact of lifestyle education in patients with Type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study. 2001 , 18, 104-8	33
952	Coronary heart disease: pathophysiological events and risk factors. 2001 , 26, 213-218	3
951	Primary stroke prevention. 2001 , 8, 1-15	23
950	Quatre cas de tendinopathie survenant au cours d'un traitement par statine. 2001 , 68, 865-869	5
949	Statins for primary prevention: at what coronary risk is safety assured?. 2001 , 52, 439-46	29
948	Primary care prevention of cardiovascular disease in diabetes. 2001 , 18, 212-216	0
947	Dyslipidaemia and diabetes. 2001 , 18, 201-207	10
946	The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases. 2001 , 10, 497-508	28
945	Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. 2001 , 70, 540-545	3

944	Novel clinical markers of vascular wall inflammation. 2001 , 89, 763-71	592
943	Lessons learned from statin trials. 2001 , 24, 277-80	10
942	Low-dose combination therapy with colesvelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. 2001 , 24, 467-74	85
941	Current perspectives on lipid lowering with statins to decrease risk of cardiovascular disease. 2001 , 24, 2-5	38
940	Treating mixed dyslipidemias: why and how. 2001 , 24, II-6-9	9
939	Long-term efficacy and safety of cerivastatin 0.8 mg in patients with primary hypercholesterolemia. 2001 , 24, IV1-9	10
938	Safety of HMG-CoA reductase inhibitors: focus on atorvastatin. 2001 , 15, 211-8	51
937	The impact of cholesterol lowering on patients' mood. 2001 , 24, 517-36	8
936	Pharmacotherapy of dyslipidemia. 2001 , 15, 413-22	37
935	Optimizing the prescription of statins after an acute coronary syndrome: the influence of coronary angioplasty and total cholesterol levels. 2001 , 15, 559-60	1
934	Statin as immunosuppressive agents. 2001 , 7, 559-61	14
933	Can the potential benefits of statins in general medical practice be extrapolated to liver transplantation?. 2001 , 7, 1009-14	8
932	The chain of survival. 2001 , 37, S5-16	19
931	Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy. 2001 , 8, 528-32	5
930	Use of cardiovascular drugs by home-dwelling coronary patients aged 75 years and older. A population-based cross-sectional survey in Helsinki, Finland. 2001 , 57, 513-6	15
929	[Interaction of the coronary macro- and microcirculation]. 2001 , 90, 946-52	4
928	Possible short-term amelioration of basilar plaque by high-dose atorvastatin: use of reductase inhibitors for intracranial plaque stabilization. 2001 , 11, 202-4	8
927	Aggressive secondary prevention: a perspective from the coronary interventional setting. 2001 , 14, 559-62	

926	Coronary revascularization: an opportunity for lipid screening and treatment. 2001 , 14, 109-12		
925	Global and societal implications of the diabetes epidemic. 2001 , 414, 782-7		4193
924	The effects of the statins lovastatin and cerivastatin on signalling by the prostanoid IP-receptor. 2001 , 132, 1639-49		17
923	NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells. 2001 , 133, 83-8		23
922	A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. 2001 , 133, 406-12		143
921	Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. 2001 , 134, 409-17		160
920	Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. 2001 , 134, 753-62		32
919	Ethnic variations in response to a statin (EVIREST). 2001 , 15 Suppl 1, S87-9		5
918	Cardiovascular monitoring and therapy for HIV-infected patients. 2001 , 946, 236-73		14
917	A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women. 2001 , 27, 353-8		3
916	Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. <i>American Journal of Cardiology</i> , 2001 , 87, 44-8	3	90
915	Effect of simvastatin in preventing progression of carotid artery stenosis. <i>American Journal of Cardiology</i> , 2001 , 87, 643-5, A10	3	14
914	Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001 , 87, 771-4, A7	3	45
913	Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management. <i>American Journal of Cardiology</i> , 2001 , 87, 2B-7B	3	45
912	Pro and con: low-density lipoprotein cholesterol lowering is and will be the key to the future of lipid management. <i>American Journal of Cardiology</i> , 2001 , 87, 8B-12B	3	42
911	Statin therapy: where are we? Where do we go next?. <i>American Journal of Cardiology</i> , 2001 , 87, 13B-18B	3	25
910	Economics of lipid lowering in primary prevention: lessons from the West of Scotland Coronary Prevention Study. <i>American Journal of Cardiology</i> , 2001 , 87, 19B-22B	3	13
909	Novel approaches to lipid lowering: what is on the horizon?. <i>American Journal of Cardiology</i> , 2001 , 87, 23B-27B	3	39

908	Statin therapy and reductions in low-density lipoprotein cholesterol: initial clinical data on the potent new statin Rosuvastatin. <i>American Journal of Cardiology</i> , 2001 , 87, 33B-36B	3	26
907	The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. <i>American Journal of Cardiology</i> , 2001 , 87, 1058-63	3	192
906	Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. <i>American Journal of Cardiology</i> , 2001 , 87, 1074-9	3	106
905	Using both "relative risk reduction" and "number needed to treat" in evaluating primary and secondary clinical trials of lipid reduction. <i>American Journal of Cardiology</i> , 2001 , 87, 1206-8; A7	3	6
904	Effectiveness of the electronic medical record in cholesterol management in patients with coronary artery disease (Virtual Lipid Clinic). <i>American Journal of Cardiology</i> , 2001 , 88, 163-5, A5	3	23
903	The platelet PL(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001 , 88, 347-52	3	54
902	Coronary artery disease progression assessed by electron-beam computed tomography. <i>American Journal of Cardiology</i> , 2001 , 88, 46E-50E	3	78
901	Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus. <i>American Journal of Cardiology</i> , 2001 , 88, 9H-15H	3	63
900	Development of tachyphylaxis on statin treatment. <i>American Journal of Cardiology</i> , 2001 , 88, 936-937	3	
899	Efficacy of cholesterol levels and ratios in predicting future coronary heart disease in a Chinese population. <i>American Journal of Cardiology</i> , 2001 , 88, 737-43	3	57
898	Going from immutable to mutable atherosclerotic plaques. <i>American Journal of Cardiology</i> , 2001 , 88, 2F-9F	3	30
897	Are we aggressive enough in lowering cholesterol?. <i>American Journal of Cardiology</i> , 2001 , 88, 10F-5F	3	10
896	Making practical sense of clinical trial data in decreasing cardiovascular risk. <i>American Journal of Cardiology</i> , 2001 , 88, 16F-20F	3	4
895	What are the priorities for managing cholesterol effectively?. <i>American Journal of Cardiology</i> , 2001 , 88, 21F-4F	3	4
894	Developing a clinical strategy for cholesterol management in an era of unanswered questions. <i>American Journal of Cardiology</i> , 2001 , 88, 25F-30F	3	2
893	Effectiveness of statins in acute coronary syndromes. <i>American Journal of Cardiology</i> , 2001 , 88, 31F-5F	3	6
892	Ongoing clinical trials of statins. <i>American Journal of Cardiology</i> , 2001 , 88, 36F-40F	3	16
891	Women and cardiovascular risk. <i>American Journal of Cardiology</i> , 2001 , 88, 48J-52J	3	22

890	What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes?. <i>American Journal of Cardiology</i> , 2001 , 88, 7J-16J	3	15
889	Postdischarge lipid management of coronary artery disease patients according to the new National Cholesterol Education Program guidelines. <i>American Journal of Cardiology</i> , 2001 , 88, 37K-41K	3	10
888	United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. <i>American Journal of Cardiology</i> , 2001 , 88, 23J-27J	3	84
887	Cholesterol lowering with statins reduces exercise-induced myocardial ischemia in hypercholesterolemic patients with coronary artery disease. <i>American Journal of Cardiology</i> , 2001 , 88, 1134-8	3	4
886	Managing the risk of atherosclerosis: the role of high-density lipoprotein. <i>American Journal of Cardiology</i> , 2001 , 88, 3N-8N	3	140
885	Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease. <i>American Journal of Cardiology</i> , 2001 , 88, 9N-13N	3	120
884	The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. <i>American Journal of Cardiology</i> , 2001 , 88, 14N-18N	3	40
883	Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans Affairs High-density Lipoprotein Intervention Trial. <i>American Journal of Cardiology</i> , 2001 , 88, 19N-23N	3	58
882	Treating lipid abnormalities in patients with type 2 diabetes mellitus. <i>American Journal of Cardiology</i> , 2001 , 88, 37N-40N	3	31
881	High-density lipoprotein cholesterol and treatment guidelines. <i>American Journal of Cardiology</i> , 2001 , 88, 41N-44N	3	6
880	Introduction. <i>American Journal of Cardiology</i> , 2001 , 88, 1-2	3	147
879	Rationale and design of the St. Francis Heart Study: a randomized clinical trial of atorvastatin plus antioxidants in asymptomatic persons with elevated coronary calcification. 2001 , 22, 553-72		29
878	Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). 2001 , 22, 674-86		33
877	Trials within trials: confirmatory subgroup analyses in controlled clinical experiments. 2001 , 22, 605-19		26
876	Effect of atorvastatin, simvastatin, and lovastatin on the metabolism of cholesterol and triacylglycerides in HepG2 cells. 2001 , 62, 1545-55		73
875	The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. 2001 , 415, 79-84		104
874	Optimal medical management of patients with chronic ischemic heart disease. 2001 , 26, 189-238		
873	The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease. 2001 , 26, 734-64		4

872	Update on statins and other lipid-lowering drugs. 2001 , 22, 276-7	7
871	Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins. 2001 , 15, 211-26	23
870	[Coronary artery bypass graft dysfunction--clinical presentation, laboratory and electrocardiographic parameters]. 2001 , 28, 5-10	
869	Four cases of tendinopathy in patients on statin therapy. 2001 , 68, 430-3	59
868	Candidate foods in the Asia-Pacific region for cardiovascular protection: relevance of grains and grain-based foods to coronary heart disease. 2001 , 10, 123-7	
867	Fenofibrate-Induced elevation in serum creatinine. 2001 , 21, 1145-9	26
866	The value of pharmacist involvement in a point-of-care service, walk-in lipid screening program. 2001 , 21, 1403-6	16
865	Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease. 2001 , 21, 1415-21	20
864	Do hypolipidemic drugs lower medical expenses?. 2001 , 21, 1583-4; discussion 1584-6	1
863	Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease. 2001 , 21, 410-5	23
862	Poor adherence with hypolipidemic drugs: a lost opportunity. 2001 , 21, 576-82	38
861	Economic impact of community pharmacist intervention in cholesterol risk management: an evaluation of the study of cardiovascular risk intervention by pharmacists. 2001 , 21, 627-35	33
860	Cholesterol risk management: a systematic examination of the gap from evidence to practice. 2001 , 21, 807-17	39
859	Assessment of hypercholesterolemia control in a managed care organization. 2001 , 21, 818-27	37
858	The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease. 2001 , 4, 165-172	22
857	Effects of yoghurt enriched with plant sterols on serum lipids in patients with moderate hypercholesterolaemia. 2001 , 86, 233-9	101
856	Diabetes. 2001 , 59, 159-72	4
855	HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. 2001 , 22, 1061-7	95

854	Population implications of lipid lowering for prevention of coronary heart disease: data from the 1995 Scottish health survey. 2001 , 86, 289-95		6
853	The genesis of atherosclerosis and risk factors: a review. 2001 , 52, 89-98		69
852	Task Force on Sudden Cardiac Death of the European Society of Cardiology. 2001 , 22, 1374-450		520
851	Time to look beyond just lowering the serum concentration of low density lipoprotein--high density lipoprotein levels are also important. 2001 , 121, 98-101		1
850	Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. 2001 , 56, M186-92		45
849	Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management. 2001 , 85, E9		28
848	Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. 2001 , 103, 792-8		104
847	HMG CoA reductase expression as a prognostic factor in Korean patients with breast cancer: A retrospective study. <i>Medicine (United States)</i> , 2019 , 98, e14968	1.8	4
846	Cardiovascular Disease in Renal Transplantation. 2019 , 496-516		
845	Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?. 2019 , 27, 242-248		4
844	Influence of hypercholesterolemia and diabetes on long-term outcome in patients with stable coronary artery disease receiving percutaneous coronary intervention. <i>Medicine (United States)</i> , 2019 , 98, e16927	1.8	7
843	Statin therapy: does sex matter?. 2019 , 26, 1425-1435		15
842	Assessment of therapeutic effects of statin on cardiac sympathetic nerve activity and cardiac events in patients with ischemic cardiomyopathy and mild to moderate heart failure. 2019 , 40, 159-168		5
841	Pharmacological Options in Atherosclerosis: A Review of the Existing Evidence. 2019 , 8, 5-20		9
840	Changing predictors of statin initiation in US women over two decades. 2019 , 28, 305-314		1
839	Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects. 2019 , 31, 75-88		4
838	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, e285-e350		895
837	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e1046-e1081		187

836	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 139, e1082-e1143		836
835	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2019 , 73, 3168-3209		654
834	PCSK9 inhibitors: clinical evidence and implementation. 2019 , 16, 155-165		84
833	Effect of Statins on Mortality in Heart Failure With Preserved Ejection Fraction Without Coronary Artery Disease - Report From the JASPER Study. 2019 , 83, 357-367		17
832	Intensity-Dependent Benefit of Statins in Survival Among Prospective Kidney Transplant Patients. <i>American Journal of Cardiology</i> , 2019 , 123, 254-259	3	5
831	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2019 , 117-138.e7		1
830	Drug Therapy of Dyslipidemia in the Elderly. 2019 , 36, 321-340		13
829	HDL and cardiovascular disease. 2019 , 51, 142-147		30
828	Plasma Growth Arrest-Specific 6 Protein and Genetic Variations in the GAS6 Gene in Patients with Metabolic Syndrome. 2019 , 17, 22-28		1
827	Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. 2019 , 39, e38-e81		231
826	Management of Dyslipidemia. 2019 , 39-69		
825	Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. 2019 , 108, 520-538		18
824	Early Acute Ischemic Stroke Management for Pharmacists. 2020 , 55, 12-25		1
823	Impact of rosuvastatin versus atorvastatin on coronary atherosclerotic plaque volume - a systematic review and meta-analysis with trial sequential analysis of randomized control trials. 2020 , 27, 2138-2141		4
822	Heart Failure as a Consequence of Ischemic Heart Disease. 2020 , 254-268.e6		2
821	2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. 2020 , 41, 111-188		2236
820	Interaction of Resistin and Systolic Blood Pressure in Psoriasis Severity. 2020 , 140, 1279-1282.e1		10
819	New potential modulators of CYP4F2 enzyme activity in angina pectoris: hsa-miR-24-3p and hsa-miR-34a-5p. 2020 , 25, 40-47		6

818	Overall Mortality and LDL Cholesterol Reduction in Secondary Prevention Trials of Cardiovascular Disease. 2020 , 20, 325-332		
817	Clinical guidelines for type 1 diabetes mellitus with an emphasis on older adults: an Executive Summary. 2020 , 37, 53-70		16
816	Targeting ROCK signaling in health, malignant and non-malignant diseases. 2020 , 219, 15-26		24
815	Persistence and adherence to nucleos(t)ide analogues in chronic hepatitis B: a multicenter cohort study. 2020 , 32, 635-641		3
814	Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. 2020 , 8, 36-49		58
813	Brothers in Arms: ABCA1- and ABCG1-Mediated Cholesterol Efflux as Promising Targets in Cardiovascular Disease Treatment. 2020 , 72, 152-190		49
812	Evolving concepts on the management of dyslipidaemia. 2020 , 75, 80-90		1
811	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. 2020 , 100, 633-672		14
810	Colorectal Cancer. 2020 , 1219-1280.e15		3
809	Current Concepts in Management of Lipid Abnormalities in Patients With Coronary Artery Disease. 2020 , 1, 164-173		
808	Diminished response to statins predicts the occurrence of heart failure after acute myocardial infarction. 2020 , 10, 705-716		1
807	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. 2020 , 32, 175-182		1
806	Lipoprotein(a) and long-term recurrent infarction after an episode of ST-segment elevation acute myocardial infarction. 2020 , 31, 378-384		2
805	Intra-coronary Imaging for the Evaluation of Plaque Modifications Induced by Drug Therapies for Secondary Prevention. 2020 , 22, 76		2
804	Statins in primary prevention: is the enthusiasm justified?. 2020 , 72, 221-224		
803	An evidence-based review of neuromodulation for the treatment and management of refractory angina. 2020 , 34, 517-528		
802	Five-Year Residual Atherosclerotic Cardiovascular Disease Risk Prediction Model for Statin Treated Patients With Known Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2020 , 137, 7-11	3	2
801	Management of multivessel coronary artery disease in patients with non-ST-elevation myocardial infarction: a complex path to precision medicine. 2020 , 11, 2040622320938527		8

800	Systematic review and meta-analysis of studies assessing the relationship between statin use and risk of ovarian cancer. 2020 , 31, 869-879		7
799	Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	6
798	Role of Lipid-Lowering Therapy in Low-Density Lipoprotein Cholesterol Goal Attainment: Focus on Patients With Acute Coronary Syndrome. <i>Journal of Cardiovascular Pharmacology</i> , 2020 , 76, 658-670	3.1	1
797	Measuring effects on intima-media thickness: an evaluation of rosuvastatin in Chinese subjects with subclinical atherosclerosis-design, rationale, and methodology of the METEOR-China study. 2020 , 21, 921		
796	The Role of Statins in Current Guidelines. 2020 , 22, 50		8
795	Sterol synthesis pathway inhibition as a target for cancer treatment. 2020 , 493, 19-30		6
794	Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies. 2020 , 9, e016506		4
793	Hit or miss: the new cholesterol targets. 2021 , 26, 271-278		5
792	Lipoproteins and lipids in cardiovascular disease: from mechanistic insights to therapeutic targeting. 2020 , 159, 4-33		23
791	Relation of Low-Density Lipoprotein Cholesterol Level to Plaque Rupture. <i>American Journal of Cardiology</i> , 2020 , 134, 48-54	3	3
790	Evaluation and Management of Patients With Stable Angina: Beyond the Ischemia Paradigm: JACC State-of-the-Art Review. 2020 , 76, 2252-2266		18
789	The role of statins in the prevention of preeclampsia. 2020 ,		9
788	Lipoprotein(a) and Cardiovascular Outcomes in Patients with Previous Myocardial Infarction: A Prospective Cohort Study. 2021 , 121, 1161-1168		1
787	Higher baseline lipid levels amplify the benefit of secondary prevention therapy with statins in Chinese patients with acute coronary syndrome. 2020 , 48, 300060520965848		
786	Comparing effectiveness of high-dose Atorvastatin and Rosuvastatin among patients undergone Percutaneous Coronary Interventions: A non-concurrent cohort study in India. 2020 , 15, e0233230		5
785	Association of lipoprotein(a) levels with recurrent events in patients with coronary artery disease. 2020 , 106, 1228-1235		11
784	Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. 2020 , 213, 107592		20
783	Effect of statins on cardiovascular complications in chronic kidney disease patients: A network meta-analysis. <i>Medicine (United States)</i> , 2020 , 99, e20061	1.8	3

782	A tale of two technologies: Can nuclear cardiology survive the emergence of cardiac CT the seventeenth annual Mario S. Verani lectureship. 2020 , 27, 865-890	
781	Hiding in plain sight-unreported osteoporotic vertebral fractures. 2020 , 30, 4711-4712	1
780	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. 2020 , 34, 723-735	3
779	Long-Term Prognosis of Patients with Myocardial Infarction Type 1 and Type 2 with and without Involvement of Coronary Vasospasm. 2020 , 9,	6
778	Schnyder corneal dystrophy-associated UBIAD1 is defective in MK-4 synthesis and resists autophagy-mediated degradation. 2020 , 61, 746-757	3
777	Coronary Artery Disease: Therapeutics and Drug Discovery. 2020 ,	2
776	The Efficacy of Squalene in Cardiovascular Disease Risk-A Systematic Review. 2020 , 12,	23
775	Pharmacological interventions for heart failure in people with chronic kidney disease. 2020 , 2, CD012466	3
774	Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. 2020 , 33, 417-430	6
773	Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis. 2020 , 21, 34	6
772	Proposed low-density lipoprotein cholesterol goals for secondary prevention and familial hypercholesterolemia in India with focus on PCSK9 inhibitor monoclonal antibodies: Expert consensus statement from Lipid Association of India. 2020 , 14, e1-e13	4
771	Statin and Cancer Mortality and Survival: An Umbrella Systematic Review and Meta-Analysis. 2020 , 9,	18
770	Outcome of pitavastatin versus atorvastatin therapy in patients with hypercholesterolemia at high risk for atherosclerotic cardiovascular disease. 2020 , 305, 139-146	12
769	Low-density lipoprotein cholesterol goal attainment rates in high-risk patients with cardiovascular diseases and diabetes mellitus in Korea: a retrospective cohort study. 2020 , 19, 5	5
768	Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. 2020 , 51, 1546-1554	35
767	Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association. 2020 , 141, e779-e806	58
766	Usefulness of 500-m walk electrocardiogram test on clinical outcomes in patients with ST-segment elevation myocardial infarction. 2021 , 36, 48-57	2
765	Clinical outcomes of high-intensity doses of atorvastatin in patients with acute coronary syndrome: A retrospective cohort study using real-world data. 2021 , 87, 2043-2052	2

764	Association between statin use and second cancer risk in breast cancer patients: a nationwide population-based cohort study. 2021 , 185, 773-783	0
763	Statins Inhibit Toll-Like Receptor 4-Mediated Growth of Human Esophageal Adenocarcinoma Cells. 2021 , 260, 436-447	2
762	Statins decrease the expression of c-Myc protein in cancer cell lines. 2021 , 476, 743-755	4
761	Impact of expanded FDA indication for icosapent ethyl on enhanced cardiovascular residual risk reduction. 2021 , 17, 155-174	7
760	Postponement of cardiovascular outcomes by statin use: A systematic review and meta-analysis of randomized clinical trials. 2021 , 128, 286-296	
759	Merchants of Death: The Effect of Credit Supply Shocks on Hospital Outcomes.	
758	Diagnosis and Management of Coronary Artery Disease in Athletes. 2021 , 211-225	
757	Optimizing medical therapy in the coronary artery bypass graft patient. 2021 , 313-336	
756	Therapeutic implications of statins in heart failure with reduced ejection fraction and heart failure with preserved ejection fraction: a review of current literature. 10, 16	
755	Dietary Approaches to Lowering LDL-C. 2021 , 193-209	
754	Recent Updates of Lipoprotein(a) and Cardiovascular Disease. 2021 , 57, 36-43	3
753	Hormone replacement therapy - where are we now?. 2021 , 24, 3-10	13
752	High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes. 2021 , 27, 263-275	3
751	Statins Directly Influence the Polarization of Adipose Tissue Macrophages: A Role in Chronic Inflammation. 2021 , 9,	1
750	Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. 2021 , 77, 620-628	19
749	Effects and Issues of Diet Fat on Cardiovascular Metabolism.	
748	Emerging views of statin pleiotropy and cholesterol lowering. 2021 ,	8
747	Inference of a causal relation between low-density lipoprotein cholesterol and hypertension using mendelian randomization analysis. 2021 , 27, 7	

746	Statins as Potential Chemoprevention or Therapeutic Agents in Cancer: a Model for Evaluating Repurposed Drugs. 2021 , 23, 29	6
745	The role of statins in the differentiation and function of bone cells. 2021 , 51, e13534	12
744	Invasive therapy versus conservative therapy for patients with stable coronary artery disease: An updated meta-analysis. 2021 , 44, 675-682	7
743	The advantages of drug treatment with statins in patients with SARS-CoV-2 infection. 2021 , 133, 958-965	6
742	A nonlinear association of total cholesterol with all-cause and cause-specific mortality. 2021 , 18, 25	3
741	Genetic meta-analysis of cancer diagnosis following statin use identifies new associations and implicates human leukocyte antigen (HLA) in women. 2021 , 21, 446-457	1
740	Short-term Effect of LDL-Apheresis on Lipid Profile of Patients with Nephrotic and Non-Nephrotic Hyperlipidemia: A Comparative Study. 2021 , 18, em295	
739	Atherosclerosis: Cholesterol Management. 1-36	
738	Three Musketeers for Lowering Cholesterol: Statins, Ezetimibe and Evolocumab. 2021 , 28, 1025-1041	3
737	Efficacy of fluvastatin and aspirin for prevention of hormonally insensitive breast cancer. 2021 , 187, 363-374	3
736	Coronary heart disease risk: Low-density lipoprotein and beyond. 2021 ,	6
735	LDL-C and Total Stent Length are Independent Predictors of Periprocedural Myocardial Injury and Infarction for Unstable Angina Patients Undergoing Elective Percutaneous Coronary Intervention. 2021 , 14, 1357-1365	
734	Which LDL Value Should Clinicians Look at?. 2021 , 13, 129-133	0
733	The Impact of Simvastatin on Lipidomic Markers of Cardiovascular Risk in Human Liver Cells Is Secondary to the Modulation of Intracellular Cholesterol. 2021 , 11,	0
732	Hydrophilic or Lipophilic Statins?. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 687585	5.4 16
731	Multidisciplinary prevention and management strategies for colorectal cancer and cardiovascular disease. 2021 , 87, 3-12	5
730	Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients. 2021 , 11, e043714	4
729	Special Considerations for Lipid-Lowering Therapy in Women Reflecting Recent Randomized Trials. 2021 , 23, 42	

728	A phenome-wide association study of genetically mimicked statins. 2021 , 19, 151		1
727	Pharmacological Management of Hyperlipidemia in Older individuals. 2021 , 36, 284-303		0
726	Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins. 2021 , 26,		3
725	Plausible Positive Effects of Statins in COVID-19 Patient. 2021 , 21, 781-789		5
724	Effect of statins on the prevention of recurrent thrombosis in thrombotic antiphospholipid syndrome. 2021 ,		1
723	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. 2021 , 335, 7-14		2
722	The Role of Antisense Therapies Targeting Lipoprotein(a). <i>Journal of Cardiovascular Pharmacology</i> , 2021 , 78, e5-e11	3.1	1
721	Immigrants, Ethnicity, and Adherence to Secondary Cardiac Prevention Therapy: A Substudy of the ISLAND Trial. 2021 , 3, 913-923		0
720	Brazilian Society of Cardiology Guidelines on Unstable Angina and Acute Myocardial Infarction without ST-Segment Elevation - 2021. 2021 , 117, 181-264		7
719	How much should LDL cholesterol be lowered in secondary prevention? Clinical efficacy and safety in the era of PCSK9 inhibitors. 2021 , 67, 65-74		9
718	Statins Protect against Thrombosis of Cannulated Radiocephalic Fistulas in Diabetic Patients. 2021 , 75, 280-286		
717	Cholesterol: the race to the bottom. 2021 , 42, 4612-4613		1
716	Variability of discharge medical therapy for secondary prevention among patients with myocardial infarction with non-obstructive coronary arteries (MINOCA) in the United States. 2021 , 16, e0255462		3
715	Statin initiation and all-cause mortality in incident statin-naïve dialysis patients. 2021 , 337, 59-65		0
714	Effect of statins use on risk and prognosis of breast cancer: a meta-analysis. 2021 , 33,		1
713	Similarities and Differences Between HFmrEF and HFpEF. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 678614	5.4	1
712	The role of atorvastatin in collateral circulation formation induced by encephaloduroarteriosynangiosis: a prospective trial. 2021 , 51, E9		0
711	Concurrent use of statins and neoadjuvant chemoradiotherapy for rectal cancer: a systematic review and meta-analysis. 2021 , 36, 2715-2727		

710	Flavonoid-statin interactions causing myopathy and the possible significance of OATP transport, CYP450 metabolism and mevalonate synthesis. 2021 , 119975	0
709	Relation of renal function to mid-term prognosis of stable angina patients with high- or low-dose pitavastatin treatment: REAL-CAD substudy. 2021 , 240, 89-100	0
708	Laboratory reporting of framingham risk score increases statin prescriptions in at-risk patients. 2021 , 96, 1-7	0
707	Anti-inflammatory potential of simvastatin loaded nanoliposomes in 2D and 3D foam cell models. 2021 , 37, 102434	0
706	Efficacy and Safety of PCSK9 Inhibitors in Stroke Prevention. 2021 , 30, 106057	1
705	The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. 2021 ,	
704	Lipoproteins in chronic kidney disease: from bench to bedside. 2021 , 42, 2170-2185	7
703	Carotenoids and Cardiovascular Diseases. 2021 , 649-696	
702	Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis. 2021 , 13, 15	3
701	Safety Considerations of Pharmacological Treatment. 2021 , 203-219	0
700	Molecules and Mechanisms to Overcome Oxidative Stress Inducing Cardiovascular Disease in Cancer Patients. 2021 , 11,	8
699	Cardiac Drugs: Antianginal, Vasodilators, and Antiarrhythmics. 2003 ,	2
698	Application of Isogeometric Analysis to Simulate Local Nanoparticulate Drug Delivery in Patient-Specific Coronary Arteries. 149-167	1
697	Principles of Pharmacology. 2003 , 65-81	4
696	Statins in Critical Illness. 2005 , 477-487	1
695	Protection of endothelial function. 2005 , 619-44	11
694	Endotheliale Dysfunktion als Ursache der kardialen Vaskulopathie. 2005 , 122-139	1
693	Dyslipidemias. 2003 , 1019-1029	1

692	Sexual Dimorphism in Cardiovascular Disease. 1999 , 187-217	3
691	Coronary Artery Disease. 2012 , 179-216	2
690	Introduction to Clinical Research and Study Designs. 2008 , 13-27	1
689	Menopausal Hormone Therapy. 2004 , 321-348	0
688	Critical Pathways for Acute Coronary Syndromes. 1999 , 611-627	4
687	Drugs That Affect Male Sexual Function. 2006 , 155-193	6
686	High-Density Lipoproteins. 2007 , 159-199	1
685	History and development of HMG-CoA reductase inhibitors. 2002 , 1-17	1
684	Kardiologie. 2008 , 343-387	2
683	Statins. 2015 , 123-147	1
682	Vaccination to Prevent Cardiovascular Disease. 2017 , 29-52	1
681	Gesundheitspolitische Aspekte und Ausblick. 2002 , 435-455	1
680	Akuter Myokardinfarkt. 2000 , 393-442	1
679	NHG-Standaard Cardiovasculair risicomanagement. 2011 , 361-408	1
678	Viability assessment: clinical applications. 2000 , 199-227	1
677	Cardiovascular complications after renal transplantation. 1999 , 81-88	2
676	Prophylactic Implantation of Implantable Cardioverter/Defibrillators in Post-Myocardial Infarction Patients. 1998 , 305-310	2
675	An Overview of the Homocysteine Lowering Clinical Trials. 2000 , 413-429	9

674	Coronary Artery Disease: From Mechanism to Clinical Practice. 2020 , 1177, 1-36	33
673	Lipid-Modifying Drugs: Pharmacology and Perspectives. 2020 , 1177, 133-148	5
672	Carotid Occlusive Disease. 2011 , 3615-3620	1
671	Epidemiology of Stroke. 2011 , 198-218	1
670	Lipid-Lowering Strategies and Reduction of Coronary Heart Disease Risk. 2010 , 81-86.e2	1
669	Colorectal Cancer. 2014 , 1278-1335.e14	1
668	High-Density Lipoprotein Metabolism. 2009 , 45-55	2
667	Special Patient Populations: Diabetes and Metabolic Syndrome. 2009 , 443-462	1
666	Lipid-lowering treatment in secondary prevention of ischaemic cerebrovascular disease. 2020 , 32, 175-182	3
665	Clinical approach to the inflammatory etiology of cardiovascular diseases. 2020 , 159, 104916	34
664	Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade. 2000 , 41, 99-108	124
663	Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin. 1997 , 38, 1496-1500	59
662	Perioperative cardiovascular evaluation: heads or tails?. 2012 , 58, 505-512	1
661	Genetics, prevention and screening for melanoma. 2005 , 22, 707-28	1
660	Prevention of cardiovascular disease and diabetes: lessons from the Malmö Preventive Project. 2000 , 248, 455-62	28
659	The new European guidelines for prevention of cardiovascular disease are misleading. 2020 , 13, 1289-1294	4
658	Overexpression of miR-431 attenuates hypoxia/reoxygenation-induced myocardial damage via autophagy-related 3. 2021 , 53, 140-148	4
657	Stroke. 2004 , 223-253	1

656	Pharmaceuticals Other Than Hormones. 2006 , 489-506		6
655	Lipids and cholesterol. 2005 , 174-186		1
654	The secondary prevention of cardiovascular disease. 2005 , 769-791		1
653	Type 2 Diabetes: An Overview. 1999 , 45, 1339-1345		101
652	ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy. 2017 , 19, D3-D54		11
651	Evidence supporting secondary prevention strategies. 1999 , 14, 303-9		5
650	Cholesterol management: an opportunity for nurse case managers. 2000 , 14, 50-8		12
649	Direct effects of statins on the vascular wall. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 31, 773-8	3.1	74
648	Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 33, 473-8	3.1	42
647	Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 164-72	3.1	44
646	Treatment of atherosclerosis in apolipoprotein E-deficient mice with 4-(3-Bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), a potent inhibitor of triglyceride synthesis. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 179-88	3.1	5
645	Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 256-62	3.1	42
644	Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 361-5	3.1	23
643	Use of statins and blood pressure control in treated hypertensive patients with hypercholesterolemia. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 549-55	3.1	122
642	Beneficial effects of fluvastatin on myocardial blood flow at two time-points in hypercholesterolemic patients with coronary artery disease. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 35, 735-40	3.1	7
641	Quality Enhancement Research Initiative in Ischemic Heart Disease. 2000 , 38, I-49-I-59		9
640	Treatment of hyperlipidemia in renal transplant recipients. 1997 , 63, 339-45		37
639	Cholesterol as an independent predictor of outcome after renal transplantation. 2000 , 69, 1704-10		67

638	Endothelial dysfunction and coronary risk reduction. 1998 , 18, 60-7	10
637	A new model for risk stratification and delivery of cardiovascular rehabilitation services in the long-term clinical management of patients with coronary artery disease. 1998 , 18, 113-23	11
636	Comprehensive cardiac rehabilitation improves the control of dyslipidemia in secondary prevention. 1998 , 18, 408-15	18
635	Recent advances in stroke therapy. 1998 , 11, 57-64	8
634	Biological basis for statin therapy in stroke prevention. 2000 , 13, 57-62	17
633	Cholesterol, endothelial function and cardiovascular disease. 1998 , 9, 237-42	40
632	Lipid-lowering drugs: who gets what?. 1998 , 9, 289-94	7
631	Lipoprotein classes and coronary disease regression. 1998 , 9, 329-36	12
630	Follow-up on primary prevention trials. 1998 , 9, 551-6	1
629	Primary and secondary prevention of coronary artery disease: a follow-up on clinical controlled trials. 1998 , 9, 557-64	5
628	Relevance of the reduction of triglycerides in the prevention of coronary heart disease. 1998 , 9, 571-4	8
627	Hyperlipidaemia and cardiovascular disease. 1998 , 9, 609-11	5
626	Progestogen effects on coronary arteries: the need for definitive clinical trials. 2001 , 8, 1-2	2
625	Nutritional and medical therapy for dyslipidemia in patients with cardiovascular disease. 2001 , 12, 40-52	1
624	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). 2003 , 10, S1-S78	145
623	Lipid levels and the use of lipid-lowering agents in England and Scotland. 2004 , 11, 484-488	10
622	Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory?. 2004 , 11, 521-528	51
621	Association between achieving treatment goals for lipid-lowering and cardiovascular events in real clinical practice. 2005 , 12, 530-534	10

620	Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. 2003 , 96, 318-20	14
619	Treatment of patients with lipid disorders in the primary care setting: new treatment guidelines and their implications. 2003 , 96, 266-75	5
618	Medical prevention of stroke, 2003. 2003 , 96, 354-8	10
617	Statin therapy in rheumatoid arthritis. 2005 , 98, 534-40; quiz 541, 572	8
616	C-reactive protein: the harbinger of cardiovascular diseases. 2008 , 101, 525-33	4
615	Moving Beyond Clinical Risk Scores with a Mobile App for the Genomic Risk of Coronary Artery Disease.	5
614	Lipids and secondary prevention of ischaemic heart disease. 1996 , 313, 1273-4	5
613	The new genetics in clinical practice. 1998 , 316, 618-20	143
612	Secondary prevention clinics for coronary heart disease: randomised trial of effect on health. 1998 , 316, 1434-7	116
611	Cholesterol: how low is low enough?. 1998 , 317, 425-6	9
610	Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. 2000 , 320, 680-5	41
609	Cellular consequences of the association of apoB lipoproteins with proteoglycans. Potential contribution to atherogenesis. 1997 , 17, 1011-7	99
608	Effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. 1996 , 94, 3054	5
607	Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. 1997 , 95, 1-4	217
606	National Cholesterol Education Program recommendations for cholesterol testing in young adults. A science-based approach. 1997 , 95, 1646-50	24
605	When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction. 1997 , 95, 1683-5	79
604	Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. 1997 , 95, 2037-43	289
603	Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. 1997 , 96, 3287-93	131

602	Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). 1997 , 96, 4211-8	339
601	Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. 1997 , 96, 4226-31	160
600	Cholesterol management in theory and practice. 1997 , 96, 4424-30	48
599	Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lipid Coronary Angiography Trial (LOCAT) Study Group. 1997 , 96, 2137-43	280
598	Cardiovascular disease in women: a statement for healthcare professionals from the American Heart Association. Writing Group. 1997 , 96, 2468-82	421
597	Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. 1997 , 96, 2534-41	233
596	Vascular effects of statins in stroke. 1997 , 28, 2315-20	85
595	Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors. 1997 , 28, 946-50	193
594	Stroke incidence and mortality correlated to stroke risk factors in the WHO MONICA Project. An ecological study of 18 populations. 1997 , 28, 1367-74	82
593	Risk Reduction. 2000 , 102,	3
592	Low-Density-Lipoprotein Cholesterol Goals for Patients With Coronary Disease. 2001 , 104, 2635-2637	5
591	Eligibility for Lipid-Lowering Drug Therapy in Primary Prevention. 2002 , 105, 136-139	3
590	Estimation of Risk Reduction. 1999 , 99,	1
589	Isoprenoids as mediators of the biological effects of statins. 2002 , 110, 285-288	307
588	Isoprenoids as mediators of the biological effects of statins. 2002 , 110, 285-8	138
587	A Review of the Pharmacologic and Pharmacokinetic Aspects of Rosuvastatin. 2002 , 42, 963-970	11
586	2016 Chinese guidelines for the management of dyslipidemia in adults. 2018 , 15, 1-29	142
585	2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension. 2019 , 16, 182-241	205

584	Does Estrogen Have a Role in the Prevention of Cardiovascular Disease?. 1999 , 84, 1806-1812	1
583	Apolipoprotein B-containing lipoproteins and atherosclerotic cardiovascular disease. 2017 , 6, 134	37
582	Current status of lipid management of hypertensive patients. 2003 , 26, 699-704	11
581	Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). 2006 , 29 Suppl, S1-105	190
580	The pleiotropic effects of simvastatin on retinal microvascular endothelium has important implications for ischaemic retinopathies. 2008 , 3, e2584	43
579	Atorvastatin therapy during the peri-infarct period attenuates left ventricular dysfunction and remodeling after myocardial infarction. 2011 , 6, e25320	19
578	Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. 2012 , 7, e29849	225
577	Genome-wide study of gene variants associated with differential cardiovascular event reduction by pravastatin therapy. 2012 , 7, e38240	29
576	Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK general practice: a national retrospective cohort study. 2013 , 8, e67611	41
575	The effect of statins on mortality in septic patients: a meta-analysis of randomized controlled trials. 2013 , 8, e82775	28
574	Plasma pentraxin 3 levels do not predict coronary events but reflect metabolic disorders in patients with coronary artery disease in the CARE trial. 2014 , 9, e94073	12
573	Co-medication of statins with contraindicated drugs. 2015 , 10, e0125180	8
572	Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis. 2015 , 10, e0126944	27
571	Camphene, a Plant Derived Monoterpene, Exerts Its Hypolipidemic Action by Affecting SREBP-1 and MTP Expression. 2016 , 11, e0147117	12
570	Genetic Variants of LDLR and PCSK9 Associated with Variations in Response to Antihypercholesterolemic Effects of Armolipid Plus with Berberine. 2016 , 11, e0150785	16
569	Statin Intensity or Achieved LDL? Practice-based Evidence for the Evaluation of New Cholesterol Treatment Guidelines. 2016 , 11, e0154952	7
568	Statins: Then and Now. 2019 , 15, 23-31	30
567	Changing lifestyle habits as secondary prophylaxis after coronary artery bypass grafting. 2008 , 11, E243-7	7

566	Impact of aspirin treatment on long-term outcome (over 10 years) after percutaneous coronary intervention. 2006 , 47, 37-45	2
565	Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure. 2004 , 45, 959-68	6
564	Effects of statins on circulating oxidized low-density lipoprotein in patients with hypercholesterolemia. 2004 , 45, 969-75	23
563	The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients. 2004 , 45, 977-87	11
562	Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease. 2001 , 12, 341-348	29
561	Quality of lipid-lowering therapy in outpatient practice: RECVAS Register data. 2016 , 19, 9	4
560	Neuroprotective effect of systemic and/or intravitreal rosuvastatin administration in rat glaucoma model. 2016 , 9, 340-7	2
559	Novel Biomarkers in Cardiovascular Disease: A Review. 2010 , 2, 66	1
558	Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study. 2016 , 7, 65270-65283	13
557	Statin use and breast cancer survival and risk: a systematic review and meta-analysis. 2015 , 6, 42988-3004	44
556	STATIN ADVERSE EFFECTS: MECHANISMS, DIAGNOSIS, PREVENTION AND MANAGEMENT. 2018 , 8, 266-276	3
555	Management of hyperlipidemia with statins in the older patient. 2006 , 1, 433-8	5
554	Differential associations between actual and expected GP practice prescribing rates for statins, ACE inhibitors, and beta-blockers: a cross-sectional study in England. 2005 , 1, 61-8	4
553	Plant sterols as dietary adjuvants in the reduction of cardiovascular risk: theory and evidence. 2006 , 2, 157-62	45
552	Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter?. 2006 , 2, 441-6	2
551	Update on the use of fibrates: focus on bezafibrate. 2008 , 4, 131-41	52
550	High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease. 2008 , 4, 39-57	38
549	Perioperative use of statins in noncardiac surgery. 2008 , 4, 75-81	8

548	Cardiovascular risk reduction in African Americans: Current concepts and controversies. 2016 , 2016, e201602	4
547	Role of Lipid-Lowering Pharmacotherapy in Children. 2000 , 2, 11-22	5
546	Statins in Stroke. 2019 , 26, 6174-6185	9
545	Current Drugs and Nutraceuticals for the Treatment of Patients with Dyslipidemias. 2019 , 25, 85-95	9
544	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors, Reality or Dream in Managing Patients with Cardiovascular Disease. 2019 , 20, 72-82	7
543	The many roles of statins in ischemic stroke. 2014 , 12, 564-74	32
542	The Pleiotropic Effects of Statins - From Coronary Artery Disease and Stroke to Atrial Fibrillation and Ventricular Tachyarrhythmia. 2019 , 17, 222-232	33
541	Relationship between Hyperlipidemia, Cardiovascular Disease and Stroke: a Systematic Review. 2020 ,	10
540	Statin treatment, carotid atherosclerotic plaque macrophage infiltration and circulating inflammatory markers. 2008 , 2, 110-4	10
539	The link between human and transgenic animal studies involving postprandial hypertriglyceridemia and CETP gene polymorphisms. 2009 , 3, 48-50	5
538	Trends in the Use of Evidence-based Therapies Early in the Course of Acute Myocardial Infarction and its Influence on Short Term Patient Outcomes. 2011 , 5, 171-8	5
537	[Endothelial dysfunction and diabetes]. 2005 , 58, 459-64	2
536	[The influence of age and the beginning of menopause on the lipid status, LDL oxidation, and CRP in healthy women]. 2007 , 135, 280-5	4
535	The risks of a new hypothesis: why did JUPITER patients have almost twice the predicted event rate of reduction?. 2011 , 12, 66-70	1
534	High-Density Lipoprotein Cholesterol. 2006 , 295-340	2
533	Diabetes Mellitus and Cardiovascular Disease in the Elderly. 2008 , 179-214	2
532	Epidemiology of Coronary Heart Disease in the Elderly. 2008 , 215-242	6
531	Trends in cardiovascular risk factors among patients with coronary heart disease: results from the EUROASPIRE I, II, and III surveys in the Münster region. 2012 , 109, 303-10	14

530	Optimal strategies for monitoring lipid levels in patients at risk or with cardiovascular disease: a systematic review with statistical and cost-effectiveness modelling. 2015 , 19, 1-401, vii-viii	23
529	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 5 mg and Atorvastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-2). 2009 , 2, 159-73	4
528	Clinical significance of on-treatment triglyceride level in patients treated by percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. 2009 , 24, 330-6	1
527	Effects of intensive versus mild lipid lowering by statins in patients with ischemic congestive heart failure: Korean Pitavastatin Heart Failure (SAPHIRE) study. 2014 , 29, 754-63	9
526	9. Statins in the treatment and prevention of cardiovascular diseases. 2016 , 155-178	2
525	The Influencing Aspects of Atorvastatin on C-Reactive Protein and Lipid Profile in Patients with Stroke. 2008 , 3, 30-34	3
524	Evaluation of the physical-mechanical properties of cement-lime based masonry mortars produced with mixed recycled aggregates. 2020 , 70, 210	7
523	Segmenting Paddy Farmer's Attitude and Behavior. 2017 , 165-190	1
522	Switching to Pitavastatin in Statin-Treated Low HDL-C Patients Further Improves the Lipid Profile and Attenuates Minute Myocardial Damage. 2012 , 4, 385-92	6
521	Secondary Prevention of Hyperlipidemia After Coronary Artery Bypass Graft: From Acute Care to Primary Care. 2004 , 13, 411-415	1
520	Recognizing and Managing Asymptomatic Left Ventricular Dysfunction. 2008 , 28, 20-37	12
519	Gender Difference in the Level of HDL Cholesterol in Korean Adults. 2011 , 32, 173-81	16
518	Immature <i>Rubus coreanus</i> Shows a Free Radical-Scavenging Effect and Inhibits Cholesterol Synthesis and Secretion in Liver Cells. 2012 , 74, 211-6	9
517	Statins: past and present. 2011 , 12, 121-7	33
516	Pleiotropic effects of statins. 2015 , 19, 554-62	88
515	Statin therapy and hepatotoxicity: Appraisal of the safety profile of atorvastatin in hyperlipidemic patients. 2014 , 3, 168	7
514	Statins and risk of cancer: A meta-analysis of randomized, double-blind, placebo-controlled trials. 2017 , 54, 470-477	6
513	Outcomes of a multidisciplinary partnership to improve cardiac wellness: an opportunity for pharmacists. 2010 , 25, 105-16	4

512	The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the AACE System of Intensive Diabetes Self-Management 2002 Update. 2002 , 8, 40-82	119
511	Effects of Statin Therapy on Endothelial Function in Asymptomatic Metabolic Syndrome. 2014 , 05, 149-156	1
510	Review of Medical Treatment of Stable Ischemic Heart Disease. 2014 , 05, 249-259	1
509	Nutritional programming of pancreatic β cell plasticity. 2011 , 2, 119-26	11
508	Favourable effect of statin therapy on early survival benefit at the time of percutaneous coronary intervention for ST-elevation myocardial infarction and shock. 2010 , 6, 350-5	10
507	An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group. 2011 , 6, 942-8	6
506	Long-term outcome after statin treatment in routine clinical practice: results from a prospective PCI cohort study. 2012 , 7, 1420-7	5
505	Endothelial progenitor cells: Exploring the pleiotropic effects of statins. 2017 , 9, 1-13	24
504	The association between the T102C polymorphism of the HTR2A serotonin receptor gene and HDL cholesterol level in Koreans. 2005 , 38, 238-42	4
503	The elderly. 2014 , 21, 180-5	1
502	Gender disparities in optimal lipid control among patients with coronary artery disease. 2014 , 21 Suppl 1, S20-8	16
501	Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese. 2010 , 17, 879-87	21
500	Treatment--drug therapy. 2008 , 15, 167-78	3
499	Elderly patients. 2008 , 15, 223-7	2
498	Women. 2008 , 15, 283-5	2
497	Collaborative cardiac care service: a multidisciplinary approach to caring for patients with coronary artery disease. 2008 , 12, 4-11	16
496	Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. 2021 , 26, 4703	16
495	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-analysis of Randomized Clinical Trials. 2021 , 181, 1575-1587	3

- 494 Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis. **2021**, 12, 713007 1
- 493 Challenges in Optimizing Lipid Management in Women. **2021**, 1 1
- 492 Anatomie und Pathologie des Koronargefäßsystems, Physiologie und Pathophysiologie der Koronardurchlutung, Pathogenese der Atherosklerose. **2000**, 295-326
- 491 Klinik und Diagnostik der koronaren Herzkrankheit. **2000**, 327-353
- 490 Insulin resistance: A pathogenic link between cardiovascular risk factors and atherosclerosis. **2000**, 171-178
- 489 Role Of Lipid Concentrations and Apolipoproteins In Altering ApoB Metabolism and Promoting Coronary Events. **2000**, 12-18
- 488 Lipidsenker und Reokklusionsprophylaxe. **2000**, 69-88
- 487 Arterielle Hypertonie. **2000**, 259-268
- 486 The BEST + ICD Trial: Is ICD Also Effective in the Presence of Optimized β -Blocking Therapy?. **2000**, 386-397
- 485 Coronary Heart Disease, Lipid Metabolism, and Steroid Hormones in Women. **2000**, 839-854
- 484 Use of Mutant Mice to Elucidate Neuroprotective and Neurotoxic Actions of Nitric Oxide in Cerebral Ischemia. **2000**, 687-694
- 483 Blind Guides for Explorers: P Values, Subgroups and Data Dredging. **2000**, 251-266
- 482 Stoffwechsel und endokrine Erkrankungen. **2000**, 255-310
- 481 Loud Messengers [P Values and Effect Size. **2000**, 97-119
- 480 P values and Multiple Endpoints II: Noxious Placebos in the Population. **2000**, 173-210
- 479 Cost-Effectiveness of Risk Factors. **2000**, 237-250
- 478 Lipid-Lowering Drugs. **2000**, 155-177
- 477 Weitere kardiovaskuläre Risikofaktoren. **2000**, 269-291

- 476 Therapie der stabilen und instabilen Angina pectoris. **2000**, 355-391
- 475 Lipidsenkende Mittel. **2000**, 382-391
- 474 Arteriosklerose und Geriatrie. **2000**, 427-432
- 473 The Heart in Diabetes: Results of Trials. **2000**, 55-65
- 472 Clinical trial designs to study antibiotic intervention in atherosclerosis. **2000**, 97-102
- 471 Mistaken Identity: P Values in Epidemiology. **2000**, 70-96
- 470 Lipid-Lowering Drugs. **2000**, 215-238
- 469 Hypertriglyceridemia and low high-density lipoprotein: risks for coronary artery disease?. **2000**, 14, 79-90 ○
- 468 Fettstoffwechsel, Bergewicht und Ernährung, Diabetes. **2000**, 239-257
- 467 Pharmacologic Treatment of Dyslipidemia. **2000**, 100, 55-60
- 466 ??????????(?????????). **2000**, 8, 143-150
- 465 ?????????? : 1.????????? : ?????????????(263? ??????????). **2000**, 8, 17-24
- 464 ?????????? : ????(?????????, ??????) : 8.?????????(264? ??????????). **2000**, 8, 315-318
- 463 A case for lipid-lowering?. **2000**, 17 Suppl 2, 4-5
- 462 Prevention. **2000**, 15, 343-7
- 461 Lipids--how low do you go: plaque regression and passivation. **2000**, 15, 43-53
- 460 Clinical usefulness of the common carotid artery blood flow velocity ratio as measured by an ultrasonic quantitative flow measurement system: evaluation with respect to prevalence of ischemic heart disease. **2001**, 68, 482-9 1
- 459 Natural History and Treatment of Extracranial Cerebrovascular Disease in the Elderly. **2001**, 497-506

458 Glukose. **2001**, 605-805

457 C-reactive Protein as Prognostic Marker of Inflammation in Atherothrombosis. **2001**, 203-220

1

456 Dietary Fat, Blood Lipids, and Coronary Heart Disease Risk. **2001**, 121-134

455 Epidemiologie zerebrovaskulärer Erkrankungen. **2001**, 123-149

454 Plötzlicher Tod: ACE-Hemmer und β -Blocker. **2001**, 60-66

453 How To Make A Mountain and A Mint Out of, At Most, A Molehill: Statin Drugs. **2001**, 95-116

452 What about the statins?. **2001**, 56, 365-366

1

451 Lipidsenkende Mittel. **2001**, 483-493

450 Lipidsenkende Mittel. **2001**, 444-454

449 Genetic Influences on Blood Lipids and Cardiovascular Disease Risk. **2001**, 157-182

448 Q-Wave Myocardial Infarction. **2001**, 177-193

447 Risk Factors for Atherosclerosis in the Elderly. **2001**, 448-459

446 Ursachen der koronaren Herzkrankheit Die Rolle von Hyperlipidämie, Bluthochdruck und Rauchen. **2001**, 86-98

445 Risk Factors for and Prevention of Atherosclerotic Cardiovascular Disease. **2001**, 97-106

444 An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. **2001**, 85, 544-548

0

443 A cardiac prevention and rehabilitation programme for all patients at first presentation with coronary artery disease. **2001**, 85, 533-538

442 Cost effectiveness of ramipril treatment for cardiovascular risk reduction. **2001**, 85, 539-543

441 Nutrition in Diabetes Mellitus. **2001**,

440 Clinical Assessment of Endothelial Function. **2002**, 691-700

439 Cerebrovascular Diseases. **2002**, 1075-1112

438 Coronary Atherosclerosis: Chronic Coronary Syndromes. **2002**, 779-820

437 Ausblick. **2002**, 211-215

436 [Hypertriglyceridemia and the atherogenic lipoprotein phenotype (triglycerides and atherosclerosis)]. **2002**, 55, 85-8

o

435 Coronary Artery Disease and Endothelial Function. **2002**, 887-912

434 Indications and contra-indications for statin treatment (primary and secondary prevention of hypercholesterolemia). **2002**, 99-120

433 Clinical experience: studies with HMG-CoA reductase inhibitors. **2002**, 121-133

432 Women and CHD: The Case for Prevention. **2002**, 377-385

431 Reducing Cardiovascular Risk in Postmenopausal Women: Estrogen or Statins?. **2002**, 123-130

430 Pleiotropic effects of HMG-CoA reductase inhibitors on cells of the vascular wall. **2002**, 81-98

429 Primär- und Sekundärprävention der KHK. **2002**, 151-182

428 Statins.

427 Long-chain polyunsaturated fatty acids. **2002**, 135-174

426 Vascular Disease in Diabetes Mellitus. **2002**, 995-1008

425 ??????? : ?????????????(1.????????????)(?66????????????). **2002**, 10, 225-232

424 Hyperlipidemia Pharmacy Practice. **2002**, 461-468

423 Statine. **2002**, 24,

422 References. **2002**, 106, 3373-3421

1

421 [Prevention of recurrent events in patients with ischemic heart disease]. **2003**, 40, 219-22

420 Erkrankungen von Herz und Gefäßen. **2003**, 1157-1263

419 Basic and Clinical Results of New Statin: Pitavastatin. **2003**, 99-106

418 Inflammation and Cardiovascular Disease. **2003**, 3-18

417 The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. **2003**, 45-50

1

416 Lipidsenkende Mittel. **2003**, 517-529

415 Cost-Effectiveness of Risk Factors. **2003**, 259-272

414 Primary and Secondary Prevention of Coronary Heart Disease. **2003**, 145-174

413 Future Directions. **2003**, 205-209

412 Pathophysiology and clinical significance of atherogenic lipoprotein phenotype and small dense LDL particles. **2003**, 22, 101-107

1

411 Antihyperlipidemic Agents. **2003**, 339-383

410 Lipid-Lowering Drugs. **2003**, 165-191

409 SNPs: Single Nucleotide Polymorphisms and Pharmacogenomics Individually Designed Drug Therapy. **2003**, 607-639

1

408 Dyslipidaemia: implications for cardiovascular risk in hypertensive diabetic subjects. **2003**, 77-96

407 C-Reactive Protein for Primary Risk Assessment. **2003**, 279-290

406 [Statins and cerebral ischemia]. **2003**, 60, 461-70

405 Management of Acute Coronary Syndromes. **2003**, 15-36

- 404 Global Approach to Cardiovascular Risk in Type 2 Diabetic Persons. **2003**, 240-276
- 403 Reductive effect of body weight in rats fed a high-fat diet by Sense-line. **2003**, 3, 29-33
- 402 Experimental findings with important clinical implications for stroke treatment. **2003**, 269-282
- 401 Clinical Features and Treatment of Coronary Heart Disease in Diabetes.
- 400 Treatment of diabetic nephropathy. **2003**, 135-141 1
- 399 Is cholesterol lowering with statins the gold standard for treating patients with cardiovascular risk and disease?. **2003**, 96, 837; author reply 837-8
- 398 Management of Unstable Angina and Non-ST Elevation Myocardial Infarction. **2003**, 109-125
- 397 Angina. **2003**, 39-53
- 396 Monitoring of Lipids in Diabetes.
- 395 The CARE trial. **2003**, 123-143
- 394 Plant Sterols and Stanols, Lipoprotein Metabolism, and Cardiovascular Disease. **2003**,
- 393 Vascular Function, Aging, and the Impact of Diet. **2004**, 379-398
- 392 Gender and Its Impact on Risk Factors for Cardiovascular Disease. **2004**, 193-214 1
- 391 Cardiovascular Disease, Genes, and Nutrition: Gender Matters. **2004**, 737-751
- 390 Verordnungsprofil der Internisten. **2004**, 1013-1041
- 389 Herz, Gefäß, Lunge. **2004**, 81-196
- 388 Risk Detection and Primary Prevention in Women. **2004**, 29-45
- 387 Lipidsenkende Mittel. **2004**, 570-583

386 Kardiologie. **2004**, 313-356

385 Lipidsenkende Mittel. **2004**, 641-658

384 Hypolipidemic Agents and Their Role in the Therapy of Diabetes Mellitus.

383 Tutorials in Therapeutics Should Cholesterol Level be lowered below Normal? Insights from the Heart Protection Study. **2004**, 2004,

382 Bedside Platelet Monitoring. **2004**, 495-520

381 Risk Factors and Prevention, Including Hyperlipidemias. **2005**, 419-437

380 Diabetes Mellitus and the Cardiovascular Metabolic Syndrome: Reducing Cardiovascular and Renal Events. **2005**, 543-556

379 Advances in the Acute Treatment and Secondary Prevention of Stroke. **2005**, 21-33

378 The influence of antibiotics and statins on inflammation in coronary disease. **2005**, 62, 661-70

377 Ischemic Heart Disease. **2005**, 567-578

376 Statin prescribing in primary care. **2005**, 2005,

375 Oxidized Products of Cholesterol. **2005**,

374 Stroke Prevention, Blood Cholesterol and Statins. **2005**, 123-150

373 Stroke. **2005**, 269-296

372 Pharmacological Treatments of Lipid Abnormalities. **2005**, 183-212

371 The impact of anti-atherosclerotic strategies on subclinical atherosclerosis. **2005**, 139-152

370 Pharmacogenetics: Focus on the Liver. **2006**, 53-66

369 Implications of Changing National Cholesterol Education Program Goals for the Treatment and Control of Hypercholesterolemia. **2006**, 060111052548001-???

- 368 Medical Treatment of Peripheral Arterial Disease. **2006**, 271-292
- 367 HMG coenzyme-A reductase inhibitors. **2006**, 1632-1639
- 366 Lower Limb Claudication due to Iliac Artery Occlusive Disease. **2006**, 147-155
- 365 Subgroup Analyses. **2006**, 205-227
- 364 Epidemiology of Cerebrovascular Disease * *This work was supported in part by the National Institute of Neurological Disorders and Stroke Grant No. 5R01 NS17950 and the National Heart, Lung, and Blood Institute's Framingham Heart Study Contract No. N01-HC-25195.. **2006**, 411-432
- 363 Is het gerechtigd om bij diabetes mellitus II statines voor te schrijven onafhankelijk van de cholesterolwaarden?. **2006**, 2153-2154
- 362 Genetic Markers in Cardiovascular Disease. **2006**, 587-608
- 361 [Clinical trials of statins and fibrates --a meta-analysis]. **2006**, 59, 213-8
- 360 Mistaken Identity: P-values in Epidemiology. **2006**, 91-115
- 359 Maakt het verschil met welke statine het serumcholesterol wordt beïnvloed?. **2006**, 2357-2359
- 358 Antianginal drugs. **2006**, 260-263
- 357 Lower Extremity Arterial Reconstruction in Patients With Diabetes Mellitus. **2006**, 473-492
- 356 Pharmacological interventions in reperfusion therapy for acute myocardial infarction. **2006**, 111-128
- 355 Statins and Toxicity. **2006**, 273-295
- 354 The evaluation of short and long-term administration of drugs improving life expectancy in patients with myocardial infarction in a Hungarian county hospital. **2006**, 14, 6-9
- 353 Statins, Inflammation, and Cardiomyopathy: Old Pathways, New Targets. **2006**, 155-166
- 352 Identification of Treatment Response Genes. **2006**, 1-19
- 351 Pharmacogenetics and Metabolic Disease. **2006**, 243-272

350 Nutrient- and Drug- Responsive Polymorphic Genes as Nutrigenomic Tools for Prevention of Cardiovascular Disease and Cancer. **2006**, 237-259

349 Management of Elevated Low-Density Lipoprotein Cholesterol. **2006**, 255-294

348 Stroke Prevention. **2006**, 545-584

347 Inflammatory Mediators and C-Reactive Protein. **2006**, 441-462

346 Cardiovascular Disease in Racial and Ethnic Minorities. **2006**, 721-751

o

345 What is sudden death? A correct identification Jorge A Salerno-Uriarte, Cecilia Fantoni and Raffaella Marazzi. **2006**, 13-24

344 Sudden cardiac death: the size of the problem. **2006**, 25-36

343 Cardiac Rehabilitation: Statins and the Rationale for Implementation of Lipid-Lowering Therapy. **2007**, 141-156

342 Pharmacological Therapy for Cardiovascular Disease. **2007**, 121-148

341 Chronic Stable Angina. **2007**, 290-313

340 4. Primary Prevention of Hypertension. **2007**, 38, 197-203

339 5. ????????????????? : ??????????????????????. **2007**, 38, 317-321

338 Management of Cholesterol Disorders. **2007**, 2667-2691

337 Management of Lipids in the Elderly. **2007**, 369-387

336 Familial Hypercholesterolemia and Lipid Apheresis. **2007**, 267-289

1

335 2. ?????????????????, ??, ?????? ? ?????????????? **2007**, 38, 299-304

334 Carotid Artery Intervention. **2007**, 1741-1753

333 ST-Elevation Myocardial Infarction. **2007**, 246-289

332 Statins, Oxidative Stress, and Polycystic Ovary Syndrome. **2007**, 263-278

331 Usefulness of Visual Aid in Drug Administration Guidance for Hyperlipidemic Patients in a Community Pharmacy. **2007**, 33, 268-273

2

330 Atherosclerotic Vulnerable Plaques: Pathophysiology, Detection, and Treatment. **2007**, 621-639

329 Common hyperlipidaemia. **2007**, 125-168

328 Nutrition in Diabetes Mellitus. **2007**, 785-813

327 Reaching target lipid levels in patients at high risk of cardiovascular event: the experience of a Canadian tertiary care lipid clinic. **2007**, 15, 106-9

1

326 Dyslipidemia and Diabetes. **2007**, 405-416

325 Rationale and Goals for Glucose Control in Diabetes Mellitus and Glucose Monitoring. **2007**, 27-43

324 The Evaluation of Cardiac and Peripheral Arterial Disease in Patients with Diabetes Mellitus. **2007**, 437-461

323 Preventie en behandeling van aandoeningen als gevolg van atherosclerose. **2008**, 57-69

322 Ventricular Arrhythmias in Patients After Myocardial Infarction. **2008**, 190-203

321 Management of Associated Cardiovascular Risk in Essential Hypertension. **2008**, 635-643

320 Overview of Evidence Supporting the Treatment of Hyperlipidemia. **2008**, 1-13

319 Traitement des dyslipidémies. **2008**, 443-462

318 Cholesterol Management in Patients with Chronic Kidney Disease. **2008**, 715-724

317 Ereigniszeiten und konkurrierende Risiken [zur Planung und Auswertung der 4D -Studie. **2008**, 379-398

316 [New trends in lipidology: the increasing role of HDL-cholesterol]. **2008**, 149, 1395-404

315 Evolving Targets of Therapy. **2009**, 387-395

314 CORONARY ARTERY DISEASE. **2009**, 321-365

313 LIPID REGULATING DRUGS. **2009**, 527-570

312 Invasive Imaging Modalities and Atherosclerosis: The Role of Intravascular Ultrasound. **2009**, 410-419

1

311 Dyslipidemia in Racial/Ethnic Groups. **2009**, 119-138

310 Drugs Used to Treat Hypertension, Heart Failure, and Angina Pectoris. **2009**, 1-196

309 Nutrition and Lifestyle Change in Older Adults with Diabetes Mellitus and Metabolic Syndrome. **2009**, 279-317

308 Coronary Artery Disease Prevention. **2009**, 17-32

307 Lipid Disorders. **2009**, 65-75

306 NHG-Standaard Cardiovasculair risicomanagement. **2009**, 106-152

2

305 Special Patient Populations: Acute Coronary Syndromes. **2009**, 473-485

304 16 Coloncarcinoom. **2009**, 191-202

303 NHG-Standaard Beleid na een doorgemaakt myocardinfarct. **2009**, 87-105

302 Management of Disease in Women with Diabetes. **2009**, 435-452

301 Are the upper limits for serum cholesterol levels necessary?. **2009**, 18, 33-50

300 Nutrition, Metabolic Syndrome, and Diabetes in the Senior Years. **2010**, 389-417

1

299 The ESCAPE randomized clinical trial: 20-80 mg of Zokor (Simvastatin) in patients with familial hypercholesterolemia in ischemia heart disease. Part 1. Hypolipidemic efficacy, safety and tolerance. **2009**, 15, 543-549

298 Pharmacogenomics. **2010**, 273-287

297 Kidney Disease and Medications. **2010**, 208-217

- 296 Medical Management of Acute Coronary Syndromes. **2010**, 867-882
- 295 HDL Infusion Therapy. **2010**, 173-179
- 294 Tumorigenic effects of drugs other than anticancer drugs and drugs used in immunology. **2010**, 603-629
- 293 Thérapeutique des troubles associés. **2010**, 175-189
- 292 Lower Limb Claudication Due to Iliac Artery Occlusive Disease. **2010**, 173-185
- 291 Bewegungstherapie bei koronarer Herzkrankheit. **2010**, 115-142 1
- 290 Clinical Effects of Statin in Elderly Patients with Acute Myocardial Infarction and Left Ventricular Dysfunction Who underwent Percutaneous Coronary Intervention. **2010**, 46, 74
- 289 Chapter 12 High Blood Cholesterol. **2010**,
- 288 Early Initiation of Statin Treatment Immediately after Acute Myocardial Infarction Improves Clinical Outcomes. **2010**, 46, 25
- 287 Acute Coronary Syndromes. **2010**, 1026-1059
- 286 Lipoprotein Metabolism and the Treatment of Lipid Disorders. **2010**, 788-807
- 285 Should We Aggressively Treat the Patient with High Levels of Cholesterol Even in Japanese?. **2010**, 37, 673-678
- 284 Adjunctive Pharmacologic Therapies. **2010**, 54-64
- 283 Evidence-based data on Simvastatin: A 15-year experience. **2010**, 16, 238-249
- 282 Risk Reduction in the Diabetic Patient. **2011**, 281-315 1
- 281 Strategies for Treating Abnormal Lipid Profiles with Drugs. **2011**, 163-193
- 280 The Statin Response Gene: KIF6. **2011**, 175-198
- 279 Drug Therapy and Follow-Up. **2011**, 563-631

278 Drug Therapy for Dyslipidemia. **2011**, 121-139

277 Low-Density Lipoprotein Cholesterol. **2011**, 215-229

276 Correlation between LDL-cholesterol and C-reactive protein among an apparently healthy population in the city of Athens. **2011**, 03, 338-342

275 Isolated Low HDL. **2011**, 159-171

274 NHG-Standaard Beleid na een doorgemaakt myocardinfarct. **2011**, 341-359

273 Risk Factors for Atherosclerosis in the Elderly. **2011**, 635-648

272 Natural History and Treatment of Extracranial Cerebrovascular Disease in the Elderly. **2011**, 673-687

271 Stabilizing unstable plaque in acute coronary syndromes. **2011**, 338-345

270 Acute Coronary Syndromes. **2011**, 548-558

269 Plaque Passivation and Endothelial Therapy. **2011**, 289-298

268 Cardiovascular risk and lipid control in secondary prevention. **2011**, 30, 210-219

267 Disorders of Lipid Metabolism. **2011**, 1633-1674

266 Acute Coronary Syndromes. **2012**, 19-50

265 Stable Angina. **2012**, 1-18

264 Chronic Stable Angina. **2012**, 271-290

263 Serum Low-Density Lipoprotein Levels Predict Mid-Term Outcomes of Diabetic Patients After Off-Pump Coronary Artery Bypass Surgery. **2012**, 58, 325-329

262 Erratum: Usefulness of LDL-C-Related Parameters to Predict Cardiovascular Risk and Effect of Pravastatin in Mild-to-Moderate Hypercholesterolemia[Journal of Atherosclerosis and Thrombosis 1902 176-185]. **2012**, 19, 881-881

261 Neurologic Aspects of Kidney Disease. **2012**, 2138-2155

- 260 Lipid Lowering in Coronary Artery Disease. **2012**, 126-141
- 259 Metabolic Disorders. **2012**, 727-766
- 258 Predictors of plaque area for culprit lesion in patients with ischemic heart disease who underwent percutaneous coronary intervention. **2012**, 18, 21-29
- 257 Lipid-lowering therapy. **2012**, 68-77
- 256 Screening and identifying high-risk individuals in the general population by using traditional risk factors. **2012**, 11-22
- 255 Lipid Management. 68-89
- 254 Combination Lipid Therapy on Lipid Profiles in Patients with Impaired Glucose Tolerance. **2013**, 04, 152-157
- 253 A Study of Coronary Heart Disease in Postmenopausal Women and Identification of Major Modifiable Determinant Risks for its Prevention. **2013**, 1, 56-62
- 252 Impact of Medical Therapy on Cardiovascular Secondary Prevention. **2013**, 1075-1100
- 251 PCSK9 - A New and Potent Approach to Lowering Cholesterol. **2013**, 28, 155-8
- 250 Incorporation of Nutritionally Important Fatty Acids into Eggs and Evaluation of "Bio-Omega-3"Eggs in Humans with Moderate Hypercholesterolemia. **2013**, 12, 907-911
- 249 Dyslipidemia. **2014**, 489-502
- 248 CVD in CKD: Focus on the Dyslipidemia Problem. **2014**, 67-91
- 247 Residual Risk and Biology of the Disease: Implications for Plaque Imaging. **2014**, 1-21
- 246 Introduction to Clinical Research Concepts, Essential Characteristics of Clinical Research, Overview of Clinical Research Study Designs. **2014**, 11-32
- 245 Thérapeutique des troubles associés. **2014**, 189-201
- 244 Dyslipidemias in the Geriatric Chronic Kidney Disease Patients. **2014**, 255-267
- 243 Monitoring the Progression and Regression of Coronary Atherosclerosis with Intravascular Ultrasound. **2014**, 67-79

- 242 Cardiovascular Disease in Renal Transplantation. **2014**, 472-490 1
- 241 Primary and Secondary Prevention of Cardiovascular Diseases in Menopausal Women: Alternative Treatment to Hormonal Replacement Therapy. **1997**, 327-338
- 240 Endothelial (dys)Function, Lipid Reduction and Balloon Angioplasty. **1997**, 55-82 1
- 239 Atherosclerosis: Implications of Angiotensin II and the AT-1 Receptor. **1998**, 233-243
- 238 Perspectives on Lipid-Lowering Therapy: Past and Present. **1998**, 25-33
- 237 When and How to Treat Hypercholesterolemia in the Elderly?. **1998**, 219-225
- 236 Sekundärprävention der koronaren Herzkrankheit in der Praxis. **1998**, 926-956
- 235 How should future angiographic trials be designed?. **1998**, 119-131
- 234 Präventive Strategien in der Ernährungsmedizin. **1998**, 203-252
- 233 Lipoproteins and Cardiovascular Risk: From Genetics to Prevention of Coronary Heart Disease. **1998**, 217-228
- 232 European Action on Secondary Prevention. **1998**, 109-117
- 231 Diabetes and Atherosclerosis: Risk Factors and Clinical Trials. **1998**, 165-170
- 230 Heart disease in patients with the diabetic renal-retinal syndrome: clinical considerations. **1998**, 211-222
- 229 Myocardial Ischemia and Cholesterol Lowering Therapy. **1998**, 109-120
- 228 The Heart in Diabetes: Results of Trials. **1998**, 51-60
- 227 Therapie von Dyslipoproteinämien. **1998**, 957-972
- 226 Das metabolische Syndrom bei Frauen. **1998**, 9-16
- 225 Molekulare Grundlagen der Herzinsuffizienz. **1998**, 147-221 0

- 224 Medical Treatment in the Case of Severe Coronary Artery Disease. **1998**, 67-77
- 223 LETTERS TO THE EDITOR. **1998**, 227, 315-316
- 222 Meta-analysis by the Program on the Surgical Control of the Hyperlipidemias (POSCH) investigators. **1998**, 227, 314-6 1
- 221 Therapy and clinical trials. **1998**, 9, 181-3
- 220 Hyperlipidaemia and cardiovascular disease. **1998**, 9, 507-10
- 219 Therapy and clinical trials. **1998**, 9, 519-20
- 218 Zerebrale Durchblutungsstörungen. **1999**, 1151-1166
- 217 Lipoproteins and Apoproteins. **1999**, 28-68
- 216 The Use of Antiestrogens in the Postmenopausal Woman. **1999**, 179-207 1
- 215 Risk Factor Modification. **1999**, 107-126
- 214 Cholesterol Lowering. **1999**, 571-592
- 213 Secondary Prevention of Myocardial Infarction. **1999**, 593-600
- 212 Lipidsenkende Mittel. **1999**, 356-365
- 211 Diabetes und koronare Herzkrankheit. **1999**, 345-418
- 210 Current therapies for secondary prevention after myocardial infarction. **1999**, 14, 155-60 2
- 209 Secondary prevention in coronary heart disease. Effects of statins have been in addition to those of aspirin and beta blockers. **1999**, 318, 1419-20
- 208 Cholesterol lowering in older patients. **1999**, 131, 155-6
- 207 Nuclear Cardiology 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging. **2015**, 463-528

206 Hallmark Clinical Trials. **2015**, 675-727

205 Clinical Feasibility and Monitoring of the Effects of Anti-inflammatory Therapy in Atherosclerosis. **2015**, 355-379

204 Clinical Significance of Non-invasive Magnetic Resonance Imaging to Identify High-risk Coronary Plaques as Potential Biomarkers for Preemptive Medicine. **2015**, 21, 278-286

0

203 Principles of Primary and Secondary Prevention of Cardiovascular Disease. **2015**, 1627-1664

202 [Not Available]. **2016**, 136, 1184-5

0

201 ??????????????????????????????. **2016**, 24, 230-236

200 Associated factors for the development of acute coronary syndrome or stable coronary artery disease. **2016**, 22, 139-144

199 Use of Cholesterol-Lowering Medications of Patients with Myocardial Infarction from 2007-2015 in Cardiology Clinic to Mother Teresa University Hospital in Albania. **2016**, 07, 236-245

198 Should Recent Clinical Trials Change Perioperative Management in Patients with Cardiac Risk Factors?. **2017**, 3-6

197 Treatment with Gefitinib, an Epidermal Growth Factor Receptor Inhibitor, Decreases Serum Cholesterol in Patients with Lung Cancer. **2016**, 25, 233-239

2

196 STATINS-Do We Know Them or Are We Alice in Wonderland?. **2017**, 5,

195 Interim Analyses: Design and Analysis Considerations for Survival Trials When Hazards May Be Nonproportional. **2018**, 347-376

194 Percutaneous Coronary Intervention: Special Considerations in Women. **2018**, 275-289

193 New clinical and pharmacological aspects of the use of atorvastatin for primary and secondary prevention of complications of cardiovascular diseases. **2018**, 110-117

192 Abdominal Aortic Occlusive Disease. **2019**, 217-230

191 Hormone Replacement Therapy and Postmenopausal Cardiovascular Events: A Meta-Analysis. **2019**, In Press,

0

190 Inflammation of adipose tissue. Is there a place for statins to correct adiposopathy?. **2019**, 16, 12-19

189 LDL as a therapeutic objective. **2019**, 31 Suppl 2, 1-15

2

- 188 Evaluation of the effectiveness of lipid-lowering agents. **2020**, 26, 78-85
- 187 Achievement of LDL-C Targets Defined by ESC/EAS (2011) Guidelines in Risk-Stratified Korean Patients with Dyslipidemia Receiving Lipid-Modifying Treatments. **2020**, 35, 367-376 1
- 186 Management of Hypertriglyceridemia (Including Fibrates and n-3 Fatty Acids). **2021**, 295-306
- 185 The Low-Density Lipoprotein Cholesterol Hypothesis: An Update. **2021**, 121-138
- 184 PRESERVATION OF ERECTILE FUNCTION BY STATINS IN A RAT MODEL OF ERECTILE DYSFUNCTION INDUCED BY HYPERCHOLESTEROLEMIA. **2020**, 16, 27
- 183 Secondary Prevention of Coronary Artery Disease. **2020**, 75-82
- 182 Discovery and Commercial Development of Cholesteryl Transfer Protein Inhibitor Evacetrapib. **2020**, 339-372
- 181 Statins, bone biology and revision arthroplasty: review of clinical and experimental evidence. **2020**, 12, 1759720X20966229 1
- 180 Segmenting Paddy Farmer's Attitude and Behavior. **2020**, 1623-1648
- 179 Keystones in hypercholesterolemia treatment epidemiology. **2020**, 4, 29-32
- 178 Analysis of drug prescription appropriateness according to the STOPP/START criteria of the elderly patients with type 2 diabetes mellitus in the endocrinology department of a multi-speciality hospital. **2020**, 47-56 1
- 177 Effects of Statin Treatment on Patients with Angina and Normal or Nearly Normal Angiograms. **2020**, 15, e15 1
- 176 Are Statins the Optimal Therapy for Cardiovascular Risk in Patients with Diabetes? What Newer Agents Are There for the Treatment for Dyslipidemia in Diabetes? Are Triglycerides an Important Risk Factor for Diabetes?. **2021**, 198-210
- 175 The Effect of Statins on Serum Vitamin D Concentrations Among Older Adults. **2020**, 12, e8950 2
- 174 A practical approach to lipid management in the elderly.
- 173 Traditional Risk Factors and Newly Recognized Emerging Risk Factors for Cardiovascular Disease. **2003**, 63-89
- 172 Group Sequential Analysis Procedures. **2006**, 113-142
- 171 Implications of changing national cholesterol education program goals for the treatment and control of hypercholesterolemia. **2006**, 21, 171-6 8

170 Akuter Myokardinfarkt. **2005**, 1132-1138

169 Störungen des Lipidstoffwechsels. **2005**, 418-423

168 Koronare Herzkrankheit und Herzinfarkt. **2006**, 27-142

167 Lipidsenkende Mittel. 698-715

166 Spezielle therapeutische Probleme im höheren Alter. **2005**, 98-122

165 Arterielle Verschlusskrankheit (AVK). **2005**, 146-149

164 Koronare Herzkrankheit – akute Verlaufsformen. **2006**, 169-201

163 Kardiovaskuläre Pharmakologie. **2006**, 1-30

162 Coronary Atherothrombosis: Pathophysiology and Clinical Implications. **1999**, 57-75

161 Prevention of Atherosclerosis: Endothelial Function, Cholesterol, and Antioxidants. **1999**, 77-106

160 Risk Factors. **2005**, 475-516

159 Oxidative Stress. **2005**, 549-562

158 Multivariable Evaluation of Candidates for Cardiovascular Disease. **2005**, 3-18

157 Stable Angina. **2005**, 451-470

156 The Unstable Plaque. **2006**, 3-17

155 Women and Coronary Artery Disease. **2006**, 217-235

154 Innovative Models for the Delivery Preventive Cardiovascular Care. **2006**, 325-338

153 Diabetes Mellitus, Hyperinsulinemia, and Coronary Artery Disease. **2006**, 113-143

- 152 Metabolic and Endocrine Effects of Statins in Polycystic Ovary Syndrome. **2008**, 241-258 1
- 151 Management of Dyslipidemias. **2007**, 307-322
- 150 Hallmark Clinical Trials. **2007**, 381-394
- 149 Exercise Training in Diabetes Mellitus: An Efficient but Underused Therapeutic Option in the Prevention and Treatment of Coronary Artery Disease. **2007**, 138-141
- 148 Pharmacotherapy in Prevention and Rehabilitation. **2007**, 439-453 0
- 147 Outcomes of a multidisciplinary team approach to cardiovascular risk reduction in patients with diabetes mellitus. **2005**, 2, 587-595
- 146 Analogpräparate. **2007**, 105-181
- 145 Lipidsenkende Mittel. **2007**, 690-708
- 144 Ereigniszeiten und konkurrierende Risiken [zur Planung und Auswertung der 4D Studie]. **2007**, 375-394
- 143 Basis of Cardiac Imaging 2: Myocardial Perfusion, Metabolism, Infarction, and Receptor Imaging in Coronary Artery Disease and Congestive Heart Failure. **2006**, 352-394
- 142 Störungen des Lipidstoffwechsels. **2007**, 466-472
- 141 Early, aggressive lipid management in the treatment of acute coronary syndromes. **2004**, 1, 213-216
- 140 Hypertension and Hypercholesterolemia: is it Time for Anti-«Lipitensive» Therapy?. **2020**, 16, 842-851
- 139 Maintenance of statin therapy among people living with HIV. **2021**, 35, 567-574 1
- 138 Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists' Collaboration. **1998**, 316, 894-8 141
- 137 Fatality outside hospital from acute coronary events in three British health districts, 1994-5. United Kingdom Heart Attack Study Collaborative Group. **1998**, 316, 1065-70 37
- 136 Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. **2000**, 163, 1263-9 6
- 135 Evidence-based medicine: a commentary on common criticisms. **2000**, 163, 837-41 58

134	Statins and bones. 2001 , 164, 803-5	1
133	Did the major clinical trials of statins affect prescribing behaviour?. 2001 , 164, 1695-6	10
132	The use of cholesterol-lowering medications after coronary revascularization. 2003 , 169, 1153-7	1
131	National service framework for coronary heart disease. Ambiguities need to be clarified. 2000 , 321, 634	1
130	Diabetes care needs evidence based interventions to reduce risk of vascular disease. 2000 , 320, 1554-5	3
129	Reporting of gender-related information in clinical trials of drug therapy for myocardial infarction. 1998 , 159, 321-7	10
128	Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias. 2000 , 162, 1441-7	46
127	Acute myocardial infarction in Canada: improvement with time. 2000 , 163, 41-2	2
126	Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. 1999 , 160, 1449-55	8
125	Ways to make "usual" and "successful" aging synonymous. Preventive gerontology. 1997 , 167, 206-15	9
124	Statins and the prevention of coronary heart disease: striking a balance that is desirable, affordable, and achievable. 2000 , 50, 693-5	1
123	The primary prevention of coronary heart disease with statins: practice headache or public health?. 2000 , 50, 695-7	3
122	Management of UTI in general practice: a cost effective analysis. A commentary to facilitate an understanding of economic evaluation. 2000 , 50, 697-8	
121	The cost-effectiveness of lipid lowering in patients with ischaemic heart disease: an intervention and evaluation in primary care. 2000 , 50, 699-705	1
120	Secondary prevention of cardiovascular disease: a randomised trial of training in information management, evidence-based medicine, both or neither: the PIER trial. 2002 , 52, 818-24	15
119	Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings. 2005 , 2, A05	3
118	Coronary heart disease prevention and age inequalities: the first year of the National Service Framework for CHD. 2005 , 55, 369-75	14
117	Management strategies of dyslipidemia in the elderly: 2005. 2005 , 7, 8	

116	Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. 1998 , 80 Suppl 2, S1-29	94
115	Fifth report on the provision of services for patients with heart disease. 2002 , 88 Suppl 3, iii1-56	3
114	Lipid-lowering update 2001. Aggressive new goals. 2001 , 47, 303-9	1
113	Primary and secondary prevention of heart disease: can we curb the global epidemic?. 2001 , 112, 89-95; discussion 95-8	3
112	Analysis of serious adverse events. Lipid-lowering therapy revisited. 2002 , 48, 486-9, 492-5	2
111	Use of lipid-lowering agents (statins) during pregnancy. 2003 , 49, 747-9	23
110	Family practice patients' adherence to statin medications. 2007 , 53, 2144-5	20
109	Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events. 2007 , 53, 1502-7	
108	Coronary artery disease in women. 1998 , 44, 2709-17	20
107	Hypercholesterolemia screening. Does knowledge of blood cholesterol level affect dietary fat intake?. 1998 , 44, 1289-97	17
106	Cholesterol lowering for secondary prevention: what statin dose should we use?. 2007 , 3, 615-27	8
105	Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions. 2007 , 12, 91-6	3
104	Statins improve human coronary atherosclerotic plaque morphology. 2008 , 35, 99-103	11
103	Stress echocardiography for risk assessment of diabetic patients. 2004 , 12, 455-458	
102	Enhancing reverse cholesterol transport/raising HDL cholesterol: new options for prevention and treatment of cardiovascular disease. 2004 , 12, 491-496	4
101	Measuring serum total cholesterol: do vascular surgeons know what they are doing?. 1999 , 81, 32-6	3
100	A guideline for uniform and optimal atherosclerotic risk factor assessment across clinical specialities in a large hospital. 2001 , 9, 282-287	
99	Managing cardiovascular risk in minority patients. 2005 , 97, 459-66	20

98	Missed opportunity in the treatment of hyperlipidemia in patients with coronary heart disease: the primary care setting. 2006 , 98, 58-62	3
97	Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia. 2000 , 92, 319-26	5
96	Atherosclerosis, cholesterol, nutrition, and statins--a critical review. 2007 , 5, Doc04	11
95	Statins in the first-line therapy of acute coronary syndrome - similar to aspirin?. 2005 , 10, 9-16	2
94	Stroke Best Practices: a team approach to evidence-based care. 2004 , 96, 5S-20S	2
93	Diabetes: managing dyslipidaemia. 2008 , 2008,	2
92	Statins do not decrease small, dense low-density lipoprotein. 2010 , 37, 421-8	17
91	Rosuvastatin-induced neuroprotection in cortical neurons exposed to OGD/reoxygenation is due to nitric oxide inhibition and ERK1/2 pathway activation. 2011 , 3, 57-64	9
90	Secondary prevention of ischaemic cardiac events. 2011 , 2011,	2
89	The effect of statin therapy in stroke outcome: a double blind clinical trial. 2012 , 3, 68-72	5
88	Concomitant administration of simvastatin with ivabradine in contrast to metoprolol intensifies slowing of heart rate in normo- and hypercholesterolemic rats. 2012 , 8, 549-54	3
87	A Randomized Controlled Study to Compare the Effects of Rosuvastatin 2.5 mg and Pravastatin 10 mg on the Plasma Lipid Profile in Japanese Patients with Hypercholesterolemia (ASTRO-1). 2009 , 2, 148-58	
86	Statins as first-line therapy for acute coronary syndrome?. 2012 , 17, 227-36	9
85	Cholesterol and cardiovascular disease in the elderly. Facts and gaps. 2013 , 4, 154-69	33
84	Statins: emerging role in chemoprevention for hepatocellular carcinoma?. 2013 , 2, 117-20	1
83	A multicentre, open-label, observational local study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. 2007 , 18, 325-9	1
82	Anticoagulants and Statins As Pharmacological Agents in Free Flap Surgery: Current Rationale. 2015 , 15, e51	6
81	Zontivity (Vorapaxar), First-in-Class PAR-1 Antagonist, Receives FDA Approval for Risk Reduction of Heart Attack, Stroke, and Cardiovascular Death. 2015 , 8, 148-51	20

80	The evidence on trial: cholesterol lowering and cancer. 2009 , 1, 6-10		
79	Comparison of efficacy and adverse effect profile of high dose versus standard dose atorvastatin in acute ST elevation myocardial infarction patients. 2011 , 3, 82-6		1
78	ANMCO/GICR-IACPR/SICI-GISE Consensus Document: the clinical management of chronic ischaemic cardiomyopathy. 2017 , 19, D163-D189		
77	Lipid Lowering Therapy for Acute Coronary Syndrome and Coronary Artery Disease: Highlights of the 2017 Taiwan Lipid Guidelines for High Risk Patients. 2018 , 34, 371-378		5
76	Red yeast rice for dyslipidemia. 2013 , 110, 349-54		3
75	Significant reduction in the LDL cholesterol increases the risk of intracerebral hemorrhage: a systematic review and meta-analysis of 33 randomized controlled trials. 2020 , 12, 463-477		6
74	Retrospective analysis of the cholesterol levels in a European mid-latitude population between 2007 and 2018: controversies and therapeutic implications. 2020 , 91, e2020063		1
73	Vulnerable atherosclerotic plaque features: findings from coronary imaging. 2021 , 18, 577-584		1
72	Statins in Non-alcoholic Steatohepatitis.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 777131	5-4	4
71	Standards of Medical Care in Diabetes 2006. 2006 , 29, s4-s42		350
70	Prevalence of statin intolerance: a meta-analysis.. 2022 ,		8
69	The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases. 2021 , 12, 1857-1871		0
68	Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East: 2021 update.. 2021 , 343, 28-50		4
67	Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.. 2022 , 24, 12		1
66	Long-term clinical impact of low-density lipoprotein cholesterol target attainment according to lesion complexity after percutaneous coronary intervention.. 2022 ,		
65	Correlation between the extent of coronary atherosclerosis and lipid profile. 2003 , 246, 25-30		12
64	The effect of early treatment by cerivastatin on the serum level of C-reactive protein, interleukin-6, and interleukin-8 in the patients with unstable angina and non-Q-wave myocardial infarction. 2003 , 246, 45-50		11
63	Cholesterol lowering with simvastatin in people with diabetes. 2004 , 6, 85-6		

62	Intensive versus moderate lipid lowering with statins in acute coronary syndromes. 2005 , 7, 85-6		1
61	Pharmacogenetic study of statin therapy and cholesterol reduction. 2005 , 7, 177-8		
60	Dyslipidemia. 2022 , 461-472		
59	Contemporary Management of Dyslipidemia.. 2022 , 1		1
58	Simultaneous evaluation of fatty acid and triglycerides after percutaneous coronary intervention.. 2022 ,		0
57	Molecular Biological and Clinical Understanding of the Statin Residual Cardiovascular Disease Risk and Peroxisome Proliferator-Activated Receptor Alpha Agonists and Ezetimibe for Its Treatment.. 2022 , 23,		0
56	New Advances in Targeted Therapy of HER2-Negative Breast Cancer.. 2022 , 12, 828438		0
55	Common genetic variants do not predict recurrent events in coronary heart disease patients.. 2022 , 22, 96		
54	LDL como objetivo terapéutico. 2022 ,		
53	Association between statin use and Parkinson's disease in Korean patients with hyperlipidemia.. 2022 , 97, 15-24		2
52	Intravascular imaging assessment of pharmacotherapies targeting atherosclerosis: advantages and limitations in predicting their prognostic implications.. 2022 ,		0
51	Longitudinal follow-up study of the association between statin use and chronic periodontitis using national health screening cohort of Korean population.. <i>Scientific Reports</i> , 2022 , 12, 5504	4.9	0
50	Associations of cardiovascular risk factors with survival outcomes in a cancer registration: Findings from the KUMAMON registry.. <i>Medicine (United States)</i> , 2021 , 100, e27921	1.8	
49	Efficacy, Safety and Protective Effects of Lipid Lowering Drugs in Patients with Diabetes. <i>European Journal of Medical and Health Sciences</i> , 2022 , 4, 89-92	2	0
48	Gender, Hyperlipidemia, and Coronary Artery Disease. <i>Comprehensive Therapy</i> , 2003 , 29, 07-17		
47	Image1.tiff. 2017 ,		
46	Rosuvastatin attenuates hypertension-induced cardiovascular remodeling without affecting blood pressure in DOCA-salt hypertensive rats. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47, 396-404	3.1	28
45	Undertreatment or Overtreatment With Statins: Where Are We?. <i>Frontiers in Cardiovascular Medicine</i> , 2022 , 9, 808712	5.4	1

44	Statins Are Associated with Improved Survival of Patients with Gastric Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Clinical Practice</i> , 2022 , 2022, 1-9	2.9	0
43	Usefulness of Statins as Secondary Prevention Against Recurrent and Terminal Major Adverse Cardiovascular Events. <i>American Journal of Cardiology</i> , 2022 ,	3	0
42	A Comparison of Rehospitalization Risks on Diabetic and Non-Diabetic Patients after Recovery from Acute Coronary Syndrome. <i>Healthcare (Switzerland)</i> , 2022 , 10, 1003	3.4	
41	Terapia endocrina para la prevención primaria del cáncer de seno: Revisión sistemática y metaanálisis actualizado. <i>Revista Colombiana De Cirugía</i> ,	0.3	
40	Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease. <i>Cancer Journal (Sudbury, Mass)</i> , 2022 , 28, 208-223	2.2	1
39	Cardiometabolic Comorbidities in Cancer Survivors. <i>JACC: CardioOncology</i> , 2022 , 4, 149-165	3.8	0
38	Harmonisation of large-scale, heterogeneous individual participant adverse event data from randomised trials of statin therapy. <i>Clinical Trials</i> , 174077452211055	2.2	
37	Tratamiento de la hipertrigliceridemia con icosapento de etilo en pacientes de alto/muy alto riesgo cardiovascular. Documento de consenso de la Sociedad Española de Cardiología y Sociedad Española de Diabetes. <i>Endocrinología, Diabetes Y Nutrición</i> , 2022 ,	1.3	0
36	Serial Changes in Coronary Plaque Formation Using CT Angiography in Patients Undergoing PCSK9-Inhibitor Therapy With 1-year Follow-up. <i>Journal of Thoracic Imaging</i> , Publish Ahead of Print,	5.6	
35	Statin Use in Cancer Patients with Acute Myocardial Infarction and Its Impact on Long-Term Mortality. <i>Pharmaceuticals</i> , 2022 , 15, 919	5.2	0
34	No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor. 2002 , 42, 1116-1121		1
33	Free Radicals in Cardiovascular Disease. 1998 , 28, 102-110		
32	The relationship between acute cardiac attack and LDL-C serum levels in cardiac and CCU inpatients in Hajar hospital: Replying to a paradox. 2022 , 24, 139-144		
31	Associations between statins and adverse events in secondary prevention of cardiovascular disease: Pairwise, network, and dose-response meta-analyses of 47 randomized controlled trials. 9,		
30	LIPIDS AND THEIR ROLE IN CORONARY HEART DISEASE. 2000 , 35, 981-991		0
29	Effects of nut consumption on the inhibition of obesity-related endothelial cell dysfunction and prevention of cardiovascular diseases. 2022 , 1-39		0
28	LDL as a therapeutic target. 2022 , 34, 271-284		0
27	Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials. 2022 , 400, 832-845		1

26	Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials. 2022 , 101, e30563	○
25	Relationship between Dielectric Relaxation Time and Permeability of High-Rank Coal in the Jiaozuo Mining Area. 2022 , 7, 38990-39001	○
24	Qualitative versus Quantitative Treatment-by-Subgroup Interaction in Equivalence Studies with Multiple Subgroups. 1-11	○
23	Treatment of hypertriglyceridaemia with icosapent ethyl in patients with high/very high cardiovascular risk. Consensus document of the Sociedad Española de Cardiología [Spanish Society of Cardiology] and the Sociedad Española de Diabetes [Spanish Diabetes Society]. 2022 ,	○
22	Optimal target of LDL cholesterol level for statin treatment: challenges to monotonic relationship with cardiovascular events. 2022 , 20,	○
21	Atherogenic Lipoproteins for the Statin Residual Cardiovascular Disease Risk. 2022 , 23, 13499	1
20	Statin associated muscle symptoms: An update and review. 2022 ,	○
19	Generating Practice-Based Evidence in the Use of Guideline-Recommended Combination Therapy for Secondary Prevention of Acute Myocardial Infarction. 2022 , 10, 147	○
18	Analysis of the structure of drug prescriptions in patients with arterial hypertension and atrial fibrillation in conditions of comorbidity and their compliance with the STOPP/START criteria. 2022 , 28, 557-572	○
17	Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study.	○
16	Angina in 2022: Current Perspectives. 2022 , 11, 6891	○
15	Lipid-Lowering Trials Are Not Representative of Patients Managed in Clinical Practice: A Systematic Review and Meta-Analysis of Exclusion Criteria.	○
14	Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome [A Post Hoc Secondary Analysis of STOPDAPT-2 ACS] 2022 ,	○
13	Pharmaco-invasive therapy: Early implementation of statins and proprotein convertase subtilisin/kexin type 9 inhibitors after acute coronary syndrome. 9,	○
12	A Hidden Organism, Chlamydia in the Age of Atherosclerosis.	○
11	Brain nuclear receptors and cardiovascular function. 2023 , 13,	○
10	In Search of Lipid Balance in Older Women: New Studies Raise Questions About What Works Best. 2000 , 108, 57-72	○
9	How Low Can You Go? New Evidence Supports No Lower Bound to Low-Density Lipoprotein Cholesterol Level in Secondary Prevention. 2023 , 147, 1204-1207	○

- 8 The Framingham Study on Cardiovascular Disease Risk and Stress-Defenses: A Historical Review. **2023**, 2, 122-164
- 7 Stroke and Nitric Oxide. **2000**, 343-355
- 6 Angiographic Outcomes for Arterial and Venous Conduits Used in CABG. **2023**, 12, 2022
- 5 Gender disparities in prevalence by diagnostic criteria, treatment and mortality of newly diagnosed acute myocardial infarction in Korean adults. **2023**, 13,
- 4 A review of research on the intersection between breast cancer and cardiovascular research in the Women's Health Initiative (WHI). 12,
- 3 Understanding the molecular mechanisms of statin pleiotropic effects.
- 2 Colorectal Cancer Chemoprevention: A Dream Coming True?. **2023**, 24, 7597
- 1 Behavioral interventions. **2023**, 87-91